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Abstract!The#majority#of#cellular#processes#are#governed#by#the#activity#of#multimeric#protein#complexes# assembled# through# specific# proteinZprotein# interactions# # (PPIs).# # With# more#than#650,000#estimated#PPIs,#less#than#0.01%#of#these#interactions#have#been#successfully#targeted##with##small##molecules.##One#processes,#transcription,#allows#for#the#regulation#and#expression# of# relevant# genes# in# both# a# cell# specific# and# tissue# specific# manner.##Dysregulation# of# the# transcription# process# is# implicated# in# the# vast# majority# of# human#diseases,#either#as#a#cause#or#consequence#of#this#dysregulation.##Given#the#significant#role#that# transcriptional# dysregulation# plays# in# human# disease,# it# is# evident# that# there# is#immense# therapeutic# potential# for# finding# strategies# to# restore# proper# transcriptional#regulation.# # There# are# three# general# strategies# for# targeting# transcriptional# activation#pathways# in# order# to# restore# normal# function:# # regulatory/masking# proteins,#transcriptional# activator# dimerization,# and# specific# contacts# made# with# coactivators# to#recruit# the# transcriptional# machinery.# # PPIs# have# traditionally# been# defined# as##“undruggable”#due#to#the#fact#that#many#proteinZprotein#interactions#lack#surface#topology#and# occur# over# large# surface# areas.# These# characterizations#make# PPIs# difficult# to# target#with# small#molecules,# particularly# large# surface# area,# low# affinity# PPIs,# a# subclass# of# PPI#often# used# by# transcriptional# activator# pathways.# Herein,# we# discuss# strategies# for#targeting# this# subclass# of# PPIs# by# using# small# molecule# # combination# # strategies,# # highZthroughput##screening##of##natural##products,##and##peptide##stabilization##methods##to##target##this##difficult#class#of#PPIs.##In# one# example,#we# demonstrated# how# i1,# an# inhibitor# of# the# ESX# transcriptional#activator,# could# be# used# in# combination# with# other# ESX# signaling# pathway# inhibitors# to#obtain#synergistic#inhibition#against#ESXZdriven#Head#and#Neck#Squamous#Cell#Carcinoma#
xvii#



















1.1!Abstract!The!majority!of!cellular!processes!are!governed!by!the!activity!of!multimeric!protein!complexes! assembled! through! specific! protein:protein! interactions! (PPIs).! One! of! these!cellular!processes,!transcription,!allows!for!the!regulation!and!expression!of!relevant!genes!in! both! a! cell:specific! and! tissue:specific! manner.! Dysregulation! of! the! transcription!process! is! implicated! in! the! vast! majority! of! human! diseases,! either! as! a! cause! or!consequence! of! this! dysregulation.! Given! the! significant! role! that! transcriptional!dysregulation! plays! in! human! diseases,! it! is! evident! that! there! is! immense! therapeutic!potential! for! finding! strategies! to! restore! proper! transcriptional! regulation.! This!introductory! chapter! defines! the! characteristics! of! protein:protein! interactions! and! the!challenges! traditionally! associated!with! targeting! these! “undruggable”! interactions.!With!these!challenges!in!mind,!new!technical!methods!and!targeting!strategies!will!be!presented!to! expand! the! number! of! druggable! targets! at! our! disposal! using! combination! therapy,!natural!product!compound!libraries,!and!novel!peptide!stabilization!methods.!!
1.2!Introduction!All!living!things!contain!the!genetic!information!needed!to!carry!out!basic,!everyday!life! functions! such! as! metabolism,! digestion,! and! movement.1! These! functions! are!accomplished! by! specialized! tissues! composed! of! differentiated! cells! that! are! capable! of!carrying! out! cell:specific! processes.! 2,3! Upon! encountering! external! or! internal! stimuli,!specific!activation!pathways!will!be!engaged,!causing!the!expression!or!repression!of!target!
! 2!
genes! needed! to! respond! to! these! stimuli.4! Although! all! cells! contain! the! same! common!DNA! template,! certain! cells! are! capable! of! carrying! out! cell:specific! processes,! whereas!other!cells!are!not.!This!is!possible!due!to!master!regulator!proteins!known!as!transcription!factors,! which! allow! cells! to! activate! or! repress! specific! target! genes! using! the! common!DNA!template!shared!among!all!cells.5!The!ability!of!transcription!factors!to!either!activate!or! repress! target! gene! expression! occurs! through! a! process! known! as! transcription.6!Dysregulation!of!the!transcription!process!is!implicated!in!the!majority!of!human!diseases,!with!transcriptional!dysregulation!arising!as!either!a!cause!or!consequence!of!disease.! 7:9!Given!the!importance!of!transcription!as!it!pertains!to!cell:specific!responses!and!its!role!in!disease,! there! is! immense! therapeutic! potential! for! finding! small! molecules! capable! of!mitigating!or!restoring!the!process!of!transcription!as!seen!in!healthy!cells.!Small!molecules!capable! of! specifically! inhibiting! a! cell! signaling! pathway! would! allow! modulation! of!transcription! factor! protein! levels! in! the! cell,! whereas! small! molecules! targeting! the!coactivators! used! by! transcription! factors! would! allow! for! modulation! by! inhibiting! the!ability!of!transcription!factors!to!initiate!transcription.!!
1.3!Transcriptional!activators!and!the!process!of!transcription!Cellular! processes! are! often! mediated! by! the! signaling! events! that! result! from!specific! activation! pathways.! One! of! these! downstream! cellular! processes! resulting! from!signaling!events,!transcription,!is!mediated!by!proteins!known!as!transcription!factors!and!more! specifically,! transcriptional! activators.! 10:12! These! transcriptional! activator! proteins!are!minimally!composed!of!a!DNA:binding!domain!(DBD)!and!a!transcriptional!activation!domain!(TAD).!13:15!The!DBD!subunit!is!used!to!recognize!and!bind!to!a!specific!promoter!sequence! located!upstream!of! the! target!gene,!whereas! the!TAD! is!used! to!make! specific!contacts!with!coactivators!needed!to!assemble!the!transcriptional!machinery!at!the!target!gene!(Figure!1.1).!Assembly!of! the!transcriptional!machinery!at! the!target!gene!results! in!upregulation!of!that!specific!target!gene!and!subsequent!protein!expression!(Figure!1.2).!In!human! disease,! it! is! common! to! observe! dysregulation! of! the! transcription! process.! For!example,! the! herpes! simplex! virus! causes! dysregulation! of! transcription! through!expression!of!herpes!simplex!virus!protein!vmw65!(VP16),!a!transcriptional!activator!that!recruits! coactivator!Med25,! a! specific! subunit! of! the! transcriptional!machinery.! 16:18!This!
! 3!
ultimately! causes! overexpression! of! VP16! target! genes! and! downregulation! of! other!transcription! factor! target! genes! that! rely! on!Med25! for! expression.! ! A! similar!mode! of!transcription!dysregulation!has!been!documented!in!breast!cancer!such!as!overexpression!of!the!transcriptional!activator!epithelial:restricted!with!serine!box!(ESX)!recruits!Med23,!a!subunit!of!the!transcriptional!machinery.!This!leads!to!overexpression!of!Human!Epidermal!growth! factor! Receptor! 2! (Her2),! a! biomarker! and! oncogene! responsible! for! the!development! and! progression! of! breast! cancer.19! Dysregulation! of! transcription! can! also!occur! through! constitutive! activation! of! a! specific! signaling! pathway.! This! occurs! in!rheumatoid! arthritis,! an! autoimmune! disease! that! cause! constitutive! activation! of! the!nuclear! factor! kappa:light:chain! enhancer! of! activated! B! cells! (NF:κB),! resulting! in!upregulation!of!NF:!κB!target!genes!that!cause!chronic!inflammation!and!tissue!injury.!20,21!!!
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gene!upregulation!During!a!cell!signaling!event,!a!transcriptional!activator!with!localize!to!the! cell! nucleus! where! the! DNA:binding! domain! will! bind! to! a! specific! DNA! promoter!sequence! located!upstream!of! the! target!gene.!The! transcriptional!activation!domain!will!then!make!specific!protein:protein!interactions!with!coactivators!that!will! in!turn,!recruit!the!transcriptional!machinery!and!upregulate!target!gene!expression.!











Figure! 1.3! Inhibition! strategies! for! transcriptional! activators! Upon! activation! of! a!signaling! pathway,! there! are! a! series! of! actions! that! take! place! including:! activation! of!regulatory! proteins,! degradation! of! masking! proteins,! homo/heterodimerization! of!transcriptional!activators,!interaction!with!specific!coactivators,!and!upregulation!of!target!genes.! These! processes! are! all! mediated! by! protein:protein! interactions! and! represent!possible!sites!of!small!molecule!intervention.!!
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phosphorylated! domain! of! EGFR! causes! an! activation! cascade! of! several! other! proteins!including! RAS,! RAF,! MEK,! and! MAPK.31! This! signaling! cascade! ultimately! results! in!activation! of! transcriptional! activators! CREB! and! c:Myc! and! upregulation! of! their!respective! target! genes.! The! above! example! highlights! the! importance! of! EGFR! as! a!regulator!protein! in! the!MAPK/ERK!signaling!pathway.! In! the!absence!of! the!EGF! ligand,!EGFR!inhibits!the!rest!of!the!pathway!from!being!activated.!!Whereas! regulator! proteins! tend! to! function! as! the! “master! switch”! for! signaling!pathways,! masking! proteins! serve! as! protein! inhibitors,! sequestering! transcriptional!activators! until! needed.! The! canonical! example! when! discussing! masking! proteins! in!signaling! pathways! is! the! p53:Mdm2! protein:protein! interaction.! The! tumor! protein! 53!(p53)!pathway!is!important!in!humans!due!to!the!role!of!the!p53!transcriptional!activator!as!a!tumor!suppressor.32!When!cells!experience!stressors!such!as!genotoxic!stress!or!DNA!damage,! p53! is! phosphorylated,! causing! the! masking! protein! Mdm2! to! release! p53,!allowing!localization!to!the!nucleus!and!upregulation!of!target!genes!for!survival.33!In!the!absence!of!genotoxic!stress,!Mdm2!binds!to!p53,!causing!p53!to!localize!to!the!cytosol!and!remain! inactive! by! sequestering! the! TAD! of! p53.34! Interestingly,! some! pathways! use! a!combination! of! regulatory! and! masking! proteins! in! order! to! regulate! activity! of!transcriptional! activators.!NF:κB! can! respond! to!numerous! stimuli! such! as!DNA!damage,!chemokines,! as!well! as! chemokines.35! In! the! presence! of! any! of! these! stimuli,! the!NF:κB!essential! modulator! (NEMO)! serves! as! a! regulatory! protein,! promoting! assembly! of! the!activation! complex! required! for! NF:κB! activation.36! Upon! assembly! of! the! activation!complex,! the! complex! will! go! on! to! phosphorylate! the! inhibitor! of! κB! (IκB),! a! masking!protein!of!the!NF:κB!transcriptional!activator.!Phosphorylation!of!IκB!promotes!the!release!of!the!transcriptional!activator!NF:κB,!localization!to!the!nucleus,!and!upregulation!of!NF:κB!target!genes!(Figure!1.4).37!!
! 7!
!
Figure! 1.4! Representation! of! regulatory! and! masking! proteins! in! transcriptional!
activator! signaling! pathways! Left!panel:! In! the!MAPK/ERK!pathway,! the! EGFR!protein!serves!a!regulatory!protein!that!serves!as!the!“master!switch”!for!activation!of!the!pathway.!Only!upon!binding!EGF!will!EGFR!be!activated,!causing!a!signal!cascade!and!activation!of!several! downstream! proteins.! Middle! panel:! Mdm2! is! the! canonical! example! used! to!illustrate!the!role!of!masking!proteins!in!transcriptional!activator!signaling!pathways.!!In!an!inactive! state,! the! p53! transcriptional! activator! is! bound! by! the!masking! protein!Mdm2!causing! it! to! be! sequestered! it! in! the! cytosol.! The! presence! of! external! stimuli! such! as!genotoxic!stress!causes!release!of!p53!from!the!Mdm2!masking!protein!and!upregulation!of!p53! target! genes.! Right! panel:! In! the! NF:κB! transcriptional! activator! signaling! pathway!both!regulatory!and!masking!proteins!are!used! to!regulate!activation.!The!NEMO!protein!serves! as! the! regulatory! protein! needed! to! assembly! of! the! activation! complex.! This!activation!complex!goes!on!to!phosphorylate!IκB,!the!masking!protein.!This!causes!release!of!the!NF:κB!transcriptional!activator!and!upregulation!of!NF:κB!target!genes.!




































































Transcriptional!activator!interactions!with!coactivators!Current!models!suggest!that!transcriptional!activators!must!recruit!multiple!protein!complexes! in! order! to! carry! out! the! process! of! transcription.! DNA! is! organized! as!chromatin,! a! compacted! form! in! which! the! DNA! is! wound! around! histones.! ! Early! in!transcription!initiation,!transcriptional!activators!recruit!chromatin!remodeling!complexes!such!as!Swi/Snf!and!SAGA!in!order!to!alter!chromatin!structure,!causing!the!target!gene!to!be! more! accessible.40! Once! chromatin! remodeling! has! taken! place,! transcriptional!activators!recruit!coactivators!to!the!target!gene!promoter!site.41!These!coactivators!serve!as!a!“bridge”!between!the!transcriptional!activator!and!the!transcriptional!machinery!that!includes!RNA!Pol!II,!the!protein!that!carries!out!synthesis!of!the!target!gene!mRNA!(Figure!1.5).!!!!
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and! other! subunits! of! the! transcriptional!machinery.! The! common! thread! between! all! of!these! processes! is! that! they! utilize! many! different! PPIs! in! order! to! accomplish! the!aforementioned! processes.! In! order! to! externally! modulate! the! transcriptional! process,!then!targeting!these!different!PPI!functional!classes!with!small!molecules!is!required!and!as!outlined,!in!the!subsequent!section,!there!are!unique!challenges!associated!with!each!type!of!PPIs.!!
1.5!Protein2protein!interactions!(PPIs)!Cellular! functions!are!carried!out!by!a!myriad!of!protein!complexes.!These!protein!complexes! are! traditionally! made! up! of! at! least! one! enzyme! protein! and! several! non:enzyme!proteins.42!The!proteins!involved!in!these!protein!complexes!are!often!assembled!in! a! combinatorial! manner! with! the! specific! combination! of! proteins! in! the! complex!dictating! the! location,! duration,! and! manner! that! the! enzymatic! activity! is! performed.!Historically,! efforts! have! focused! on! targeting! the! enzymatic! activity! of! these! complexes;!however,!with!more! than! 650,000! estimated! PPIs,! less! than! 0.01%! of! these! interactions!have! been! successfully! targeted! with! small! molecules.43! This! presents! an! incredible!opportunity!and!immense!therapeutic!potential!to!find!additional!inhibitors.!Although!the!idea! of! targeting! protein:protein! interactions! has! been! around! for! several! years,! these!interactions!have!largely!been!classified!as!“undruggable”!due!to!the!challenges!associated!with!targeting!them.44!! In!contrast!with!protein:ligand! interactions,!protein:protein! interactions!are!much!larger! and! lack! surface! topology.! Protein:protein! interactions! occur! over! an! average!surface!area!of!1940!+!760!Å2!and!these!interactions!can!use!a!small!number!of!residues!or!a! large! number! of! residues! to! facilitate! binding.45! Consistent!with! the! range! of! residues!facilitating! binding,! the! affinities! of! these! interactions! can! span! from! picomolar! to!millimolar!affinities.46!The!visual! representation!of! the! ranges!and!affinities! that!protein:protein! interactions! use! can! be! seen! in! Figure! 1.6.! Unsurprisingly,! the! high:affinity,! low!surface!area!interactions!have!been!the!most!successfully!targeted!PPIs.!This!is!largely!due!to! the! fact! that! these! interactions!most!closely!resemble!protein:ligand! interactions,!with!very!few!molecules!targeting!large!surface!area!protein:protein!interactions.!This!is!mostly!
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due!to!the!fact!that!large!surface!areas!tend!to!use!several!residues!to!facilitate!binding!to!its!target!protein.!Additionally,!deciphering!which!residues!contribute!most!to!the!binding!free! energy! of! two! proteins,! more! commonly! known! as! “hot! spots”,! is! not! a! easy! task,!making!small!molecule!discovery!and!design!efforts!immensely!challenging.!47,48!!
!
Figure!1.6!Scope!of!protein2protein!interactions!The!left!panel!is!a!visual!representation!of! the!affinity!and!surface!area!of!various!characterized!protein:protein! interactions.!The!right!panel! illustrates! the!number!of! small!molecule! inhibitors! that!have!been!developed!for!the!various!classes!of!protein:protein!interactions.!!
1.6!Targeting!protein2protein!interactions!
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there! are! often! a! great! number! of! proteins! that! are! dysregulated! in! a! disease,!making! it!difficult!to!initially!target!the!necessary!protein!for!the!desired!biological!effect.!Due! to! both! the! costly! and! timely! endeavor! associated!with! developing! a! drug,! it!would! be! beneficial! to! have! methods! of! speeding! up! the! drug! discovery! process.! By!developing! chemical! probes! targeted! at! a! specific! protein! of! interest,! we! can! afford!ourselves! the! ability! to! investigate! the! cellular! effects! of! inhibiting! a! targeted! protein.54!Although!chemical!probes!are!not!drugs,!we!can!use!these!probes!to!give!us!new!insights!into! the!molecular!mechanism!of!a!disease!on!a! cellular! level!and! in! some!cases,! even! in!animals.55!These!probes!are!not!drugs,!but!they!can!give!us!a!good!idea!of!the!therapeutic!potential!of!developing!a!drug!for!the!targeted!protein.!This!is!due!to!the!ability!of!chemical!probes!to!effectively!mimic!the!function!of!a!drug.!There!are!a!number!of!diseases!that!lack!targeted! drugs! including! some! types! cancers! and! most! neurological! diseases! such! as!Alzheimer’s!and!Parkinson’s!disease.!Using!chemical!probes!in!combination!with!molecular!biology! will! aid! in! speeding! up! the! process! of! future! drug! discovery! efforts! as! well! as!identifying!potential!target!proteins!associated!with!the!disease!state.!
Challenges!of!targeting!PPIs!! Protein:protein! interactions!have! traditionally!been!defined!as! “undruggable”,! this!is! largely!due!to! the! fact! that!many!protein:protein! interactions! lack!well:defined!surface!topology!and!occur!over!large!areas.!56,57!This!is!problematic!because!classic!drug!discovery!efforts!have!focused!on!protein:ligand!interactions,!which!occur!over!small!areas!and!are!often!associated!with!well:defined!binding!sites.!The!features!of!protein:ligand!interactions!make!them!well!suited!for!small!molecule!screening!efforts.!The!compound!libraries!used!to! carry!out! these! screens! are! largely! guided!by!Lipinski’s! rules,!which! are!based!on! the!observation! that! most! orally! administered! drugs! are! relatively! small! and! moderately!lipophilic!molecules.!Unfortunately,!only!a!small!subclass!of!protein:protein!interactions!is!amenable! to! screening!with! these! types!of! small!molecules,! specifically! the! small! surface!area,! tight! affinity! protein:protein! interactions.58! This! is! further! evidenced! by! figure! 1.6,!which!highlights!the!fact!that!over!70%!of!known!inhibitors!of!protein:protein!interactions!target!this!specific!subclass.!!
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Strategies!used!to!target!PPIs!!! Protein:protein! interactions! that! occur!within!protein! complexes! are!mediated!by!specific! contacts! that! are! spatially! arranged! by! the! tertiary! structure! of! the! individual!proteins.! Tertiary! structure! of! proteins! is! facilitated! by! both! “regular”! and! “non:regular”!structures!at!the!interfaces!of!these!PPIs.59!“Regular”!structures!are!classified!as!helical!and!strand!residues,!while!“non:regular”!structures!include!coils,!turns,!and!loops.!Although!the!design! of! inhibitors! can! be! quite! convoluted,! peptides! and! other! peptiomimetics! are!promising!due!to!their!ability!to!directly!mimic!specific!secondary!structure.!β:turns!and!β:strands! have! been! successfully! mimicked! using! diverse! libraries! of! small:molecule! and!peptide! libraries.60! Several! strategies! have! been! developed! to! mimic! α:helices! such! as!amphipathic!chemical!scaffolds,61!as!well!as!several!peptidomimetic!strategies!such!as!side!chain:to:side! chain! crosslinks,62! back! bone:to:side! chain! crosslinks,63! and! back! bone:to:back! bone! crosslinks.64! Other! non:peptidic! scaffolds! have! been! used! as! well,! including!terphenyls!and!macrocycles.65!These!strategies!have!had!varying!degrees!of!success,!but!a!recent!study!on!PPI! interface!structure!using! the!Protein!Data!Bank!(PDB)!demonstrated!that! 26%! of! interface! residues! have! α:helical! structure,! 24%! have! β:strand! secondary!structure,! and! the! remaining! 50%! have! non:regular! secondary! structure,! with! this! last!category!representing!a!tremendous!opportunity!to!develop!new!inhibitors.59!!
Strategies!used!to!target!βEstrand!structure!! Secondary!structures!containing!β:turns!and!β:strands!have!been!targeted!using!a!combination!of!chemical!and!peptidomimetic!strategies!over!the!years.!β:sheets!consist!of!β:strands! that! interact! with! at! least! two! or! three! backbone! hydrogen! bonds! in! either! a!parallel!or!anti:parallel!orientation!and!are!connected!by!β:turns.!Nowick!and!coworkers!pioneered! several! of! the! chemical! strategies! use! to! target! β:sheet! structure! and!interactions.60!Their!early!efforts!consisted!of!synthesis!of!a!diurea!turn,!which!they!termed!“molecular!scaffold”.!This!allowed!for!assembly!of!a!hydrogen:bonded!10:membered!ring,!the!same!as!seen!in!traditional!β:turns.!This!led!to!further!studies!that!indicated!that!this!molecular! scaffold! could! be! used! to! make! artificial! β:sheets.! This! concept! was! further!improved!by!the!addition!of!5:amino:2:methoxybenzoic!acid!amide!into!the!peptide!chain,!allowing!for!enhanced!folding!and!reduced!uncontrolled!intermolecular! interactions.!This!
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also! allowed! for! synthesis! of! a! template! that! better! mimicked! the! pattern! of! hydrogen!bonding! observed! in! β:strands.! In! addition! to! these! peptidomimetic! strategies,! other!chemical! scaffolds! have! been! developed! to! mimic! these! β:sheet! structures.66! The! work!pioneered! by! the!Nowick! lab!was! later! expanded! on! by! Cheng! and! coworkers!who!used!these!methods!to!develop!ABSM!1a,!an!inhibitor!of!Aβ!aggregation!with!an!EC50!<!1!μM.67!Given! the! success! of! these! peptidomimetic! strategies! to! target! β:sheets,! Webb! and!coworkers! later! developed! a! chemical! scaffold! to! mimic! β:sheets.! Webb! and! coworkers!developed! a! chemical! scaffold! based! on! the! Garland:Dean! triangles,! the! connections! of!atoms!that!mimic!the!C:α!atom!positions!in!peptide!β:turns.!They!were!able!to!accomplish!this!through!the!use!of!a!spirocycle!chemical!scaffold!that!contained!four!substituents,!the!same!number!of!substituents!in!a!β:turn.!This!strategy!was!used!to!develop!new!agonists!of!melanocortin!type:4!receptor!(MC4R),!a!G:coupled!receptor,!which!has!an!IC50!of!5.6!μM.68!
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generic spirocycle scaffold for
β-turn mimicry
Compound 26 EC50 = 5.6 µM 
 β-turn mimic agonist of MC4R, a
G-protein coupled receptor
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Chemical!strategies!used!to!target!αEhelices! !In!addition! to! the!development!of!peptidomimetic!and!chemical!strategies!used! to!target!β:sheets,!there!has!also!been!significant!work!done!to!target!α:helices.!These!include!both! chemical! and! peptidomimetic! strategies.! Hamilton! and! coworkers! have! made!significant! contributions! to! targeting! α:helices! with! chemical! scaffolds! through! their!development!of! terphenyl:based! inhibitors.!Hamilton!demonstrated!that!regularly!spaced!terphenyls!with! substituents! located! in! the! ortho! position! of! the! aryl! ring!mimicked! the!spacing! seen! in! α:helices,! specifically! the! spacing! of! the! i,! i+4,! and! i+7! amino! acid! side!groups! in!an!α:helix.! 65,69!This!allowed!for!effective!mimicking!of! the!hydrophobic! face!of!amphipathic!helices!and!although!effective! for! in:vitro!applications,! concerns!about! their!solubility! have! limited! their! use! for! in:cellulo! and! other! in:vivo! applications.! Mapp! and!coworkers!demonstrated!that!isoxazolidines!could!also!be!used!as!mimics!of!amphipathic!helices.! Isoxazolidine!i1!was!developed!as!a!mimic!of!ESX!and!had!a!Ki!of!620!nM!for!the!target!protein!Med23.70!More!recently,!other!chemical!scaffolds!have!been!discovered!as!α:helix!mimics.!In!one!example,!Majmudar!and!coworkers!discovered!sekikaic!acid!in!a!high:throughput! screen! of! the! MLL:KIX! interaction! using! natural! product! extracts.71!Deconvolution!of!the!natural!product!extracts!resulted!in!the!discovery!of!sekikaic!acid,!a!natural! product! derived! from! lichens.! Computational! modeling! of! sekikaic! acid!demonstrated! that! the! lowest! energy! conformation! of! the! molecule! resembles! an!amphipathic!helix,!providing!a!possible!mode!of!action!for!the! inhibitor.!The!discovery!of!sekikaic!acid!suggests!that!other!chemical!scaffolds!may!exist!in!natural!products!that!could!later!be!developed!as!inhibitors!of!α:helices.!!Peptidomimetic!strategies!used!to!α:helices!In! addition! to! the! development! of! α:helix! chemical! scaffolds,! there! has! been!considerable!research!and!development!devoted!to!peptidomimetic!inhibitors!of!α:helices.!Peptoids! have! had! moderate! success! in! mimicking! α:helices,! but! the! sterics:driven!approach! to! inducing! α:helicity! has! limited! their! use.! 72,73! Other! methods! utilizing!peptidomimetics!with! side:chain! to! side:chain,! side:chain! to!backbone,! and!backbone:to:backbone! crosslinks! have! yielded! more! promising! results.! Although! some! of! the! above!strategies!have!employed!using!both! lactams!and!disulfides,! these! functionalities!are!still!susceptible! to! proteolysis! through! lysozymes! and! proteases.! Verdine! pioneered! a! new!
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method! of! peptide! stabilization! utilizing! olefin!metathesis! to! stabilize! α:helix! secondary!structure,!which!he!termed!“peptide!stapling”.74!Verdine!and!coworkers!accomplished!this!“peptide!stapling”!strategy!through!the!incorporation!of!unnatural!olefin:containing!amino!acids! that!were! incorporated! during! solid! phase! peptide! synthesis.75! Once! the! sequence!was!finished,!olefin!cross!metathesis!was!performed!to!yield!a!“stapled!peptide”,!trapping!the!peptide!in!an!α:helical!conformation.!Verdine!and!coworkers!demonstrated!that!these!“staples”! could! be! incorporated! in! a! variety! of! ways,! but! the! constructs! that! utilized! a!“staple”!between! the! i!and! i+4!or! i!and! i+7!position!of!a!peptide!yielded! the!most!helical!constructs,!which!also!led!to!higher!affinity!for!its!target!protein!and!enhanced!protection!from!proteolysis.76!This!strategy!was!utilized!to!develop!a!peptidomimetic!inhibitor!based!on! the! p53! sequence! responsible! for! binding! to! the! masking! protein! MDM2.77!Incorporation!of!a!“staple”!on!the!solvent!exposed!face!of!the!helix!at!the!i!and!i+7!position!resulted! in! a! peptidomimetic! inhibitor! that! was! more! proteolytically! stable! and! had! 8x!greater! affinity! for! MDM2! compared! to! the! unmodified,! wild:type! p53! sequence.! This!“peptide!stapling”!strategy!was!also!applied!to!other!biological!systems!including!BCL:2,78!NOTCH,79!and!even!resulted!in!the!formation!of!the!company!Aileron!Therapeutics,!which!now!has!one!drug!based!on!“stapled!peptide”!technology!in!phase!II!clinical!trials.!Although!“stapled! peptide”! technology! works! well! for! amphipathic! α:helices! with! well:defined!hydrophilic!and!hydrophobic!faces,!it!can!cause!problems!for!interfaces!that!rely!on!amino!acid! side! chains! located! on! the! solvent! exposed! face! for! recognition! and! specificity.80! In!order! to! circumvent! this! problem,! Arora! and! coworkers! have! developed! hydrogen! bond!surrogates! (HBS).81! These! HBS! peptides! utilize! a! side! chain:to:backbone! crosslink! also!utilizing! olefin! metathesis.! The! additional! benefit! afforded! by! HBS! peptides! is! that! they!utilize! only! one! amino! acid! side! chain! to! stabilize! α:helical! formation.! This! is! particular!advantageous! for! systems! that! do! not! allow! for! modification! or! substitution! of! solvent!exposed! residues.! This! strategy! was! utilized! to! develop! an! inhibitor! of! the! p300! CH1!domain!using!an!HBS!of!HIF!1α.63!The!HIF!1α!HBS!was!based!on!the!portion!of!the!sequence!required!for!binding!to!CH1!and!resulted!in!an!inhibitor!with!2x!greater!affinity!for!the!CH1!domain!compared!to!the!unmodified!sequence.!HIF!1α!HBS!was!also!demonstrated!to!have!an!IC50!of!1!μM!against!HIF!1α:mediated!transcription,!whereas!the!unmodified!sequence!had! no! inhibitory! effects! presumably! due! to! proteolytic! degradation.! To! a! lesser! extent,!
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cyclic!peptides!containing!a!backbone:to:backbone!cyclization!have!also!been!identified!as!inhibitors!of!α:helices.!The!natural!product!chlorofusin!was!identified!as!an!inhibitor!of!the!p53:HDM2!interaction,82!however,!development!of!cyclic!peptides!as!inhibitors!of!α:helices!has! been! limited! due! to! the! fact! that! the! spacing! of! the! amino! acid! side! chains! are! not!oriented!in!in!the!correct!3:dimensional!space!to!inhibit!α:helices.!
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Strategies!for!targeting!nonEregular!secondary!structure! !Although! there! has! been! considerable! success!mimicking! the! β:sheet! and! α:helix!secondary! structure,! this! secondary! structure! only! accounts! for! half! of! the! types! of!structure!found!at!protein:protein!interfaces.59!The!Kritzer!group!has!recently!highlighted!the! vast! number! of! “non:regular”! structure! involved! at! the! interface! of! protein:protein!interactions.83!This!non:regular! structure! consists!of! turns,! coils! and! loops.!Furthermore,!Kritzer! et! al.! have! demonstrated! that! several! of! these! non:regular! secondary! structures!exist!within! the!structures!submitted! to! the!PDB.!A!systematic!screen!of! the!PDB!yielded!25,005!non:redundant!loops,!representing!a!large!number!of!possible!sites!for!mimicking!with!chemical!or!peptidomimetic!strategies.!These!interface!loops!were!then!sorted!by!the!presence!and!location!of!hot!spot!residues,!with!hot!spots!defined!as!ΔΔGresidue!>!1!kcal!mol:1.!To!further!refine!this!data,!Kritzer!et!al!identified!“hot!loops”,!which!were!determined!by!identification!of! loops!with!two!consecutive!hot!spots,! loops!with!at! least!three!hot!spots,!and! loops! for! which! the! average! ΔΔGresidue! was! greater! than! 1! kcal! mol:1.! This! further!refinement,! resulted! in! identification!of! 1,407!hot! loops.!Additionally,! the! total! predicted!binding!energy!associated!with!the!hot! loop!was!compared!to!the!total!predicted!binding!energy!of!the!corresponding!interface.!This!examination!revealed!that!36%!of!hot!loops!are!responsible!for!over!half!of!the!predicted!binding!energy!associated!with!an!interface!and!67%!of!hot!loops!are!responsible!for!more!than!a!quarter!of!the!predicted!binding!energy!associated! with! an! interface.! Given! the! substantial! percentage! of! binding! energy!contributed!by!hot!loops,!these!hot!loops!serve!as!ideal!starting!points!for!identifying!new!inhibitors.!
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!
Figure!1.9!Overview!of! PPI! hot! loop! identification!A.!Overview!of!analysis!performed!using! LoopFinder! B.! Example! of! hot! loop! identified! by! LoopFinder! analysis! C.! Peptide!inhibitor!developed!based!on!Nrf2:Keap1!hot!loop.!One!of! the! loops! that!LoopFinder!was!able! to! identify!was!a! β:hairpin! loop! in! the!Nrf2:Keap1!PPI.!The!full! length!interaction!between!Nrf2:Keap1!has!a!Kd!of!5:9!nM84!and!peptides! developed! based! on! this! hot! loop! possessed! a! Kd! of! 115! nM,! similar! to! the! full!length!interaction.! !More!recently,!development!of!macrocyclic!peptides!derived!from!this!loop!have!been!able!to!attain!IC50!values!in!the!15!nM!range.85!In!the!Nrf2:Keap1!example,!LoopFinder!was!able!to!identify!a!hot!loop!that!has!resulted!in!inhibitory!peptides!with!low!nanomolar!affinities!and!validates!other!potential!hot!loops!for!inhibitor!development.!
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surprising!since!transcriptional!activators!initiate!transcription!through!a!complex!series!of!low!affinity!PPIs!with!domains!of!coactivators!that!are!designed!to!accommodate!a!variety!of! non:homologous! activation! domains.! This! suggests! that! there! may! be! a! limit! to! the!affinity! and! biological! activity! that! can! be! achieved! using! small! molecules! or! short!peptidomimetics.!Although!this!selectivity!is!modest!and!prohibits!further!development!of!
i1!as!drug!to!be!used!as!a!single!agent,!i1!can!be!utilized!in!combination!therapy.!Taylor!et!al!demonstrated!how!i1,!an!inhibitor!of!ESX:mediated!erbB2!protein!expression,!and!other!existing!therapeutic!inhibitors!of!erbB2!activity!lead!to!dose!reductions!of!greater!than!15:fold!for!both!agents!and!increased!selectivity!for!erbB2+!cells!up!to!30:fold.86!This!strategy!is!readily!applicable!to!other!systems!and!will!be!highlighted!in!chapter!2.!! The! aberrant! function! of! transcriptional! activators! is! associated! with! human!diseases! such! as! cancer.! Developing! small! molecules! that! can! inhibit! that! ability! of!transcriptional!activators!to!control!target!gene!expression!have!immense!potential!as!both!biochemical! tools! and! therapeutics.! One! of! the! challenges! of! targeting! the! interactions!between!transcriptional!activators!and!the!transcriptional!machinery!proteins!is!that!these!interactions!are!transient,!their!affinities!are!modest!(high!nanomolar!to!low!micromolar),!and!often!bind!over!large!surface!areas.!Traditional!small!molecules!are!not!well!suited!for!screening!against!these!interactions!due!to!their!development!for!small!surface!area,!high!affinity! PPIs.! One! strategy! that! has! had! some! success! for! targeting! these! types! of!interactions!has!been!screening!against!natural!product!extracts.!A!screen!against!the!MLL:KIX!interaction!identified!sekikaic!acid!and!lobaric!acid,!a!depside!and!depsidone!isolated!from! lichens.! Molecular! dynamics! modeling! of! these! molecules! demonstrated! that! the!lowest!energy!conformation!resembled!an!amphipathic!α:helix,!providing!a!possible!mode!of!action!for!these!depside!and!depsidone!inhibitors.!In!chapter!3!we!will!show!how!a!high:throughput!screen!of!the!Med25:VP16!interaction!using!natural!product!extracts!can!yield!additional!amphipathic!molecules!capable!of!inhibiting!this!PPI.!! Given! the! importance! of! “non:regular”! secondary! structure! at! the! interface! of!protein:protein! interactions,! macrocycles! and! cyclic! peptides! have! garnered! renewed!interest!as!potential! therapeutics.!There!are! several!efforts!ongoing! in!both! industry!and!academia! for! identifying! new! macrocycles! and! cyclic! peptides;! however,! these! two!scaffolds!are!unlikely!to!be!able!to!target!all!possible!hot!loop!types!at!PPIs.!Given!the!need!
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2.1!Abstract!The!epithelial!growth! factor!receptor! (EGFR)! is!elevated! in!90%!of!head!and!neck!squamous! cell! carcinoma! (HNSCC),! yet! the! majority! of! patients! do! not! respond! to! anti:EGFR! therapeutics.! The! possible! modes! of! mechanism! for! this! insensitivity! to! EGFR!inhibitors!could!be!due!to!kinase:independent!actions!of!EGFR!and/or!activation!of!Her2.!Therapies! that! utilize! strategies! capable! of! reducing! levels! of! EGFR! and! Her2! in!combination! with! anti:EGFR! therapeutics! could! enhance! the! efficacy! of! the! current!therapeutics.! In! this! chapter,! we! show! that! knockdown! of! the! transcription! factor!epithelial:restricted! with! serine! box! (ESX)! decreased! EGFR! and! Her2! promoter! activity,!expression! and! protein! levels.! Additionally,! ESX! levels! were! elevated! in! primary! HNSCC!tumors! and! associated! with! the! increased! EGFR! and! Her2! levels! seen! in! these! primary!tumors.! Knockdown! of! ESX! using! shRNA! enhanced! the! effects! of! EGFR/Her2! tyrosine!kinase!inhibitors!(TKI)!lapatinib!and!afatanib.!Biphenyl!isoxazolidine!(i1),!a!small!molecule!inhibitor!of!ESX!transcription,!was!able!to!reduce!EGFR!and!Her2!levels!and!enhanced!the!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*! The! research! described! in! chapter! 2! is! a! collaborative! effect.! P.A.! Bruno! performed!synthesis,!purification,!characterization,!and!validation!of!inhibitor!of!i1.!M.!Zhang,!L.!Piao,!J.! Datta,! S.! Bhave,! T.! Su,! J.C.! Lang,! X.! Xi,! and! T.N.! Teknos! performed! cellular! assays,!immunohistochemical!analysis,!gene!expression!analysis,!and!murine!in!vivo!studies.!Parts!of!this!chapter!are!reproduce!in!Zhang,!M.;!Taylor,!C.!E.;!Longzhou,!P.;!Datta,!J.;!Bruno,!P.!A.;!Bhave,!S.;!Tizhi,!S.;!Lang,!J.!C.;!Xie,!X.;!Teknos,!T.!N.;!Mapp,!A.!K.;!Pan,!Q.!Genetic!and!Chemical!Targeting!of!Epithelial:Restricted!with!Serine!Box!Reduces!EGF!Receptor!and!Potentiates!the!Efficacy!of!Afatinib.!Mol.!Cancer!Ther.!2013,!12,!1515:1525.!!
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efficacy!of!afatinib!when!used!in!combination.!When!i1!was!used!as!a!single!agent,! it!was!able!to!reduce!tumorigenicity!of!HNSCC!cells,!but!more!importantly,!when!i1!was!used!in!combination!with!afatinib,! the! combination!was! superior! to! the! single! agents! in!vivo! and!resulted!in!a!100%!response!rate!with!a!94%!reduction!in!tumor!volume.!
!
2.2!Introduction!! Over! 600,000! cases! of! head! and! neck! squamous! cell! carcinoma! (HNSCC)! are!identified! globally! each! year,! making! HNSCC! the! sixth! most! abundant! cancer.1! The!predominant! phenotype! of! HNSCC! is! dysregulation! of! epithelial! growth! factor! receptor!(EGFR),!specifically!overexpression!of!EGFR.!HNSCC!patients!with!overexpression!of!EGFR!are! associated! with! inferior! clinical! outcomes.! Although! the! predominant! phenotype! of!HNSCC!is!overexpression!of!EGFR,!only!5:15%!of!patients!respond!to!anti:EGFR!therapy.2!This!suggests!that!inhibiting!EGFR!activity!and/or!downstream!signaling!is!insufficient!for!clinical! response.! One! possibility! for! this! low! response! rate! could! be! due! to! kinase:independent!actions!of!EGFR.3!It!has!been!demonstrated!that!EGFR!can!translocate!to!the!nucleus! to! regulate! genes! associated! with! cellular! proliferation! and! survival.4! An!alternative!mechanism!for!the!lack!of!response!rate!from!anti:EGFR!therapy!could!be!due!to!a!compensatory!mechanism!where!EGFR!family!members!Her2!and!Her3!are!activated.5!! The! ETS! transcription! factor! family! is! largely! responsible! for! regulation! of! genes!involved! in! angiogenesis,! invasion,! and! proliferation.6! One! of! the! family!members! of! the!ETS! transcription! factor! family,! epithelial:restricted!with! serine! box! (ESX),! is! exclusively!expressed!in!differentiated!epithelial!cells,!further!suggesting!the!importance!of!ESX!in!the!control! of! cellular! differentiation.7! ESX! overexpression! is! a! common! phenotype! seen! in!breast!cancer,!specifically!the!correlation!of!overexpression!of!ESX!with!overexpression!of!Her2.8! Furthermore,! the! association! of! ESX! overexpression! with! activation! and!overexpression! of!Her2! has! been! demonstrated! in! several! studies.9! This! association!was!further! complicated! by! the! fact! that! Her2! was! found! to! enhance! ESX! promoter! activity,!presenting! a! two:pronged!problem.10! Therefore,! these! findings! suggest! that! this! positive!ESX/Her2!feedback!loop!may!be!critical!for!tumorigenesis.!!!
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CHALLENGES!ASSOCIATED!WITH!USING!SINGLE!AGENT!THERAPIES!! As! noted! in! Chapter! 1,! protein:protein! interactions! in! the! large! surface! area,! low!affinity! regime! are! particularly! difficult! to! target! for! inhibition.11! The! transient! and! low!affinity! interactions!between!transcriptional!activators!and!the! transcriptional!machinery!often!leads!to!development!or!discovery!of!small!molecules!that!have!similar!affinities.!This!results!in!having!to!use!high!effective!concentrations!of!the!molecule!for!the!desired!effect.!Additional! problems! with! specificity! can! also! arise! when! targeting! large! surface! area!protein:protein!interactions.!In!the!case!of!small!molecule!inhibitors,!the!small!surface!area!associated!with!some! inhibitors!cannot!completely! inhibit! the!protein:protein! interaction!of! interest,! causing! an! incomplete! phenotypic! response.! Furthermore,! the! low! affinity! of!these!inhibitors!can!make!them!promiscuous,!causing!off:target!effects!with!other!protein:protein! interactions! necessary! for! cellular! function.! Furthermore,! these! inhibitors! are!designed! to!mimic! a! peptide!motif! that! itself! is! a! promiscuous! binder! and! therefore,!we!cannot!expect!a!TAD!mimic!to!have!a!more!selective!binding!profile!that!the!TAD!itself.12!!! Selectivity! is! not! the! only! concern! for! developing! single! agent! therapies! for! the!protein! of! interest.! Whereas! inhibitors! developed! for! large! surface! area,! low! affinity!protein:protein! interactions! can! lack! affinity! and! specificity;! kinase! inhibitors! can! be!developed!with!high!affinity!and!good!selectivity.! 13,14!Kinases!possess!enzymatic!activity!and! are! traditionally! defined! by! a! binding! interface! with! a! small! surface! area! and! high!affinity!for!its!substrate.!As!a!result,!both!industry!and!academia!has!had!success!targeting!these! proteins! and! developing! drugs! against! them.! ! One! of! the! issues! that! can! severely!affect!the!affinity!of!these!inhibitors!is!when!mutations!occur!in!the!target!protein.15!These!mutations!can!cause!misfolding!or!structural!shifts!in!the!protein,!causing!these!inhibitors!to!no!longer!bind!as!well!or!to!lose!the!ability!to!bind!completely.16!The!combination!of!the!factors!noted!above!ultimately!result!in!drug!resistance.!!COMBINATION!THERAPY!! One! of! the!ways! to! counter! the! effects! of! inhibitors!with! low! affinity! and!modest!selectivity! or! inhibitors! that! have! a! tendency! to! be! rendered! ineffective! due! to! drug!resistance,!is!to!utilize!combinations!of!two!or!more!drugs.17!These!combinations!can!result!in!an!antagonistic,!additive,!or!synergistic!effect!with!the!last!being!the!effect!with!the!most!
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efficacious! clinical! outcomes.18! As! a! result! of! identifying! a! combination! with! synergistic!effects,! a! lower!effective! concentration!can!be!used! for!both! single!agents!and!ultimately!leads! to! less! off:target! effects.19! These! combination! therapies! have! had! considerable!success,! particularly! against! breast! cancer.! In! one! study,! the! response! rate! between!carboplatin! (DNA! alkylating! agent)! as! a! single! agent! was! compared! to! carboplatin! in!combination!with! trastuzumab!(Her2!monoclonal!antibody)!against!Her2+!breast! cancer.!When! using! carboplatin! as! a! single! agent,! the! response! rate! was! 32%! compared! to! the!carboplatin/trastuzumab! combination! that! yielded! a! response! rate! of! 50%.20! Although!most! combination! therapies! have! focused! on! DNA! alkylating! molecules! and! antibodies,!herein!chapter!2!we!will!describe!how!the!protein:protein! interaction!inhibitor!i1!can!be!used! with! kinase! inhibitors! to! develop! combination! therapies! that! are! more! efficacious!than!either!of!the!inhibitors!as!single!agents.!!
i1!AS!AN!INHIBITOR!OF!HER2+!BREAST!CANCER!CELLS!
Her2!phenotype!and!upregulation!through!ESXEMed23!interaction!! Her2! (neu/ErbB2)! is! a!member!of! the! epidermal! growth! factor! receptor! family!of!extracellular! receptors.21! Her2! has! gained! considerable! attention! due! to! its! use! as! a!biomarker!for!breast!cancer.22!Amplification!or!overexpression!of!Her2!plays!a!key!role!in!the! progression! and! metastatic! potential! of! breast! cancer! with! overexpression! of! Her2!found! in! approximately! 30%! of! breast! cancers.23! Trastuzumab,! an! antibody! developed!against! the! Her2! protein,! has! had! considerable! clinical! success! against! Her2+! breast!cancer.24!This!clinical!success!further!highlights!the!importance!of!Her2!in!the!progression!and!metastatic! potential! of! breast! cancer.! Given! the! importance! of! this! protein! in! breast!cancer,! other! strategies! that! led! to! down:regulation! of! Her2! protein! levels! would! have!therapeutic! potential.! One! of! the! possible! ways! to! down:regulate! Her2! levels! would! be!directly! inhibiting! the! expression! of! the!Her2! gene.! One! of! the! transcriptional! activators!that! has! been! demonstrated! to! control! Her2! gene! expression! is! the! epithelial:restricted!with! serine!box! (ESX)! transcriptional! activator.9!ESX! is! expressed! solely! in!differentiated!epithelial!cells,!particularly!mammary!tissue.!Previous!studies!have!demonstrated!that!ESX!strongly!activates!the!Her2!gene!and!that!the!ESX!promoter!site!is!required!for!high:level!expression! of! Her2! expression.25! There! also! exists! a! correlation! between! ESX! and! Her2!
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levels! in! breast! cancer,! suggesting! a! positive! feedback! loop! involved! between! the! two!proteins.10!ESX!also!has!a! strong! transcriptional!activation!domain! that!displayed!similar!potency!to!the!viral!transcriptional!activator!VP16.26!Asada!and!coworkers!demonstrated!a!strong! affinity! for! the! 130! kDa! mediator! protein! Med23! (CRSP3/DRIP130/Sur2)! when!performing! pull:downs! with! GST! appended! with! the! 17! amino! acid! ESX! transcriptional!activation! domain! and!HeLa! nuclear! extracts.9! In! their! studies,!Med23! had! no! affinity! in!pull:downs!using!analogous!transcriptional!activation!domains!from!NF:κB!p65,!ALL1,!and!C/EBPβ,! suggesting! that! Med23! binds! specifically! to! the! transcriptional! activator! ESX.!Asada!and!coworkers!went!on! to!demonstrate! that! the! subdomain!of!Med23!responsible!for!binding!to!the!ESX!transcriptional!activation!domain!was!the!Med23352:625!subdomain.!Overexpression! of!Med23352:625! inhibited! the! ability! of! the! ESX! transcriptional! activation!domain! to! activate! transcriptional! activity,! while! it! did! not! inhibit! the! transcriptional!activation! domains! of! NF:κB! p65,! ALL1,! and! C/EBPβ.! Furthermore,! dosing!Her2+! breast!cancer!cells!with!a!cell:penetrating!peptide!appended!to!the!ESX!transcriptional!activation!domain! resulted! in! downregulation! of! Her2! protein! levels,! suggesting! that! targeting! the!ESX:Med23!complex!could!have!therapeutic!potential.!
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i1!as!an!amphipathic!helix!mimetic!of!ESX!Asada! and! coworkers! performed! mutational! analysis! on! the! ESX! transcriptional!activation! subdomain! to! determine! the! importance! of! individual! residues! on! binding! to!Med23.!From!these!studies,!Asada!and!coworkers!were!able!to!determine!that!the!sequence!required! for! Med23! could! be! localized! to! residues! ESX135:144.! Additionally,! they!demonstrated!the!critical!importance!of!Trp138!for!binding!to!Med23!since!substitutions!to!Phe,!Leu,!and!Ala!resulted!in!complete! loss!of!ESX!binding!to!Med23.!The!results!of!these!experiments!are!summarized!in!Table!2.1.!
Table! 2.1!Analysis! of! the! ESX!TAD!A.!Truncation!studies!on!the!ESX!TAD!to!determine!minimal! sequence! required! for!Med23! binding! B.! Mutational! analysis! of! ESX! TAD! using!alanine!scanning!to!determine!important!residues!
!!Lee!and!coworkers!synthesized!several!isoxazolidines!to!investigate!the!effects!that!these!molecules!would!have!on!ESX:Med23!binding.27!In!Figure!2.2!A,!the!general!notation!is!presented!for!the!isoxazolidine!ring.!Although!the!synthesis!of!these!isoxazolidines!is!not!convergent,!but! rather! iterative,!many!of! the! same! intermediates! can!be!used! to!develop!several! other! derivatives.! Using! this! synthetic! strategy,! Lee! and! coworkers!were! able! to!synthesize!several!analogs!using!the!isoxazolidine!scaffold.!The!general!synthetic!strategy!involves!a!1,3:dipolar! cycloaddition! to!generate! the! isoxazoline! ring.!The!use!of!different!
ESX$TAD$Sequence$ Med23$Binding$
129TSSSSDELSWIIELLEK145 +$
     134DELSWIIELLEK145 +$
          139IIELLEK145 5$
      135ELSWIIELLEK145 +$
       136LSWIIELLEK145 +$
        137SWIIELLEK145 +$
         138WIIELLEK145 5$
        137SWIIELLE144 +$
















oximes! and! alkenes! determines! the! functionality! at! C3! and! C5,! respectively.! The! other!substituents! are! installed! in! the! isoxazolidine! ring! through! nucleophilic! addition! at! C3!followed! by! substitution! at! N2! using! a! reductive! amination! or! direct! N! alkylation! to!generate!isoxazolidine!derivatives!(Figure!2.2).!!
!
Figure! 2.2! Notation! of! isoxazolidine! and! general! synthetic! scheme! The! general!synthetic! scheme! of! isozolidines! involves! a! 1,3:dipolar! cycloaddition,! followed! by!nucleophilic!addition!at!C3!and!finally!substitution!at!N2.!Lee!and!coworkers!developed!a!series!of!tryptophan!mimics!based!on!experiments!demonstrated!by!Asada!and!coworkers!that!identified!tryptophan!as!a!key!residue!for!the!ESX:Med23! interaction.! The! isoxazolidines! synthesized! by! Lee! and! coworkers! were!modified!at! the!N2!position!with! substituents!designed! to!mimic! the! functionality!of!Trp!138!in!the!ESX!TAD.!
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From! the! studies! performed! by! Lee! and! coworkers,! i1! was! the! most! active!isoxazolidine! tested.! Although! substituents! substituted! with! a! nitrogen! N2! aromatic!functional!group!such!as!an!indole!would!be!more!obvious!indole!mimics,!these!compounds!were!less!active!owing!mostly!to!the!reduced!stability!of!the!compounds!due!to!the!redox!sensitive! nature! of! the! indole! functional! group.! Work! by! Lee! and! coworkers! also!demonstrated! that! positional! isomers! of! i1!were! not! as! effective,! suggesting! the! relative!position!of! the!substituents! is! important! for! inhibition.!This! is! further!demonstrated!by!a!crystal! structure! of! i1! that! demonstrates! that! the! position! of! the! substituents! closely!mimics!the!spatial!arrangement!of!side!chains!in!an!α:helix.!This!suggests!that!i1!not!only!acts! as! a! tryptophan!mimic,! but! could! also! be! acting! as! a! helix!mimetic! as! suggested! by!experiments!with!the!positional!isomers!and!crystal!structure!of!i1.!
!
Figure!2.4!Isoxazolidine!i1!designed!as!a!tryptophan!mimic!and!helix!mimetic!A.!3D!respresentation!of!the!ESX!TAD!with!the!relative!distances!between!i,!i+1,!and!i+4!residues!on!the!ESX!TAD!hydrophobic!face.!B.!Isoxazolidine!i1!and!the!distance!between!the!N2!and!C3!substituent.!The!hydroxyl!substituent!on!C3!positions!i1!for!binding!to!Med23.!











i1!is!and!inhibitor!of!the!ESX:Med23!protein:protein!interaction.!Isoxazolidine!i1!reduced!Her2!mRNA!and!protein!levels,!indicating!that!this!molecule!can!inhibit!the!ability!of!ESX!to!activate!the!target!gene!Her2.!However,!i1!requires!micromolar!concentrations!to!exert!its!cellular! effects.! This! is! likely! due! to! a! lack! of! complete! inhibition! of! the! ESX:Med23!interaction!due!to!its!large!surface!area!and!possible!off:target!effects!of!i1!at!micromolar!concentrations.!! Taylor!and!coworkers! followed!up!on!the! initial!studies!of! i1! that! investigated!the!ability! of! i1! to! be! used! in! a! multi:pronged! intervention! approach! against! Her2!overexpressing!breast!cancer!cells.!This!study!was!carried!out! in!order! to! investigate! the!ability! of! a! multi:pronged! approach! to! mitigate! the! potency! and! selectivity! concerns!associated!with! i1!as!a!single!agent! inhibitor.17! Isoxazolidine! i1!was!used! in!combination!with! three!other! agents! (lapatinib,! efatinib,! and!geldanymicin)! that! target! cellular! events!related! to! Her2! activity! such! as! protein! folding! or! receptor! dimerization! required! for!downstream! signaling.! Two! of! these! combinations! exhibited! synergistic! increase! to!potency!and! selectivity,! leading! to!an!overall!decrease! in! the!dose!of!both!agents.! In!one!example,!i1!and!geldanamycin!allowed!for!dose!reductions!of!greater!than!15:fold!for!both!agents! and! increased! selectivity! for! Her2+! cells! by! as!much! as! 30:fold! compared! to! the!individual!agents,!suggesting!that!combination!approaches!have!therapeutic!potential.!!
2.3!Results!and!Discussion!
i1! AND! AFATINIB! COMBINATION! IN! HEAD! AND! NECK! SQUAMOUS! CELL! CARCINOMA!(HNSCC)!! Several!types!of!breast!cancer!possess!a!phenotype!characterized!by!overexpression!of!one!of! the!EGFR! family!members.28!The!emergence!of! targeting!EGFR! family!members!through!the!use!of!monoclonal!antibodies!and!small!molecules!inhibitors!of!these!kinases!has! provided! several! effective! therapeutic! strategies! for! breast! cancer! patients.! These!therapies!have!resulted!in!high!response!rates!and!increased!survival!rates!for!patients.!It!has! been! demonstrated! that! HNSCC! also! displays! a! similar! phenotype! characterized! by!overexpression!of!EGFR.2!Given!the!success!that!these!anti:EGFR!family!member!therapies!
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have!had!against!several!types!of!breast!cancer,!it!seems!intuitive!that!these!effects!should!also! translate! to! HNSCC;! however,! this! has! not! been! the! case.! Only! 5:15%! of! HNSCC!patients!respond!to!anti:EGFR!therapies!and!this!is!in!contrast!to!the!response!rates!seen!in!breast!cancer,!which!tend!to!be!much!higher.!This!lack!of!response!to!anti:EGFR!therapies!could!be!due!to!kinase:independent!actions!of!EGFR3!or!due!to!compensatory!mechanisms!involving!activation!of!Her2!or!Her3.5!
!
Investigating!the!connection!between!ESX,!Her2,!and!EGFR!in!HNSCC!! In!order!to!assess!the!relative!levels!of!ESX,!Her2,!and!EGFR!in!HNSCC,!the!relative!levels!of!each!protein!were!compared!for!HNSCC!cell!lines!SCC15,!SCC25,!and!CAL27,!using!oral!epithelial!cells!(NOEs)!as!a!baseline!negative!control.!This!analysis!demonstrated!that!HNSCCs!possess!increased!protein!levels!of!ESX,!Her2,!and!EGFR!compared!to!NOEs!(Figure!2.5A).!In!order!to!investigate!the!relationship!between!ESX!expression!on!EGFR!and!Her2!protein! levels,! an! ESX:deficient! CAL27! cell! line!was! generated! using! shRNA! against! ESX.!This! experiment! demonstrated! that! reduced! ESX! translated! to! decreased! levels! of! both!Her2! and! EGFR! (Figure! 2.5B).! This! was! further! validated! at! the! mRNA! level,! in! which!decreased! EGFR! and!Her2!mRNA! expression!was! observed(Figure! 2.5C),! suggesting! that!ESX! has! a! direct! role! in! transcriptional! control! of! EGFR! and!Her2! in!HNSCCs.! Luciferase!driven! reporters! containing! either! the! Her2! or! EGFR! promoter! site! further! corroborate!these! findings.!When! CAL27/shRNA:control! or! CAL27/shRNA:ESX! cells!were! transiently!transfected!with! an!EGFR!or!Her2:promoter! luciferase! reporter,! significantly! lower!Her2!and! EGFR! promoter! activity!was! observed! in! ESX! deficient! cells! (Figure! 2.5D).! Next,!we!sought!to!determine!whether!ESX!is!associated!with!increased!Her2!and!EGFR!in!primary!tumors!from!previously!untreated!patients!with!HNSCC.!Using!this!data,!patients!were!split!into!two!groups:!low!ESX!and!high!ESX.!The!high:ESX!group!had!an!11:fold!increase!in!ESX!expression!compared!to!the!low:ESX!HNSCC!patients!(Figure!2.5E).!This!also!corresponded!to!a!93%!increase!in!EGFR!expression!and!an!83%!increase!in!Her2!expression!for!the!high:ESX!patients.!Together,!these!results!suggest!that!there!is!a!significant!correlation!with!ESX!and!EGFR!in!addition!to!ESX!and!Her2!(Figure!2.5F).!!! Given!the!connection!between!ESX,!EGFR,!and!Her2!in!cells,!we!next!examined!the!role!of!ESX!on!the!tumorigenicity!of!HNSCC!cells!in!vitro!and!in!vivo.!Experiments!designed!
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to! look!at!HNSCC!cell!proliferation!demonstrated! the! importance!of!ESX!expression,!with!CAL27/shRNA:ESX! cells! experiencing! a! 42%! decrease! in! cell! proliferation! compared! to!CAL27/shRNA:control! cells! (Figure!2.6A).!These! results! also! correlate! to! results! from!an!invasion!assay,!in!which!displayed!a!67%!reduction!in!cellular!invasion!(Figure!2.6B).!With!the! observed! effects! that! ESX! has! on! cellular! proliferation! and! invasion,! we! sought! to!determine! the! effect! that! silenced!ESX!would! have! on! cellular!migration.!Wound!healing!assays! performed!with! CAL27/shRNA:ESX! cells! compared! to! CAL27/shRNA:control! cells!displayed!reduced!migration!(Figure!2.6C).!
!
Figure! 2.5! ESX! regulates! EGFR! and!Her2! in!HNSCC!Performed!by! the!Pan! lab.!A,!ESX,!EGFR,!and!Her2!levels!in!HNSCC!cells.!ESX,!EGFR,!and!Her2!protein!levels!were!determined!by! immunoblot! analyses.! B,! generation! of! ESX:deficient! CAL27! cells.! CAL27! cells! were!transduced! with! shRNA:control! or! shRNA:ESX! and! selected! in! antibiotics! to! generate!polyclonal! CAL27/shRNA:control! and! CAL27/shRNA:ESX! cells.! ESX,! EGFR,! and! Her2!
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Figure! 2.6! Genetic! ablation! of! ESX! reduces! EGFR! and! Her2! levels! and! inhibits!
tumorigenicity! in!vitro! and! in!vivo.!Performed!by! the!Pan! lab.!A,!cell!proliferation.!Cell!proliferation! was! assessed! using! the! CCK:8! reagent! to! detect! metabolically! active! cells.!Data!are!presented!as!mean!!±!SEM.!*,!P!<!0.005;!n!=!3.!B,!cell!invasion.!Invasive!cells!were!visualized! with! fluorescence! microscopy.! A! representative! field! for! each! experimental!condition! is! presented.! Data! are! presented! as! mean! ±! SEM.!*,! P! <! 0.01;! n! =! 5.! C,! cell!migration.! Cell! migration! was! determined! using! the! wound:healing! assay.! Confluent!monolayers!were!scratched!using!a!sterile!pipette!tip,!washed,!and!incubated!in!complete!medium.! A! representative! field! for! each! experimental! condition! at! 0! and! 24! hours! is!presented.!Bar,!150!mm.!Percentage!of!cleared!area!is!calculated!and!presented!as!mean!±!SEM.!*,!P!<!0.01;!n!=!3.!D,!tumor!volume.!CAL27/shRNA:control!or!CAL27/shRNA:ESX!cells!(1x106!cells)!were!implanted!into!the!flanks!of!athymic!nude!mice.!Tumors!were!measured!using!a!digital!caliper!and!tumor!volumes!were!calculated.!Data!are!presented!as!mean!±!SEM.! *! ,! P! <! 0.01;! n! =! 7.! E,! representative! tumors.! Five! largest! tumors! originated! from!
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cells! were! treated!with! lapatinib! or! afatinib! at! various! concentrations.! Cell! proliferation!was!assessed!using!the!CCK:8!reagent!to!detect!metabolically!active!cells.!Dose–!response!curves!and!IC50!values!were!generated!using!GraphPad!Prism!4.0.!C,!clonogenic!survival.!CAL27/shRNA:control,! CAL27/! shRNA:ESX,! SCC15/shRNA:! control,! and! SCC15/shRNA:ESX! cells!were! treated!with! lapatinib!or! afatinib! at! the! IC50!dose.! Colonies!were! stained!with! crystal! violet.!Data! are!normalized! to! shRNA:control/vehicle! cells! and!presented! as!mean!±!SEM.!*,!P!<!0.01,!shRNA:control!versus!shRNA:ESX!for!vehicle,!lapatinib,!or!afatinib;!*,! P! <! 0.01,! shRNA:control/vehicle! versus! shRNA:control/lapatinib! or! shRNA:control/afatinib,!n!=!3.!Reproduced!from!Zhang,!M!et!al.!Mol!Cancer!Ther!2013,!12,!1515:1525.!
Modified!and!optimized!synthesis!of!i1!! We!decided!based!on!the!promising!results! from!the!above!studies! that!we!would!investigate! the! possible! inhibition! effects! of! using! chemical! targeting! of! ESX.! In! order! to!investigate! the! possible! effects! of! chemically! targeting! ESX,! we! decided! to! use! inhibitor!
i1(mESX),! the! molecule! that! was! noted! upon! earlier.! Inhibitor! i1! was! previously!demonstrated! to! be! an! inhibitor! of! ESX,! leading! to! downregulation! of! Her2.! Taylor! and!coworkers!followed!up!on!this!work!to!demonstrate!that!combination!studies!with!i1!and!other! inhibitors! involved! in! the! Her2! activation! pathway! could! enhance! potency! and!selectivity.!Based!on!these!observations,!we!hypothesized!that!i1!could!have!similar!effects!in! HNSCC.! This! would! include! both! cellular! studies! and! in! vivo! mouse! studies! requiring!scale:up!and!optimized!synthesis!of! i1.!The!optimized!synthetic! scheme!used! to!produce!gram!quantities!of!i1!is!depicted!in!Figure!2.8.!!
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Figure! 2.8! Optimized! synthesis! of! i1(mESX)! Performed!by!Paul!Bruno.!The!optimized!synthetic! scheme! used! to! scale:up! synthesis! of! i1.! Steps! were! followed! as! previously!reported,!steps!were!optimized!for!synthesis!of!il25!to!i1.!
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followed!by!deprotection!of! the!TBS!protecting!group!using!tetrabutylammonium!(TBAF)!to! yield! i126! with! a! yield! of! 46%.! Optimization! of! the! reaction! consisted! of! trying! to!perform! the! N2! functionalization! using! a! reductive! amination,! but! these! efforts! proved!unsuccessful.! The! reductive! amination! was! sluggish! (>24! hours! for! completion)! and! a!competing! reduction! of! biphenyl:4:carboxaldehyde! to! biphenyl:4:methanol!made! it! very!difficult! to! separate! from! the!desired!product! due! to! similar! polarity.! Furthermore,! after!deprotection!of!the!TBS!protecting!group,!the!yield!of!this!reaction!over!these!three!steps!never!exceeded!35%.!Based!on!these!results,!we!attempted!another!alkylation!reaction!by!deprotonating!N2!to!increase!nucleophilicity.!This!was!accomplished!by!deprotonating!the!amine!using!nBuLi,!!followed!by!!addition!of!4:(bromomethyl)biphenyl,!and!deprotection!of!the!TBS!protecting!group!using!TBAF.!This! route!was!able! to!obtain!a!yield!of!63%!over!three! steps! and! had! the! added! benefit! of! reducing! the! equivalents! of! 4:(bromomethyl)biphenyl!from!5!equivalents!to!2!equivalents!when!compared!to!the!original!published!microwave!reaction.!! The!synthetic!step!from! i126! to! i127! involves!conversion!of! the!primary!alcohol!at!C5!to!an!azide.!The!original!published!synthesis!converted!the!alcohol!to!the!mesylate!and!followed! by! displacement! with! sodium! azide,! but! these! reaction! conditions! produced! a!yield!of!48%.!In!the!optimized!reaction,!the!primary!alcohol!was!concerted!to!the!nosylate.!This!was!done!since!the!nosylate!is!a!better!leaving!group!compared!to!the!mesylate!and!is!typically! more! easily! displaced! by! the! azide.! By! converting! the! alcohol! to! the! nosylate!instead!of!the!mesylate,!the!number!of!equivalents!of!sodium!azide!was!reduced!from!10!to!2! and! the! reaction!mixture! only! needed! to! be! heated! to! 40°! C! compared! to! the! original!synthetic!route!which!required!80°!C!to!drive!reaction!to!completion.!This!was!particularly!important! since! synthesis! of! this! intermediate! on! gram! scale!would! have! required! large!amount!of!sodium!azide,!an!explosive!material.!The!optimization!of!this!step!resulted!in!a!yield!of!85%!compared!to!the!original!published!yield!of!48%.!!! The! last! synthetic! step! that! was! optimized! was! the! dihydroxylation! of! i127.! The!original! published! synthesis! of! this! molecule! performed! the! dihydroxylation! using! 10!mol%!of!osmium!tetroxide!and!required!6:12!hours!before!reaching!completion.!In!order!to!optimize!this!step,!we!used!a!citric!acid:catalyzed!dihydroxylation!of!i127.!This!citric!acid!catalyzed!dihydroxylation!is!based!on!methodology!developed!by!the!Sharpless!lab.29!This!
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allowed! for! a! reduction! in! the! osmium! tetroxide! used! to! only! 1!mol%,! Additionally,! the!reaction!was!consistently!finished!after!30!minutes,!a!significant!improvement!over!the!6:12!hour!reaction!originally!published.!
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cells!Performed!by!Paul!Bruno.!SkBr3!or! IMR90!cells!were!plated!at!a!density!of!3!x!103!cells!per!well!in!a!96:well!format.!Cells!were!left!to!adhere!overnight.!Media!was!removed!and!cells!were!dosed!with!varying!concentrations!of! i1.!Cells!were! left! to! incubate! in! the!presence!of!media!containing!molecule!of!vehicle!for!a!total!48!hours.!Media!was!replaced!with! fresh! compound! of! vehicle! after! 24! hours.! After! 48! hours,! added! WST:1! viability!reagent!to!each!well!and!let!incubate!for!3!hours!before!reading!the!plate!at!440!nm!using!a!microplate!reader.!Data!curves!were!fit!using!GraphPad!4.0!to!determine!IC50s.!
Chemical!targeting!of!EGFR!and!Her2!using!i1(mESX)!in!HNSCC!! As! mentioned! earlier,! based! on! the! promising! effects! we! observed! with! genetic!ablation!of!ESX! in!HNSCC,!we!sought! to!determine! if!we!could!chemically! target!ESX!and!observe! the! same! effects! both! in! cellular!models! and! an! in!vivo! clinical!mouse!model! of!HNSCC.! In! order! to! carry! out! the! following! studies,!we!had! to! optimize! and! scale! up! the!synthesis!of!i1!to!finished!all!the!required!experiments.!These!efforts!produced!1.4!g!of!the!purified!compound.!When!i1!was!used!to!treat!HNSCC!cells,!similar!effects!were!seen!with!small!molecule! inhibition! as! compared! to! ESX! knockdown! in!HNSCC! cells.! ! Isoxazolidine!
i1(mESX)!was!able! to!decrease!protein! levels!of!EGFR!and!Her2!at!concentrations! lower!than! the! cellular! proliferation! IC50! for! CAL27! cells! (Figure! 2.11B:C).! Isoxazolidine!
i1(mESX)!also!did!not!show!any!viability!effects!against!IMR90!cells!after!incubating!with!molecule! for! 24!hours! (Figure!2.11D).! Furthermore,! treating!CAL27! cells!with! i1(mESX)!
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also!resulted! in!decreased! invasion!and!migration!of!CAL27!cells! (Figure!2.11E:F).!These!results! were! encouraging! since! they! closely! mirrored! the! effects! of! ESK! knockdown! in!CAL27!cells,!suggesting!that!ESX!activity!can!be!chemically!targeted!using!i1(mESX).!!
!
Figure!2.11! i1(mESX)! reduces!EGFR!and!Her2! levels! and! inhibits! tumorigenicity! in!
vitro!Performed!by!Pan!lab.!A,!structure!of!i1(mESX).!B,!EGFR!and!Her2!levels.!CAL27!cells!were!treated!with!vehicle!or!biphenyl! isoxazolidine! for!24!hours.!EGFR!and!Her2!protein!levels! by! immunoblot! analyses.!C,! cell! proliferation! of! HNSCC! cells.! CAL27! cells! were!treated!with!vehicle!or! i1! (ESXm)! for!24!hours.!Cell!proliferation!was!assessed!using! the!CCK:8!reagent! to!detect!metabolically!active!cells.!Dose–response!curves!and!IC50!values!were!generated!using!GraphPad!Prism!4.0.!IC50!was!calculated!to!be!46.8!mmol/L.!D,!cell!proliferation! of! normal! IMR90! fibroblasts.! IMR90! cells! were! treated! with! vehicle! or!i1(ESXm)! (50! mmol/L)! for! 24! hours.! Cell! proliferation! was! assessed! using! the! CCK:8!
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reagent!to!detect!metabolically!active!cells.!E,!cell!invasion.!CAL27!cells!were!treated!with!vehicle!or!biphenyl! isoxazolidine!for!24!hours,!harvested,!and!resuspended!in!serum:free!medium.! An! aliquot! of! the! prepared! cell! suspension!was! added! to! the! top! chamber! and!10%!FBS!was!added!to!the!bottom!chamber.!After!24!hours,!invasive!cells!were!stained!and!visualized.! A! representative! field! for! each! experimental! condition! is! presented.! Data! are!presented!as!mean!±!SEM.!*,!P!<!0.01;!n!=!3.!F,!cell!migration.!CAL27!cells!were!seeded!and!allowed! to! grow! until! confluence.! Confluent! monolayers! were! treated! with! biphenyl!isoxazolidine!for!24!hours,!scratched!using!a!sterile!pipette!tip,!washed,!and!incubated!in!complete!medium.!A!representative!field!for!each!experimental!condition!at!0!and!24!hours!is!presented.!Bar,!150!mm.!Percentage!of!cleared!area!is!calculated!and!presented!as!mean!±!SEM.!*,!P!<!0.01;!n!=!3.!Reproduced!from!Zhang,!M!et!al.!Mol!Cancer!Ther!2013,!12,!1515:1525.!
Enhanced!potency!from!i1(mESX)/afatinib!combination!in!HNSCC!Next,! we! wanted! to! determine! if! i1(mESX)! could! potentiate! the! effects! of! TKIs!lapatinib! and! afatatinib! in!HNSCC! cells.! In! order! to! investigate!whether! i1(mESX)! could!potentiate! the!efficacy!of! lapatinib!or!afatinib,!CAL27!cells!were! treated!with! lapatinib!or!afatinib! at! various! concentrations!with! and!without! an! IC50! dose! of! biphenyl! isoazoidine!(Figure!2.12A).!Single!agent!dosing!with!lapatinib!or!afatinib!resulted!in!cell!proliferation!IC50s!of!11.8!μM!and!1.3!μM,!respectively.!Importantly,!the!combination!of!i1(mESX)!with!either! lapatinib! or! afatinib! decreased! cell! proliferation! by! 90%! or!more! in! CAL27! cells.!These!results!translated!to!clonogenic!survival!assays.!Single!agent!dosing!with!i1(mESX),!lapatinib,!and!afatinib!blocked!clonogenic!survival!by!49%,!45%,!and!72%,!respectively.!In!contrast,!the!clonogenic!survival!of!CAL27!cells!was!reduced!by!89%!with!combination!of!
i1(mESX)! and! lapatinib! and! was! completely! abalted! (100%)! with! the! combination! of!
i1(mESX)! and! afatinib! (Figure! 2.12B).! These! results! demonstrate! that! by! targeting! both!EGFR/Her2!protein! levels! in! concert!with!EGFR/Her2!kinase!activities,! that!highly!active!therapeutic!combinations!can!be!developed!against!HNSCC.!
!
In!vivo!efficacy!of!i1/afatinib!combination!in!preclinical!mouse!model!of!HNSCC!! Finally,! the! in! vivo! efficacy! of! i1(mESX)! and! afatinib! as! single! agents! and! in!combination!were!assessed!in!a!preclinical!mouse!model!of!HNSCC.!CAL27!cells!(1!x!106)!were!implanted!into!the!flank!of!8:week:old!athymic!nude!mice!and!tumors!were!allowed!to! develop! without! treatment.! At! 3! weeks! after! tumor! cell! implantation,! mice! with!established! tumors! were! randomly! assigned! to! 4! treatment! arms;! vehicle,! i1(mESX),!
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afatinib,! and! a! combination! of! i1(mESX)! and! afatinib.! Single! agent! i1(mESX)! decreased!tumor! volume! by! 51%! and! single! agent! afatinib! decreased! tumor! volume! by! 87%!compared! to! vehicle.! Importantly,! the! combination! of! i1(mESX)! and! afatinib! reduced!tumor! volume! by! 94%! compared! to! vehicle(Figure! 2.13A).! It! should! also! be! noted! that!treatment!with! either! of! the! single! agents! or! the! combination! treatment! in!mice! did! not!produce!abnormal!behavior!nor!significant!weight!loss!compared!to!the!vehicle!treatments.!
!
Figure!2.12!i1(mESX)!potentiates!the!antitumor!efficacy!of!afatinib!in!vitro!Performed!by!Pan!lab.!A,!cell!proliferation.!CAL27!cells!were!treated!with! lapatinib(Lapa)!or!afatinib!(Afat)! at! various! concentrations!with! and!without! an! IC50! dose! of! biphenyl! isoxazolidine!(ESXm).! Cell! proliferation!was! assessed! using! the! CCK:8! reagent! to! detect!metabolically!active!cells.!Dose–response!curves!and!IC50!values!were!generated!using!GraphPad!Prism!4.0.! IC50! was! 11.8! μmol/L! for! lapatinib!and! 1.5! μmol/L! for! afatinib! in! CAL27! cells.! IC50!ESXm!+!IC50! lapatinib!decreased!cell!proliferation!by!90.4%!and!IC50!ESXm!+!IC50!afatinib!decreased! cell! proliferation! by! 96.3%! in! CAL27! cells.! B,! clonogenic! survival.! CAL27! cells!were!treated!with!vehicle,!biphenyl! isoxazolidine!(ESXm;!IC50!dose),! lapatinib!(IC50!dose),!
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afatinib! (IC50! dose),! ESXm! +! lapatinib,! or! ESXm! +! afatinib.! Colonies! were! stained! with!crystal!violet.!Data!are!normalized!to!shRNA:control/vehicle!cells!and!presented!as!mean!±!SEM.! *,! P! <! 0.01,! vehicle! versus! treatment;! **,! P! <! 0.01! single:agent! treatment! versus!combination!treatment,!n!=!3.!Reproduced!from!Zhang,!M!et!al.!Mol!Cancer!Ther!2013,!12,!1515:1525.!Immunohistochemical! analysis!of! the! tumors! after! treatment! assessed! levels!of! total! and!phosphorylated! EGFR! and! Her2.! From! this! analysis,! it! was! demonstrated! that! both! the!intratumoral! levels! of! total! and! phosphorylated! EGFR! and! Her2! was! decreased! with!treatment!of!single:agent!i1(mESX)!or!afatinib.!In!contrast,!the!combination!of!i1(mESX)!and!afatinib!led!to!further!decreases!in!total!and!phosphorylated!Her2!levels!compared!to!the! single:agent! treatments.! Interestingly,! afatinib! altered! the! cellular! localization! of!phosphorylated! EGFR! from! the! cytosol! to! the! nucleus;! however,! in! the! combination!treatment,!phosphorylated!EGFR!was!not!detected!in!the!nucleus!but!in!the!cytosol!of!most!of! the! tumor!cells! albeit! at! a! lower! intensity! that! the!vehicle! treatment.!As!noted!earlier,!one!of!the!possible!reasons!that!HNSCC!patients!may!not!respond!to!anti:EGFR!therapies!is!due! to! the!kinase! independent! actions!of!EGFR,!more! specifically,! the! translocation! from!the! cellular! membrane! to! the! nucleus! to! activate! target! genes! responsible! for! cell!proliferation!and!survival.!The!results!observed!suggest!that!afatanib!actually!enhanced!the!nuclear:dependent! actions! of! EGFR,!whereas! the! i1(mESX)/afatinib! reduced! the! nuclear!accumulation!of!EGFR!and!reduced!the!levels!of!Her2.!
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!
Figure! 2.13! Biphenyl! isoxazolidine! potentiates! the! antitumor! efficacy! of! afatinib!
(Afat)! in!vivo.!Performed!by!Pan!lab.!A,!tumor!volume.!Athymic!nude!mice!with!palpable!CAL27! tumors! (~50! mm3)! were! randomly! assigned! to! 4! experimental! groups;! vehicle,!
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biphenyl! isoxazolidine! (100! μg/mouse,! 5x! week),! afatinib! (0.4! mg/mouse,! 5x! week),! or!biphenyl!isoxazolidine!+!afatinib.!Tumors!were!measured!using!a!digital!caliper!and!tumor!volumes! were! calculated.! Data! are! presented! as! mean! ±! SEM.! *,! P! <! 0.01;! n! =! 10.! B,!immunohistochemical! staining.! EGFR,! pEGFR! (Y1173),! Her2,! and! pHer2! (Y1221/1222)!staining! is!shown!for!a!representative! tumor! from!each!treatment!arm.!Reproduced! from!Zhang,!M!et!al.!Mol!Cancer!Ther!2013,!12,!1515:1525.!IDENTIFYING!OTHER!SYNERGISTIC!SMALL!MOLECULE!COMBINATIONS!
! There! are! two! accepted! and! quantitative! measures! of! evaluating! synergistic!combinations! of! small!molecules.!One! is! an! effect! based!methods! that!was!developed!by!Bliss! and! the! other! is! an! isobolographic!method,!which!measures! the! dose! reduction! as!developed! by! Loewe! and! Chou.! 19,30,31! The! Bliss! method! looks! at! statistically! expected!additive!effects!of!two!separate!agents!(A!and!B)!at!particular!doses.!When!combined,!these!two!doses!of!A!and!B!are!expected!to!have!an!effect!equal!to!(eA!+!eB):(eA*eB),!where!eA!and! eB! are! the! effects! of! A! and! B.! For! example,! if! a! dose! of! A! causes! a! 50%! viability!reduction!in!a!cell!population!and!a!dose!of!B!also!causes!a!50%!viability!reduction!of!the!same! cell! population,! the! calculated! effect! of! the! A! and! B! combination!would! be! a! 75%!viability! reduction! in! cell! population! (Figure! 2.14).! For! a! synergistic! combination,! the!combined! effect! will! be! greater! than! 75%.! This! method! was! recently! demonstrated! by!Cokol!and!coworkers!with!a!small!molecule!combinations!against!S!cerevisae.18!
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Although!this!method!is!relatively!straight!forward,!it!does!not!account!for!effects!observed!at!multiple!dose!values.!The!isobolographic!method!for!evaluating!synergy!is!based!on!the!principle! of! dose! equivalence! and! accounts! for! the! effects! demonstrated! at! several! A+B!combinations.! This! is! accomplished! through! dose:effect! curves! evaluated! for! both! of! the!individual!agents!and! for!several! fixed!ratio!combinations.!The! IC50! for!each!of! the!single!agents!is!determined!as!well!as!the!IC50!for!each!of!the!agents!in!some!combination!of!A+B.!!To!calculate!the!dose!fraction,!you!divide!the!IC50!of!the!selected!agent!by!the!IC50!for!the!single!agent.! !For!example,!to!determine!the!dose!fraction!of!A!used!as!a!single!agent,!the!IC50!of!the!single!agent!A!is!divided!by!the!IC50!of!the!single!agent!A,!providing!you!with!a!dose!fraction!of!1.!For!the!fixed!combination!of!A+B,!the!IC50!of!the!combination!of!A!as!a!combination!with!B!is!divided!by!the!IC50!of!the!single!agent!A!(Figure!2.15).!
!
Figure! 2.15! The! isolobolographic! definition! of! synergy! Hypothetical! combinations!tested! for! inhibition! using! the! Loewe! (isobolographic)! method.! This! method! uses! dose!response!curves!generated! for! fixed!dose!ratios.!Each!combination!has! two!IC50s! that!are!normalized!to! the! IC50s!of! the! individual!components!and!each!combination! is!plotted!on!the! x,! y! coordinate! plot.! The! dotted! line! is! the! calculated! effect! based! on! the! amount! of!compound!required!for!50%!effect!in!the!combination!divided!by!the!amount!of!the!same!agent! in! isolation! for! 50%.! The! example! above! is! looking! at! an! additive! example.! A!synergistic!combination!would!result!in!a!dose!response!curve!that!is!left:shifted,!resulting!in!a!lower!dose!fraction.!
























































































In! figure! 2.15,! we! demonstrate! a! hypothetical! set! of! dose! curves! for! an! additive!combination!example.!More!specifically,!the!graph!is!depicting!the!set!of!curves!that!would!result!form!a!1:1!combination!of!agent!A!and!agent!B.!In!the!above!hypothetical!example,!both!single!agent!A!and!single!agent!B!have!an!IC50!of!75!μM,!whereas!in!the!combination!of!1:1! A:B,! single! agent! A! and! single! agent! B! have! an! IC50! of! 37.5! μM.! When! dividing! the!combination!IC50!by!the!single!agent!IC50,!the!resulting!dose!fraction!is!equal!to!0.5.!These!dose! fractions! are! then! plotted! out! on! an! isobologram!with! the! additivity! line! indicated!(dotted! line).! Single! agents! are! always! represented! as! a! value! of! one! on! isobolograms,!setting!where!the!line!of!additivity!should!be!indicated.!Combination!indexes!(CIs)!are!the!sum!of! the! dose! fraction! of! A! and! the! dose! fraction! of! B.! For! additive! combinations,! the!combination! index! is! equal! to! 1! (CI! =! 1).! For! combinations! that! are! antagonistic,! the!combination! index! is! >! 1! (CI! >! 1),! and! for! combinations! that! are! synergistic,! the!combination!index!is!<!1!(CI!<!1).!The!above!examples!are!for!an!additive!combination,!but!in! the! case! of! a! synergistic! combination,! the! combination! curves! would! be! left:shifted,!resulting! in! a! lower! IC50.! These! lower! IC50s! would! result! in! lower! dose! fractions,! which!would!result!in!synergistic!combination!indexes!for!the!various!ratios!of!combinations!used!(CI!<!1)!(Figure!2.15,!lower!right).!! One! pathway! that! has! been! of! significant! interest! to! us,! is! the! crosstalk! between!Her2!and!NF:κB!in!breast!cancer.!It!has!recently!been!demonstrated!that!overexpression!of!Her2! leads! to!constitutive!activation!of!NF:κB!activity.! 32:34!Together! these! two!pathways!result!in!a!highly!aggressive!breast!cancer!phenotype!that!is!prone!to!metastasis,!resulting!in!lower!survival!rates!for!patients.35!It!has!been!hypothesized!that!the!mechanism!of!this!dual!activation!of!the!Her2/NF:κB!pathway!is!due!to!overexpression!of!Her2.!This!results!in!amplification! of! Her2! protein! levels! and! activation! through! dimerization!with! EGFR! and!erbB3! to! activate! the! canonical! NF:κB,! resulting! in! constitutive! activation! of! the! NF:κB!pathway!(Figure!2.16!A!and!B).!
! 57!
!
Figure! 2.16! Mechanism! of! Her2! overexpression! and! resulting! constitutive! NF2κB!





























transcriptional! activator! inhibitor.! For! NF:κB! inhibitors,! we! chose! to! use! KG:501,! an!inhibitor! of! the! p65:CBPKIX! interaction36! and! bortezomib,! a! proteasome! inhibitor!responsible!for!degradation!of!the!inhibitor!of!κB!(IκB).!Results!of!these!combinations!are!depicted!in!Figure!2.17.!
!
Figure! 2.17! Isobolograms! of! biphenyl! isoxazolidine! (i1)! and! NF2κB! inhibitor!
combinations! in! SkBr3,! MCF27,! and! IMR90! cells! Performed! by! Paul! Bruno.! The! two!combinations!that!were!tested!were!1:1!biphenyl:KG:501!and!500:1!biphenyl:bortezomib.!The!ratio!used!for!the!combinations!were!pre:determined!in!a!previous!viability!assay.!For!the!two!combinations!tested,!the!results!are!presented!for!SkBr3!cells!(left!panel),!MCF:7!cells!(middle!panel),!and!IMR90!cells!(right!panel).!The!biphenyl:KG:501!combination!did!not!exhibit!synergy!against!any!of!the!cell!lines.!Interestingly,!the!biphenyl:bortezomib!did!exhibit!synergy!against!SkBr3!cells,!whereas!no!synergy!was!demonstrated!against!MCF:7!cells!and!IMR90!cells.!This!result!is!compelling!because!it!validates!the!crosstalk!between!the!two!signaling!pathways.!Additionally,!the!combination!is!only!synergistic!in!SkBr3!cells,!which! are! characterized! as! Her2! overexpressing! with! constitutive! NF:κB! activation,!whereas!MCF:7!cells!are!not!Her2!positive!and!do!not!display!constitutive!NF:κB!activation.!


























































































































This!is!important!because!this!combination!validates!the!crosstalk!between!Her2!and!NF:κB! in! Her2! overexpressing! cells,! whereas! it! had! no! synergistic! effects! against! another!breast! cancer! cell! line! (MCF:7)! that! are! not! characterized! by! Her2! overexpression.!Furthermore,! the! effects! appear! additive! in! non:tumorigenic! fibroblast! IMR90! cells,!suggesting! that! this!combination!would!be!more!selective!compared! to! the!single!agents.!Based! on! these! results,! we! plan! to! test! other! ratios! with! the! biphenyl:bortezomib!combination! to! validate! the! synergistic! effects! observed! as! well! as! test! other! NF:κB!inhibitors! in! combination! with! biphenyl! isoxazolidine! to! see! if! more! synergistic!combinations!exist.!!
2.4!Conclusions!! Herein,! we! described! how! a! top:down! approach! could! be! used! to! develop! an!inhibitor! of! the! ESX:Med23! interaction.! The! ESX:Med23! relies! on! a! critical! tryptophan!residue! (Trp! 138)! for! interaction! with! Med23.! Through! the! ESX:Med23! interaction,! the!transcriptional! activator!ESX! is!presumably! able! to! recruit! the! rest!of! the! transcriptional!machinery,! resulting! in! activation! of! target! genes! such! as! Her2.! Her2! is! a! particularly!important!oncogene!overexpressed!in!breast!cancer!and!strategies!that!have!the!ability!to!reduce! the! cellular! protein! levels! of! Her2!would! have! immense! benefit! as! a! therapeutic!strategy.! By! utilizing! an! isoxazolidine! scaffold,! a! tryptophan! mimetic! was! developed!utilizing! the! α:helix! mimetic! isoxazolidine! scaffold.! This! molecule,! i1(mESX)! was!previously!demonstrated!to!downregulate!Her2!mRNA!levels!and!protein! levels! in!Her2+!breast! cancer! calls.!Additionally,! combination! therapy!utilizing! i1(mESX)! in! concert!with!other!inhibitors!targeting!Her2:mediated!cellular!events!such!as!protein!folding!or!kinase!activity!results!in!combinations!that!were!15:fold!more!potent!and!30:fold!more!selective!than!either!or!the!single!agents.!! HNSCC!is!the!sixth!most!common!cancer!reported!globally.!EGFR!protein!levels!are!universally!upregulated!in!HNSCC,!yet!HNSCC!patients!often!do!not!responds!to!anti:EGFR!therapies! that! have! proven! to! be! effective! against! other! cancers! with! the! EGFR:overexpression!phenotype! such!as!breast! cancer.!Genetic! studies!performed!with!HNSCC!cells!demonstrated!that!there!is!a!correlation!between!ESX,!Her2,!and!EGFR!in!HNSCC!with!ESX!activity!regulating!the!relative!protein!levels!of!Her2!and!EGFR.!Knockdown!of!ESX!in!
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HNSCC!cells!decreased!cellular!proliferation,!cell!invasion,!and!cell!migration,!leading!to!an!overall! decrease! in! tumorigenicity! of! HNSCC.! Knockdown! of! ESX! also! sensitized! and!increased!the!potency!of!anti:EGFR!therapies!against!HNSCC!cells.!Based!on!these!findings,!we!sought!to!determine!if!the!same!effects!could!be!achieved!through!chemical!targeting!of!ESX,! resulting! in! inhibitor! i1(mESX)! being! used! to! chemically! target! ESX.! In! order! to!complete! a! full! study! of! in! vitro,! in! cellulo,!and! in! vivo! of! chemically! targeting! ESX! gram!quantities!of!i1(mESX)!had!to!be!synthesized,!purified,!characterized,!and!quality!checked.!In! order! to! accomplish! this! feat,! we! optimized! the! 11:step! synthesis! of! i1(mESX)!previously!reported.!The!major!steps!that!were!optimized!included:!N:alkylation!at!the!N2!position,!conversion!of!the!C5!alcohol!to!a!nosylate!leaving!group,!which!resulted!in!higher!yields! for! the! azide! displacement,! and! a! citric! acid! catalyzed! dihydroxylation! that!dramatically!reduced!reaction!times!and!reduced!mol%!of!osmium!tetroxide!10:fold.!Using!this!optimized!synthetic!route,!we!produced!gram!quantities!of!i1(mESX)!for!the!first!time.!This! allowed! for! a! full! study! on! the! effects! of! i1(mESX)! and! i1(mESX)/afatinib!combinations! in! a! preclinical! mouse! model! of! HNSCC.! The! combination! therapy! of!









Chemicals!and!Instrumentation!Unless! otherwise!noted,! starting!materials! and! reagents!were!obtained! from!commercial!sources!and!were!used!without!additional!purification.!All!reactions!were!carried!out!under!anhydrous! conditions! (N2! atmosphere)! unless! otherwise! noted.! Et3N! was! distilled! from!CaH2.! Purification! by! flash! chromatography! was! carried! out! with! E.! Merck! Silica! Gel! 60!(230:400! mesh)! according! to! the! procedure! of! Still,! Kahn,! and! Mitra.! 1H! spectra! were!recorded! in!CDCl3! at! 400!MHz!or! 500!MHz.! Large:scale! purification! of! final! product!was!carried!out!on!a!Jones!Chromatography!FlashMaster!II!using!a!gradient!of!ethyl!acetate!and!hexanes! as! the! mobile! phase.! Purification! of! final! product! was! verified! using! analytical!reverse:phase! HPLC! purification! on! a! Hitachi! 7000! series! using! a! Beckman! Coulter! FC!(Fraction!Collector)!Module.!The!HPLC!was!equipped!using!a!C18!(8x100mm)!Radial:PakTM!cartridge!using!a!gradient!of!0.1%!TFA!in!H2O!and!CH3CN!as!the!mobile!phase.!
!
Cells!SkBr3,!IMR90,!SCC15,!SCC25,!and!CAL27!cells!were!purchased!from!American!Type!Culture!Collection! (ATCC).! SkBr3! and! IMR90! cells! were! grown! in! Dulbecco’s! Modified! Eagle!Medium!(DMEM).!SCC15!and!SCC25!cells!were!grown!in!a!1:1!mixture!of!Ham’s!F:12!and!DMEM!supplemented!with!10%!FBS,! 0.4!mg/mL!hydrocortisone,! 2!mmol/L!L:glutamine,!100! mg/mL! streptomycin,! and! 100! U/mL! penicillin.! CAL27! cells! were! grown! in! DMEM!supplemen:!ted!with!10%!FBS,!2!mmol/L!L:glutamine,!100!mg/mL!streptomycin,!and!100!U/mL!penicillin.!Cell!lines!were!authenticated!using!short!tandem!repeat!profiling!(ATCC).!!!
Generation!of!CAL27/shRNAEESX!cells!CAL27! cells! were! transduced! with! shRNA:control! or! shRNA:ESX! (10:1! MOI,! pGIPZ!Lentiviral!shRNAmir;!Open!Biosystems)!and!selected!in!puromycin!to!generate!polyclonal!CAL27/shRNA:control!and!CAL27/shRNA:!ESX!cells.!!!
Western!blot!analysis!Cells! were! washed! in! ice:cold! PBS! and! lysed! in! buffer! containing! 1%! Triton! X:100,! 50!mmol/L! HEPES,! pH! 7.4,! 10%! glycerol,! 137!mmol/L! NaCl,! 10!mmol/L! NaF,! 100!mmol/L!
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Na3VO4,! 10! mmol/L! Na4P2O7,! 2! mmol/L! EDTA,! 10! mg/mL! leupeptin,! and! 1! mmol/L!phenylmethylsulfo:! nylfluoride.! Whole:cell! lysates! were! mixed! with! Laemmli! loading!buffer,! boiled,! separated! by! SDS:PAGE,! and! trans:! ferred! to! a! nitrocellulose! membrane.!Subsequently,! immu:! noblot! analysis! was! conducted! using! an! ESX:specific! anti:! body!(GenWay!Biotech),!an!EGFR:specific!antibody!(Cell!Signaling!Technology),!a!Her2:specific!antibody! (Santa! Cruz! Biotechnology),! or! a! glyceraldehyde:3:phosphate! dehydrogenase!(GAPDH):specific!antibody!(Sigma).!!!
Cell!proliferation!CAL27! and! SCC15! cell! proliferation! was! assessed! using! the! CCK:8! reagent! to! detect!metabolically!active!cells!(Dojindo!Inc.).!The!absorbance!at!450!nm!was!quantitated!using!a!microplate! reader! (Molecular! Devices).! Dose–response! curves! and! IC50! values! were!generated! using! GraphPad! Prism! 4.0! (GraphPad! Software).! SkBr3! and! IMR90! cell!proliferation!was!assessed!using!WST:1!reagent!(Roche).!The!absorbance!at!440!nm!was!quantified!using!a!microplate!reader!(Genios!Pro,!TECAN).!Dose!response!curves!and!IC50!values!were!generated!using!GraphPad!Prism!4.0!(Graphpad!Software).!!
Cell!invasion!and!migration!Cell! invasion! was! determined! as! described! from! the! Cell! Invasion! Assay! Kit! (Chemicon!International).!Cells!were!harvested!and!resuspended!in!serum:free!medium.!An!aliquot!(1!105!cells)!of!the!prepared!cell!suspension!was!added!to!the!top!chamber!and!10%!FBS!was!added!to!the!bottom!chamber.!After!24!hours,!noninvading!cells!were!gently!removed!from!the! interior! of! the! inserts! with! a! cotton:tipped! swab.! Invasive! cells! were! stained! and!visualized.! Cell! migration! was! determined! using! the! wound:healing! assay.! Cells! were!seeded!and!allowed!to!grow!until!confluence.!Confluent!monolayers!were!scr:!atched!using!a!sterile!pipette!tip,!washed,!and!incubated!in!complete!medium.!!!
EGFR!and!Her2!promoter!activity!Cells!were!cotransfected!with!an!EGFR!or!Her2!pro:!moter:Renilla!luciferase!vector!and!a!CMV:Firefly!lucif:!erase!vector!(SwitchGear!Genomics)!using!FuGENE!HD!(Promega).!After!24! hours,! cells! were! washed! with! PBS,! lysed! in! passive! lysis! buffer,! and! measured! for!
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Renilla/!Firefly!luciferase!activities!in!a!luminometer!using!the!Dual:Light!System!(Applied!Biosystems).!EGFR!and!Her2!promoter!Renilla! luciferase!activities!were!normalized!with!Firefly!luciferase!activities!to!control!for!transfection!efficiency.!!!
Gene!expression!analysis!of!primary!HNSCC!tumors!Sixteen!primary!tumors!were!collected!at!The!Ohio!State!University!James!Cancer!Hospital!(Columbus,!OH)!from!patients!with!HNSCC!at!the!time!of!surgical!resec:!tion!between!1997!and! 2000.! All! tissues! were! diagnosed! histologically! as! HNSCC! by! a! board! certified!pathologist.!Written!informed!consent,!as!required!by!the!Institutional!Review!Board,!was!obtained!from!all!patients.!Collected!samples!were!stored!immediately!in!liquid!nitrogen!at!_80_C! until! analysis.! Total! RNA! was! isolated! from! the! frozen! tumors! with! TRIzol!(Invitrogen).! Expression! of! ESX,! EGFR,! and! Her2! was! determined! using! the! Applied!Biosystems!7900HT!Fast!Real:Time!PCR!System!with! validated!TaqMan!gene! expression!assays!(Applied!Bio:!systems).!Gene!expression!was!normalized!to!GAPDH!using!theDDCt!method.!!!
In!vivo!tumorigencity!and!efficacy!For!the!in!vivo!tumorigenicity!study,!CAL27/shRNA:!control!or!CAL27/shRNA:ESX!cells!(1!106!cells)!mixed!with!Matrigel! (1:1)!were! implanted! into! the! flanks!of!6:! to!8:!week:old!female! athymic! nude! mice! (National! Cancer! Institute,! Frederick,! MD).! Tumors! were!measured! and! resected! for! analysis! at! 18!days!postimplantation.! For! the! in! vivo! efficacy!study,!CAL27!cells!(1!106!cells)!mixed!with!Matrigel!(1:1)!were!implanted!into!the!flanks!of!6:!to!8:!week:old!female!athymic!nude!mice!(National!Cancer!Institute).!Mice!with!palpable!tumors! ($50! mm3)! were! randomly! assigned! to! 4! experimental! groups;! vehicle! (vehicle!intratumoral! injection! and! oral! gavage),! biphenyl! isoxazolidine! (100! mg/mouse!intratumoral!injection,!5!week),!afatinib!(0.4!mg/mouse!oral!gavage,!5!week),!or!biphenyl!isoxazolidine!þ!afatinib.!Tumors!were!measured!using!a!digital!caliper!and!tumor!volumes!were!calculated!using!the!formula:!tumor!volume!1⁄4!length!width!height!0.5.!Any!mouse!with!a!tumor!volume!equal!to!or!more!than!1,000!mm3!was!euthanized!and!removed!from!the! study.! All! animal! work! was! conducted! in! accordance! with! and! approved! by! the!Institutional!Animal!Care!and!Use!Committee!at!the!Ohio!State!University.!!
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Immunohistochemical!analysis!Resected! tumors! were! fixed! in! 10%! formalin! and! paraf:! fin:embedded.! Slides! were!incubated! in!citrate!buffer!(pH!6.0)! for!antigen!retrieval!and! immunohistochemical!stain:!ing! was! carried! out! using! Peroxidase! Histostain:Plus! Kit! (Invitrogen)! according! to! the!manufacturer’s! protocol.! ESX! antibody! (LifeSpan! Biosciences! Inc.)! was! used! at! a! 1:500!dilution,!EGFR!antibody!(Millipore)!was!used!at!a!1:10!dilution,!Her2!antibody!(Santa!Cruz!Biotechnology)!was!used!at!a!1:100!dilution,!pEGFR:Y1173!antibody!(Millipore)!was!used!at!1:100!dilution,!and!pHer2:Y1221/1222!anti:!body!(Cell!Signaling!Technology)!was!used!at! 1:100! dilu:! tion.! Slides!were! counterstained!with! hematoxylin! and! coverslipped! using!glycerin.!!!
Statistical!analysis!Data!were!analyzed!by!two:tailed!Student! t! test.!P!values! less! than!0.05!were!considered!significant.!!!
2.6!Synthesis!and!characterization!of!i1!and!intermediates!
!
32methylbutanal!oxime!(i122)!Hydroxylamine! hydrochloride! (13.9! g,! 200! mmol)! and! sodium! carbonate! (21.0! g,! 200!mmol)!were!combined!in!400!mL!and!heated!to!70°!C!for!1!hour!with!continuous!stirring.!Reaction!was!cooled!and!isovaleraldehyde!(21.7!mL,!200!mmol)!was!added!dropwise.!The!reaction!was!stirred! for!additional!5!mins!and!was! then!heated! to!a! light! reflux! (100°!C)!and!stirred!for!an!additional!4!hours!until!complete!by!TLC.!The!reaction!mixture!turned!from! a! pale! orange! with! white! precipitate! to! a! colorless! opaque! solution! upon! heating.!After!4!hours,!the!reaction!mixture!was!cooled,!filtered!through!a!scintered!glass!frit,!and!washed!with!toluene.!The!filtrate!was!concentrated!under!reduced!pressure!and!distilled!at!100°!C!under!reduced!pressure!using!an!aspirator!to!yield!i122!as!pale!yellow!oil!(19.1!g,!93%).!!
!
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(32isobutyl24,52dihyrdoiisoxazol252yl)methanol!(i123)!Oxime!i122!(9.46!g,!93!mmol)!and!allyl!alcohol!(50!mL,!700!mmol)!were!combined!in!100!mL!toluene!in!a! foil!wrapped!round!bottom!flask!with!vigorous!stirring,!cooled!to!0°!C.!A!6%! solution! of! sodium! hypochlorite! (‘Chlorox! bleach’,! 250!mL,! 200!mmol! hypochlorite)!was! added! dropwise! using! an! addition! funnel.! The! reaction!was! allowed! to!warm! up! to!room! termperature! and! stirred! for! an! additional! 12! hours! upon! warming! to! room!temperature.! The! crude! reaction! was! partitioned! between! toluene! and! water.! Organics!were! dried! over! sodium! sulfate! and! concentrated! under! reduced! pressure! to! yield!isoxazoline!i123!as!a!yellow!oil!(9.6!g,!62%).!!
32allyl232isobutylisoxazolidin252y)methanol!(i124)!Distilled!BF3!Et2O!over!CaH!under!reduced!pressure!at!150°!C!using!a!still!head!distillation!apparatus! according! to! procedure! outlined! in!Purification!of!Laboratory!Chemicals,!1997.!All! glassware!was! oven! dried! prior! to! running! reaction.! Distilled! BF3!Et2O! (11.2!mL,! 90!mmol)! was! added! to! isoxazoline! i123! (4.8! g,! 30! mmol)! in! 300! mL! dry! tetrahydrofuran!under! nitrogen! at! :78°! C.! Monitored! temperature! of! reaction! using! a! cold! temperature!thermometer.! Allylmagnesium! chloride! (2M! in! hexanes,! 75! mL,! 150! mmol)! was! added!dropwise! using! a! syringe! pump! over! 45!minutes.! Let! reaction! slowly!warm! up! to! room!temperature!and!let!stir!for!an!additional!8!hours.!Quenched!reaction!in!1M!HCl.!Added!1M!NaOH! until! aqueous! layer! had! pH! of! 10.! Extracted! aqueous! layer! with! ethyl! acetate.!Combined!organics!were!dried!over!sodium!sulfate,!concentrated!under!reduced!pressure!and!purified!by!column!chromatography!to!yield!isoxazolidine!i124!(9.5!g,!79%).!!
22([1,1’2biphenyl]242ylmethyl)232allyl232isobutylisoxazolidin252yl)methanol!(i126)!Tert:butyldimethylsilyl! trifluoromethanesulfonate!(0.72!mL,!3.125!mmol)!was!added!to!a!solution!of! isoxazolidine!i124! (0.5!g,!2.5!mmol)!and!imidazole!(0.452!g,!6.25!mmol)! in!25!mL!dry!THF!under!nitrogen.!Reaction!was!stirred!at!room!temperature!and!monitored!by!TLC.!After!1!hour,!15!mL!of!3M!NaOH!was!added!dropwise!to!reaction.!The!crude!mixture!was! partitioned!with!water! and! extracted!with! DCM!The! combined! organics!were! dried!over!magnesium!sulfate!and!concentrated!under! reduced!pressure.!Crude!product! (i125)!was!dissolved!with!20!mL!dry!THF!under!nitrogen.!The!crude!mixture!was!cooled!to!78°!C!
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with! temperature! monitored! with! a! cold! temperature! thermometer.! After! the! crude!mixture!was!sufficiently!cooled,!nBuLi!(2.38M!in!hexanes,!1.15!mL,!2.75!mmol)!was!added!to! dropwise! and! left! with! continuous! stirring! for! 15! minutes.! Added! a! solution! of!bromomethyl! biphenyl! (0.925! g,! 3.75!mmol)! in! 5!mL! of! dry! THF! dropwise! to! the! crude!reaction!mixture.!The!crude!reaction!mixture!turned!from!pale!yellow,!to!orange,!to!blood!red,!and!finally!back!to!pale!yellow.!Allowed!reaction!to!slowly!warm!to!room!temperature!and! left! stirring! for! an! additional! 8! hours.! Quenched! reaction! by! adding! saturated!ammonium! chloride! until! solution! no! longer! bubbled! upon! addition! of! saturated!ammonium! chloride! solution.! Extracted! reaction! mixture! with! hexanes,! dried! combined!organics! over! magnesium! chloride,! filtered! and! concentrated! under! reduced! pressure.!Dissolved! crude! product! with! 10! mL! dry! THF! under! nitrogen.! Added! tetra:n:butylammonium!fluoride!(1M!in!THF,!3.75!mL,!3.75!mmol)!dropwise!to!reaction!mixture.!Reaction!was!stirred!at!room!temperature!an!monitored!by!TLC.!After!1!hour,!added!10!mL!of!3M!NaOH!dropwise!to!the!crude!reaction!mixture.!Crude!reaction!mixture!turned!into!a!cloudy!white!solution.!Removed!THF!under!reduced!pressure.!Extracted!aqueous!solution!with! ethyl! acetate,! dried! combined! organics! over! magnesium! sulfate,! filtered,! and!concentrated!under!reduced!pressure!and!purified!by!column!chromatography!to!yield!i12
6!(0.48!g,!63%).!!
22([1,1’2biphenyl]242ylmethyl)232allyl252(azidomethyl)232isobutylisxazolidine!(i127)!Dissolved!isoazolidine!XX!(1.78!g,!5!mmol)!in!200!mL!of!dry!DCM!and!added!Et3N!(1.4!mL,!10! mmol),! and! a! catalytic! amount! of! dimethylaminopyridine! (0.122g,! 1! mmol)! to! the!reaction!solution.!Once!all!solids!were!dissolved,!2:nitrobenzene!sulfonyl!chloride!(1.65!g,!7.5!mmol)!was! added! to! the! crude!mixture.!Reaction!was! left! at! room! temperature!with!vigorous!stirring! for!2!hours!and!monitored!by!TLC.!After!2!hours,! saturated!ammonium!chloride!was! added! to! the! crude!mixture.! Extracted! aqueous! layer!with! DCM,! combined!organics,!dried!over!magnesium!sulfate,!and!concentrated!under!reduced!pressure!to!a!pale!yellow!oil.!Crude!product!was!dissolved!in!25!mL!dry!DMF!under!nitrogen!atmosphere.!Let!solution! vigorously! stir! until! all! solids! were! dissolved! and! added! sodium! azide! to! the!solution.! All! steps! were! carried! out! behind! blast! shield.! Upon! addition! of! sodium! azide,!reaction!mixture!changed!from!pale!yellow!to!orange.!Reaction!mixture!was!stirred!at!room!
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temperature!for!1!hour!with!vigorous!stirring!at!which!point,!reaction!mixture!was!heated!to!50°!C!and!left!to!stir!for!additional!12!hours.!Added!100!mL!of!H2O!to!reaction!mixture!and! extracted! with! diethyl! ether.! Combined! organics,! dried! over! magnesium! sulfate,!concentrated!under!reduced!pressure,!and!purified!by!column!chromatography!to!yield!i12
7!(1.61!g,!85%).!!
22([1,1’2biphenyl]242ylmethyl)252(azidomethyl)232isobutylisoxazolidin232yl)ethanol!
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3.1!Abstract!! Mediator!subunit!25!(Med25)!is!a!component!of!the!megadalton!Mediator!complex,!whose!recruitment!is!required!for!the!expression!of!most!genes!in!eukaryotic!organisms.!1,2!The!Activator!Interaction!Domain!(ACID)!is!a!key!component!of!the!Med25!protein!that!has!been!recently!shown!to!make!critical!contacts!with!several!transcription!factors,!allowing!for! the! recruitment! of! the! full! mediator! complex! to! target! genes! (Figure! 3.1).! These!transcription!factors!include!VP16,!a!crucial!component!of!the!herpes!simplex!virus!(HSV)!responsible!for!the!switch!from!latent!to!lytic!infection3,4;!ATF6α,!an!endoplasmic!reticulum!stress!response!transcription!factor5;!and!ERM,!a!member!of!the!Ets!family!of!transcription!factors! that! has! been! implicated! in! the! progression! of! cancer.! 6,7! Given! the! functional!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*!The!research!described!in!chapter!3!is!a!collaborative!effect.!P.A.!Bruno!!and!S.!M.!Sturlis!synthesized! and! purified! tracers,! expressed! and! purified! protein,! developed! high:throughput! assay,! performed! pilot! screen! with! high:throughput! assay,! performed! mass!spectrometry!of!covalent!adducts,!and!performed!screen!with!natural!product!extracts.!S.!M.! Sturlis! performed! KIX! counter! screen,! mutational! analysis! with! ACID! protein,! and!investigated!effects!of!electrostatics.!P.!A.!Bruno!performed!mass!spectrometry!analysis!for!other!aldehyde!containing!molecules,! cellular!assays!with!ATF6α,!ERM,!and!RAR,!Protein!NMR! and! performed! additional! counter! screens.! Felicia! Grey! (Cierpicki! Lab)! performed!protein! NMR! analysis.! Jessica! Gagnon! (Brooks! Lab)! performed! molecular! dynamics!experiments.! Identified! compounds! were! obtained! from! Giselle! Tamayo:Castillo.! Screen!was! performed! in! University! of! Michigan! Center! for! Chemical! Genomics.! Parts! of! this!chapter!are!reproduced!in!Paul!A.!Bruno,+!Steve!M.!Sturlis,+!Felicia!Grey,!Jessica!K!Gagnon,!Giselle! Tamayo:Castillo,! David! H.! Sherman,! and! Anna! K.! Mapp*! Identifying! Depside! and!Depsidone!Inhibitors!of!Med25!ACID:mediated!transcription.!Manuscript!in!progress.!
! 79!
importance! of! Med25! recruitment! by! various! transcription! factors,! inhibitors! of! these!interactions!would!be!useful!mechanistic!probes!for!interrogating!Med25!dependent!gene!expression.! Herein! chapter! 3,! we! demonstrate! how! a! high:throughput! assay! can! be!developed!based!on!the!Med25:VP16! interaction.!Using!this!assay!that!we!developed,!we!performed!high:throughput!screening!to!yield!depside!and!depsidone!inhibitors!of!Med25!ACID.! These! inhibitors! described! herein! are! the! first! discovered! inhibitors! of! ACID! and!demonstrate! inhibition! of! Med25:dependent! transcription! is! achievable! with! small!molecules.!
!
Figure!3.1!Mediator!subunit!(Med25)!mediated!gene!upregulation!The!transcriptional!activation!domains!of!VP16,!ATF6α,!and!ERM!make!specific! interaction!with!Med25.!This!interaction! recruits! the! Mediator! complex,! leading! to! assembly! of! the! transcriptional!machinery!and!target!gene!upregulation.!!










complexes.11! As! a! result,! targeting! these! types! of! interfaces! with! small! molecules! is!particularly!challenging.!!The! megadalton! Mediator! complex! is! a! critical! component! of! the! transcriptional!machinery,!whose!recruitment! is!required!for!the!expression!of!most!genes! in!eukaryotic!organisms.1! Recently,! the! Activator! Interaction! Domain! (ACID)! of! subunit! Med25! has!emerged!as!an!important!contact!within!this!complex!for!several!transcriptional!activators,!allowing! for! the! recruitment! of! the! full! mediator! complex! to! target! genes.! These!transcriptional!activators!include!VP163,4,!a!crucial!component!of!the!herpes!simplex!virus!(HSV)! responsible! for! the! switch! from! latent! to! lytic! infection;! ATF6α,! an! endoplasmic!reticulum!stress!response!transcription!factor5,12;!and!ERM,!a!member!of!the!Ets!family!of!transcription! factors! that!has!been! implicated! in! the!progression!of!a!variety!of! cancers.6!The!ACID!domain!consists!of!a!seven:stranded!beta!barrel!flanked!by!three!alpha:helices,!a!highly!uncommon! fold! identified! in!only!one!other!protein!of!unknown! function.13!Given!the!large!interaction!surface!area!of!approximately!3700!Å2!used!to!bind!its!transcriptional!activators,! identifying! small! molecule! inhibitors! capable! of! disrupting! such! broad!interaction!surfaces! is!a! remarkable!challenge.!This!multifaceted!problem! is!underscored!by! a! lack! of! critical! structural! information! that! identifies! the!minimal! binding! domain! of!transcriptional! activators! to! Med25! or! how! specific! mechanistic! features,! such! as!electrostatics,! contribute! to! binding! affinity.! Despite! these! challenges,! the! role! of!Med25!dependent!gene!expression! in! cellular!processes! such!as!advanced!viral! infection,! cancer!metastasis,!and!stress!response!makes!the!AcID!domain!an!extremely!attractive!target!for!small!molecule!intervention.!!Such!molecules!would!be!useful!as!mechanistic!probes!in!the!further!characterization!of!Med25!dependent!processes!and!could!serve!as!potential! lead!molecules!in!the!development!of!novel!antiviral!and!anticancer!therapeutics.!It! has! recently! been! reported! that! two! subdomains! of! the! VP16! transcriptional!activation! domain! (TAD)! interact! with! Med25! ACID.! 3,4! However,! given! the! limited!structural!information!about!Med25!and!the!intractable!nature!of!the!VP16!subdomains!we!sought! to! identify! the!minimal!VP16!sequences!required! for!binding! to!Med25!ACID!as!a!means! to! reduce! the! interaction! surface! area! to! a! size!more! amenable! to! small!molecule!intervention.! Additionally,! we! identified! additional! biophysical! contributions! to! binding,!such!as!electrostatics,!that!could!be!exploited!in!the!identification!of!inhibitors.!From!these!
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studies,! we! were! able! to! develop! a! fluorescence! polarization! based! assay! that! was! well!adapted! for! high:throughput! screening! against! the! ACID! domain.! A! screen! of! known!biologically!active!compounds!revealed!depsides!and!depsidones,!natural!products!derived!from! lichens,! as! a! compelling! class! of! potential! inhibitors.14! Compounds! containing! the!depside! or! depsidone! core! were! then! selected! and! utilized! in! a! dose! response! assay,!revealing!norstictic!acid!as!the!first!in!vitro!inhibitor!of!Med25.!!BACKGROUND!OF!MEDIATOR!SUBUNIT!25!(MED25)!
The!Mediator!complex!! Mediator!subunit!25!(Med25)!is!a!component!of!the!Mediator!complex,!a!coactivator!required!for!nearly!all!RNA:polymerase!II:dependent!genes.2!The!Mediator!complex!serves!as!a!bridge!between!the!gene:specific!regulatory!proteins!such!as!transcriptional!activators!and!the!basal!RNA!polymerase!II!transcription!machinery.9!When!the!mediator!complex!is!recruited!to!gene!promoter!sites!by!direct! interactions!with!regulatory!proteins,! it!serves!as!a!scaffold!for!the!assembly!of!a!function!preinitiation!complex!with!RNA!polymerase!II!and!the!general!transcription!factors.!The!subunits!of!Mediator!complex!form!at!least!three!structurally! distinct! submodules:! head,! middle,! tail,! and! CDK8! module,! with! the! latter!serving!mostly!a!support!role!for!the!rest!of!the!complex.15!The!head!and!middle!modules!of! the! Mediator! complex! interact! directly! with! RNA! polymerase! II,! whereas! the! tail!submodules! interacts! with! gene:specific! regulatory! proteins,! such! as! transcriptional!activators.16! It!was! initially! thought! that!Med23:30!were! specific! to! higher! eukaryotes17,!but! recently! Med24,! Med27,! and! Med29! have! been! proposed! to! be! distantly! related!orthologs! of! S.! cerevisiae! Mediator! subunits! Med5,! Med3! and! Med2,! respectively.18! The!Mediator!tail!is!perhaps!the!most!evolutionarily!divergent!module!of!the!Mediator!complex,!but!this!would!not!be!surprising!given!the!role!of! the!Mediator!tail! to! interact!with!DNA:binding! transcriptional! activators.! 19,20! The! Mediator! tail! includes! conserved! subunits!Med15,!Med16,!in!addition!to!the!subunits!Med23,!Med24,!and!Med25.!Med23!and!Med25!make! specific! contact! with! a! variety! of! transcriptional! activators.! In! the! case! of! Med23,!specific!contacts!are!made!through!its!various!subdomains!with!transcriptional!activators!Elk121,! ESX22,! and! even! C/EBPβ23.! As! for! Med25,! specific! interactions! have! been!demonstrated! with! the! activators! VP16,! ERM,! ATF6α,! RARα,! and! ERα.! 3,4,24,25! Given! the!
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importance! of! the! tail! Mediator! subunits! and! their! distinct! role! of! interacting! with!transcriptional!activators,!targeting!these!activator:coactivator!interactions!could!prove!to!be!highly!effective!against!these!activators!ability!to!upregulate!their!target!genes.!
!
Mediator!subunit!25!(Med25),!a!subunit!of!the!Mediator!complex!One! of! the! subunits! that! is! of! particular! interest! to! us! is! the! Med25! subunit!introduced! above.! Biochemical! experiments! performed! by! Tomomori! and! coworkers!demonstrated!that!Med25!is!a!bona!fide!subunit!of!the!Mediator!complex!and!is!only!found!in! mammals.26! Med25! is! ubiquitously! expressed! and! found! in! several! tissues! including!brain,!heart,!kidney,!peripheral! leukocytes,!placenta,!skeletal,!muscle,!and!spleen!tissue.27!Furthermore,! Med25! consists! of! three! defined! domains:! the! von! Willibrand! factor! A!domain!(VWA),!the!activator!interaction!domain!(ACID),!and!a!nuclear!receptor!LXXLL!box!(Figure!3.2A).28!!The!VWA!domain!is!used!for!binding!to!the!mediator!complex,!whereas!the!ACID!domain!is!used!to!make!specific!interaction!with!the!TADs!of!VP16,!ERM,!ATF6α,!as!well!as!the!N:terminus!of!CBP.!24There!is!also!a!nuclear!receptor!(NR)!box!containing!the!LXXLL! sequence! required! for! coactivator! binding! to! nuclear! receptors! Retinoic! Acid!Receptor!α!(RARα)24!and!Estrogen!Recepter!α!(ERα).25!Given!the! importance!of! the!ACID!domain! for! interaction! with! transcriptional! activators,! inhibitors! developed! against! this!domain! would! presumably! be! an! effective! method! of! targeting! these! transcriptional!activators.!!
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Figure! 3.2! Subdomains! of!Med25! and!unique! structure! of!Med25!ACID!A.!A!protein!map!of!human!Med25.!The!Med25!protein!consists!of! three!domains:! the!von!Willibrand!factor!A!domain!(VWA),!the!activator!interaction!domain!(ACID),!and!the!nuclear!receptor!(NR)! box.! Known! interaction! partners! are! listed! below! their! respective! subdomains.! B.!NMR! solution! structure! of! Med25! ACID! highlighting! the! 7:stranded! β:barrel! (green)!flanked!by!3!α:helices!(blue).!C.!Surface!representation!of!Med25!highlighting!topology.!!
The!Med25!Activator!Interaction!Domain!(ACID)!In! addition! to! the! importance! of! the! ACID! domain! for! transcriptional! activator!binding,! the! unique! structural! features! of! ACID! suggests! that! selective! inhibitors! can! be!developed! against! this! domain! due! to! the! lack! of! similarities! shared! with! other! known!activator! interaction! domains.! One! notable! example! is! the! KIX! domain! in! Med15.! The!Med15!KIX!domain! is!made!up!of!purely!α:helical!secondary!structure.!This! is! in!obvious!contrast! to! the! ACID! domain,! which! consists! of! a! 7:stranded! β:barrel! flanked! by! 3! α:helices(Figure!3.2B).!!Furthermore,!the!ACID!domain!is!quite!different!from!other!activator!interaction!domains!such!as!CBPKIX29,!CH130,!BRD431,!and!NCOA332,!which!are!also!largely!α:helical!(Figure!3.3).!This!further!highlights!the!unique!structural!characteristics!of!ACID!domain!that!could!possibly!be!exploited!for!development!of!inhibitors.!
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Figure! 3.3! Comparing! the!Med25! activation! interaction! domain! (ACID)! with! other!















rationale! for! how! immobilized!VP16!TAD! can!purify! the!Mediator! complex! from!nuclear!extracts.33! Parallel! experiments! performed! by!Milbradt! and! coworkers! as!well! as! Vojnic!and! coworkers! reached! the! same! conclusion! that! Med25! ACID! contains! two! distinct!binding! sites,! denoted! H1:! and! H2:binding! site.! However,! contradicting! data! from! both!groups!makes!it!challenging!to!conclude!whether!the!H1:binding!site,!the!H2:binding,!or!a!combination!of!the!two!is!important!for!the!VP16:ACID!interaction.!With!the!importance!of!Med25!in!cellular!processes!such!as!viral!activation,!cellular!stress,!and!cancer,!it!is!obvious!that! small! molecules! targeting! Med25:mediated! transcription! would! possess! enormous!therapeutic!potential.!However,!given!the!conflicting!and!undetermined!importance!of!the!VP16(413:451)! and! VP16(452:490)! subdomains! to! overall! VP16! TAD! binding,! small!molecule! inhibitors! of! Med25! ACID! would! also! prove! to! be! highly! beneficial! as! in! vitro!chemical! probes.! Developing! inhibitors! against! ACID! would! allow! us! to! determine! the!minimal!binding!interaction!between!VP16!and!ACID!as!well!as!determine!the!importance!of! specific! contributions! to!binding,! such! as! electrostatics.!The! size!of! the!VP16!TAD! (81!amino! acids)! or! either! of! the! subdomains! (~40! amino! acids)! and! the! large! surface! area!used!to!interact!with!either!site!of!ACID!(1500!Å)!classically!defines!this!interaction!in!the!large! surface! area! regime.11! Additionally,! the! affinities! of! both! the! VP16(413:451)! and!VP16(452:490)! subdomains!of!VP16!have!been! reported! to!be! in! the!high!nanomolar! to!low! micrmolar! range.! 3,4! Together,! the! large! surface! area! and! the! low! affinity! (high!nanomolar!to! low!micromolar)!classifies!this!protein:protein!interaction!as!a! low!affinity,!large! surface! area! interaction.! As! noted! in! chapter! 1,! there! are! several! challenges!associated!with!targeting!these!large!surface!area,!low!affinity!interactions!such!as!the!need!for! high! effective! concentrations! of! inhibitor! needed! to! completely! block! the! interaction,!off:target! effects,! and! the! lack! of! suitable! molecule! libraries! to! target! these! types! of!interactions.!!
Using!natural!products!to!target!the!Med25EVP16!interaction!! Small! molecules! have! become! powerful! tools! for! impacting! both! biology! and!medicine.! In! biology,! these! small!molecules! have! served! as! probes! to! aid! researchers! in!deciphering! complex! biological! processes.34! In! medicine,! small! molecules! have! been!developed!as!therapeutics!to!combat!various!ailments.!These!characteristics!have!resulted!
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in! a! explosion! of! small! molecule! compound! libraries! to! screen! both! phenotypic! and!biochemical! assays.! A! number! of! these! efforts! have! ended! in! disappointment,! partly!because! we! do! not! possess! a! full! understanding! of! all! the! factors! required! to! create!libraries! containing! molecules! that! possess! high! potency,! but! also! specific! biochemical!activity.! ! It! can! be! assumed! that! researchers! and! scientists! have! only! sampled! a! small!fraction!of!possible!chemical!space.!This!is!partly!due!to!the!limits!of!synthetic!methods!as!well! as! the! inability! to! make! an! endless! number! of! analogs.! One! way! to! tackle! these!challenges!would!be! to!use!natural!products.!By! testing!against!natural!products,!we!are!afforded! the! ability! to! encounter! new! chemical! matter,! dramatically! increasing! the!likelihood! of! finding! novel! inhibitors.! Additionally,! the! increased! complexity! of!biomolecules!offered!by!organisms!provides!us!with! the!ability! to! test!a!greater! range!of!molecules! from! small,! hydrophobic!molecules! to! large,! polar!molecules.! These!molecules!will! also!have! the! added!benefit! of! being!amphipathic! and!mostly!membrane!permeable.!This!expanded!range!will!be!particularly!helpful!when!screening!against!low!affinity,!large!surface!area!interactions!such!as!ACID:VP16,!which!are!not!well!targeted!by!small!molecule!libraries.!!
3.3!Results!and!Discussion!ASSAY!DEVELOPMENT!FOR!HIGH:THROUGHPUT!MOLECULE!SCREEN!OF!MED25!ACID!
Protein!expression!! In! order! to! carry! out! high:throughput! screening! of! the! VP16:ACID! interaction,!protein! expression,! purification,! and! characterization! needed! to! be! carried! out.! The!Med25(392:543):His6!plasmid!was!obtained!from!the!Cramer!group.3!The!first!step!was!to!optimize!the!expression!conditions!in!order!to!obtain!enough!protein!for!high:throughput!screening.! The! original! published! procedure! called! for! expression! in! LB! broth! and!induction!overnight,!with!average!yields.!In!order!to!optimize!the!expression,!we!expressed!the! protein! in! terrific! broth! (TB! broth).! Terrific! broth! is! useful! for! protein! expression!because!it!is!a!buffered!medium,!allowing!for!higher!OD600!values!to!be!obtained,!resulting!in!a!greater!number!of!protein!expression!bacteria.!Additionally,!terrific!broth!also!contains!glycerol,! as! an! additional! carbon! source! for! the! bacterial! cells! to! use! as! fuel.! Using! this!
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media! in! place! of! LB! broth! allowed! us! to! obtain! consistent! yields! of! 20+!mg/L! of! ACID!protein!post!purification!of!the!protein.!!































Direct binding experiments of VP16-ACID interaction










Kd  > 50 µM
Kd = 3.4 ± 0.2 µM
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affinities!reported!by!Milbradt!et!al!and!Vojnic!et!al.!Perhaps!more!surprising!were!the!Kds!that! were! obtained! by! VP16(438:454)! and! VP16(467:488),! the! peptides! containing! the!minimal! α:helical! domains! of! VP16(413:451)! and! VP16(452:490),! respectively.! The! Kds!obtained! with! the! minimal! α:helical! domains! were! within! error! of! the! larger! parent!peptides.! This! result! suggests! the! majority! of! the! binding! affinity! of! the! VP16:ACID!interaction!is!provided!by!the!interaction!of!ACID!with!the!two!α:helical!domains!of!VP16,!a!hallmark! of! activator:coactivator! protein:protein! interactions.37! Additionally,! smaller!peptides! capable! of! recapitulating! the! binding! affinity! of! the! larger! VP16(413:451)! and!VP16(452:490)! subdomains! validates! that! there! are! smaller,! more! specific! interactions!that! can! be! targeted! to! inhibit! the! VP16:ACID! interaction! compared! to! the! originally!predicted!3000!Å2!VP16:ACID!interaction.!Although!beyond!the!scope!of!this!dissertation,!binding! studies! with! various! VP16! mutants! to! identify! specific! amino! acids! that! most!contribute!to!the!binding!interaction!are!a!critical!next!step!and!are!the!focus!of!others!in!the!research!group.!!
Determining!parameters!for!highEthroughput!screening!of!FP!assay!! Based! on! the! excellent! dynamic! range! observed! with! Flo:VP16(465:490)! in! the!binding!assays!of!Figure!3.6!and!the!affinity!comparable!to!the!longer!VP16!peptides,!this!was! chose! as! the! tracer! for! the! development! of! an! assay! suitable! for! high:throughout!screening.! First,!we!determined!whether! tracer! concentration!had!a! substantial! effect!on!the! dynamic! range! obtained! from! our! tracer.! We! decided! to! test! two! different!concentrations!(20!nM!and!50!nM)!of!our!tracer!based!on!previous!FP!assay!developed!in!our! lab.14! Results! from! directing! binding! experiments! using! Flo:VP16(465:490)!demonstrated!that!20!nM!of!tracer!could!be!used!in!the!high:throughput!assay!since!50!nM!did!not!boost!the!dynamic!range!(Figure!3.8).!
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Figure!3.8!Comparison!of!tracer!concentration!Performed!with!Steve!Sturlis.!Compared!the!effects!of!either!20!nM!or!50!nM!of!Flo:VP16(465:490)!on!dynamic!range!of!FP!assay.!Less! than! 5%! change! in! dynamic! range! observed!with! 50! nM! trace! compared! to! 20! nM!tracer.!We! also! tested! the! effects! of! DMSO! and! NP:40! on! our! FP! assay.! When! testing! against!compounds!in!a!high:throughput!screen,!samples!are!added!as!a!solution!of!DMSO!and!it!is!sometimes! necessary! to! use! high! concentrations! of! DMSO! in! order! to! obtain! the!appropriate! effective! concentration! to! test! compound! stocks! at! lower! starting!concentrations! or! to! obtain! full! dose! curves! when! validating! initial! hits.! Therefore,! it! is!critical!to!determine!the!effects!of!DMSO!on!the!high:throughput!assay.!Additionally,!NP:40!is!often!used!in!high:throughput!assays!in!order!to!inhibit!non:specific!binding!and!also!to!help! solubilize! less! soluble! compounds! to! prevent! them! from! precipitating! in! the! assay!buffer.!It!is!often!sufficient!to!add!NP:40!to!a!final!concentration!of!0.001%!v/v.!The!results!of! the! assay! looking! at! the! effects! of! DMSO! and! NP:40! on! the! Flo:VP16(465:490):ACID!interaction!are!depicted!in!Figure!3.9.!Based!on!the!results!demonstrated!in!Figure!3.9,!we!conclude!that!NP:40!(0.001%!v/v)!has!no!effects!on!the!high:throughput!assay!and!DMSO!up!to!5%!v/v!is!well!tolerated!as!evidenced!by!the!Kd!being!perturbed!only!2:fold!from!the!original!Kd!determined!(Figure!3.9).!
Flo-VP16(465-490)




















Figure! 3.9! Effect! of! DMSO! and! NP240! on! the! Kd! of! Flo2VP16(4652490)2ACID!
interaction!Performed!with!Steve!Sturlis.!A!directing!binding!assay!was!set!up!using!20!nM!of!tracer!titrated!with!increasing!concentration!of!ACID!protein.!Effects!of!DMSO,!NP:40,!or!the!a!combination!of!the!two!were!investigated!by!adding!DMSO!(5%!v/v),!NP:40!(0.001%!v/v),!or!DMSO!(5%!v/v)!and!NP:40!(0.001%!v/v).!These!three!conditions!were!monitored!over!6!time!points:!1,!2,!4,!6,!8,!and!20!hours.!The!last!parameter!that!we!investigate!for!the!high:throughput!screen!was!determining!the!Z’!score!of!our!assay.!The!Z’!statistic! is!used!to!determine!the!quality!of! the!assay.!The!Z’!score!was!determined!at!three!protein!concentrations:!500!nM,!850!nM,!and!2.5!μM!using!the!following!equation:!!!! !! = !1− 3 !! + !!!!! − !!! ! (Equation!!3.1)!σ!=!standard!deviation!of!positive/negative!population!μ!=!mean!value!of!positive!and!negative!population!
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1"hour" 2"hour" 4"hour" 6"hour" 8"hour" 20"hour"
+"NP/40" 0.72"μM" 0.75"μM" 0.80"μM" 0.81"μM" 0.88"μM" 0.95"μM"
+DMSO" 1.5"μM" 1.6"μM" 1.6"μM" 1.7"μM" 1.7"μM" 1.8"μM"
+"NP/40"and"DMSO" 1.5"μM" 1.7"μM" 1.6"μM" 1.7"μM" 1.7"μM" 1.8"μM"
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!All!three!protein!concentrations,!produced!Z’!scores!>0.75,!substantially!higher!than!the!0.6!Z’!score!used!to!define!a!good!high:throughput!assay.38!Therefore,!we!chose!to!use!the!850!nM!concentration!point! for! the!high:throughput!screen.!Utilizing! this!concentration!point!for!ACID!allows!us! to!obtain!Z’! scores!>0.8! and!allows!us! to!use!3:fold! less!protein! than!afforded! by! the! 2.5! μM! concentration! of! ACID! point,! all! whiling! obtaining! a! suitable!dynamic!range!for!the!assay.!Together!all!of! these!results!demonstrate! that!we!can!develop!a!very!robust!high:throughput!assay!against!the!VP16:ACID!interaction.!We!demonstrated!that!we!can!express!and!purify!ACID!protein!in!high!yield!(>!20!mg/L)!and!that!we!can!develop!effective!tracers!that!define!the!minimal!binding! interaction!of!VP16:ACID.!Through!development!of! these!tracers,!we!obtained!data!that!suggests!that!the!majority!of!the!VP16:ACID!binding!affinity!is!derived!from!the!reported!α:helical!domains!of!VP16.!The!effects!of!DMSO!and!NP:40!had!minimal! effects! on! the! binding! affinity! of! the! tracer! and! the! assay!was! incredibly! stable!over! long! periods! of! time! as! evidenced! by! the!minimal! drift! in! Kd! seen! during! the! time!course!as!illustrated!in!Figure!3.9.!Lastly,!using!the!parameters!noted!above,!we!were!able!to!consistently!obtain!Z’!scores!>!0.8,! resulting! in!a!robust!assay!with!a!suitable!dynamic!range!required! for!high:throughput!screening.!Taken! together,! these!results!demonstrate!that!this!is!a!robust!assay!suitable!for!an!HTS!campaign!against!the!VP16:ACID!interaction.!!PILOT!SCREEN!OF!VP16:ACID!INTERACTION!
Pilot!screen!of!the!VP16EACID!interaction!Using!the!screen!developed!above,!a!total!of!4,046!compounds!were!screened!at!the!University! of!Michigan! Center! for! Chemical! Genomics! (CCG),!which! included! compounds!from!the!MS!Spectrum!2000,!Focused!Collections,!BioFocus!NCC!compound! libraries.!The!pilot!screen!had!a!Z’!score!of!0.84!and!had!a!hit!rate!of!1.6%.!The!threshold!for!hits!was!set!at! 3! standard! deviations! from! the! mean.! Compounds! were! removed! if! they! had! been!flagged!as! reactive! from!previous! screens!or!displayed! significant! fluorescence! (>10%!of!the! fluorescence!of! tracer).!All! the!hits!were! tested! in! triplicate! to! confirm! their! activity.!This!filtering!resulted!in!the!identification!of!CCG:38381,!CCG:38361,!CCG:40171,!and!CCG:40095!as!confirmed!hits!(Figure!3.10).!
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Figure!3.10!Pilot!screen!against! the!Flo2VP162ACID!interaction!Performed!with!Steve!Sturlis.! A.! Campaign! view!of! the! pilot! screen! run! against! 4,046! compounds.! The! red! and!blue!dots!represent!the!negative!and!positive!controls,!respectively.!Green!dots!represent!the!tested!compounds!with!all!compounds!above!the!red!line!(>3SD)!representing!hits.!B.!The!identified!hits!from!the!pilot!screen!with!the!initial!inhibitions!noted!as!a!%.!





























































































































































































































4,046 biologically active compounds
Substructure search for related
depsides and depsidones
IC50 < 100 µM
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IC50 = 106.6 ± 15.6 µM





































































































IC50 = 13.02 ± 0.96 µM
Ki = 4.40 ± 0.32 µM
log [Norstictic Acid] (µM)
m
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IC50 = 80.9 ± 6.1 µM
























































































IC50 = 241.2 ± 42.9 µM
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Steve!Sturlis.!All!DRCs!were!produced!with!8!dose!points!run!in!triplicate!and!fitted!using!graphpad!4.0!In! the! first! row!of!Figure!3.12,! lobaric!acid! (CCG:38587)! is!highlighted!with!a! red!box! to!demonstrate!the!lack!of!inhibition!observed!with!this!compound!(IC50!>>!250!μM).!This!is!a!significant! finding! because! lobaric! acid! was! identified! as! an! inhibitor! of! the! MLL:KIX!protein:protein! interaction,! but! exhibits! no! inhibition! against! the! VP16:ACID! protein:protein!interaction,!suggesting!that!the!substituents!on!the!depside/depsidone!core!affect!selectivity! of! the! protein:protein! interaction! that! these! molecules! inhibit.! In! the! second!row,!are!three!compounds!outlined!in!green!boxes.!In!the!middle!is!compound!CCG:38381!(norstictic! acid)! and! directly! adjacent! to! norstictic! acid! are! two! closely! related! analogs,!CCG:38361!(psoromic!acid)!and!CCG:38584!(stictic!acid).!Psoromic!acid!exhibited!modest!inhibition! (IC50! =! 106! μM)! against! the! VP16:ACID! interaction,! whereas! stictic! acid!displayed! no! inhibition! (IC50! >250! μM).! Norstictic! acid! contains! a! lactone! ring! that! can!tautomerize!between!the!open!and!closed!ring.!In!the!open!form,!norstictic!acid!contains!a!carboxylic! acid!and!an!aldehyde!substituent,!but! in! the! closed! form,! it! contains!a! lactone!ring,! suggesting! that! the! presence! of! a! carboxylic! acid! is! required! for! binding! to! ACID.!Conversely,!the!presence!of!carboxylic!acid!functionality!does!not!seem!to!be!sufficient!for!binding!to!ACID.!In!the!case!of!stictic!acid,!methylation!of!the!ortho!phenol!to!aldehyde!on!the! A! ring! abolished! the! inhibitory! activity! observed!with! norstictic! acid,! suggesting! the!presence!of!an!ortho!phenol!to!the!aldehyde!on!the!A!ring!is!required!for!inhibition!of!ACID!(Figure!3.13).!
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Figure!3.13!Inhibition!of!depsidone!derivatives!on!the!VP162ACID!interaction!A.!The!depsidone!and!depside!core!with!the!A!and!B!rings!highlighted.!B.!Tautomerization!of!the!lactone!ring! in!norstictic!acid.!C.! IC50s!of!depsidones!and!depsides!against! the!VP16:ACID!interaction.!








































































































which!has! two!subdomains! that!possess!high:nanomolar! to! low:micromolar!affinities! for!ACID,!it!may!be!absolutely!crucial!to!inhibit!both!interactions!in!order!to!obtain!the!desired!inhibition.!This! sets!up!a! scenario!where!a!dual!orthosteric!or!dual!orthosteric/allosteric!inhibitor!of!the!interaction!between!the!two!VP16!subdomains!and!ACID!would!be!highly!desirable.!!
Assessing!selectivity!with!counter!screens!! Based!on! the! inhibition! that!we!observed!with! the!compounds! identified! from!the!pilot! screen,! we! tested! their! inhibitory! properties! on! an! assay! developed! for! another!protein:protein! interaction.! We! chose! to! investigate! the! inhibitory! properties! of! the!identified! compounds!against! the!MLL:KIX! interaction!and! the!CREB:KIX! interaction.!We!choose!to!use!this!counter!screen!for!several!reasons.!First,!the!KIX!protein!is!a!domain!of!the! central! hub! coactivator! CBP/p300! and! is! utilized! by! several! different! transcriptional!activators! to!upregulate! transcription!of! target!genes! including:!NF:κB41,!p5342,!MLL43,! c:Myb44,! and! CREB45.! We! reasoned! that! inhibition! of! this! domain! with! the! identified!inhibitors!would!likely!translate!to!off:target!effects!since!there!are!structurally!similar!KIX!domains! in!several!proteins!such!as!CBP,!p300,!and!Med15.!Second,!KIX!has! two!binding!sites!similar!to!ACID,!which!have!been!identified!as!the!“MLL!site”!and!the!“CREB!site”.! If!our! inhibitors! were! general! amphipathic! helix!mimics,! we! should! see! inhibition! of! both!MLL:KIX!and!CREB:KIX.!Third,!using!MLL:KIX!and!CREB:KIX!would!allow!us!to!determine!if! the! identified! molecules! demonstrate! inhibition! consistent! with! a! general! dual!orthosteric! or! dual! orthosteric/allosteric! mechanism! as! observed! with! ACID.! The! KIX!domain! serves! as! a! good! surrogate! to! test! this! possibility! due! to! the! presence! of! two!binding!sites!and!the!well:defined!allosteric!communication!between!the!two!binding!sites.!46:48!
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Figure! 3.15! Inhibitory! effects! of! depsidones! against! MLL2KIX! and! CREB2KIX!
interaction!Performed!by!Steve!Sturlis.!A.!The!KIX!protein!with!the! identified!“MLL!site”!and!“CREB!site”!denoted!in!red!and!blue,!respectively.!B.!Dose!response!curves!generated!with!the!depsidones!against!the!MLL:KIX!and!CREB:KIX!interaction.!On!the!left!graph,!the!dose! response! curve! for! psoromic! acid! against! the!MLL:KIX! and!CREB:KIX! interaction! is!depicted.!On!the!right!graph,!the!dose!response!curve!for!norstictic!acid!against!the!CREB:KIX!interaction!is!depicted.!Interestingly,!the!depsidone!inhibitors!identified!in!the!pilot!screen!did!not!inhibit!the!MLL:KIX!or! the!CREB:KIX! interaction! (Figure!3.15).!This! result! suggests! that! the! inhibition!of!ACID! is! selective! over! other! coactivator! domains! such! as! KIX.! Furthermore,! the! results!demonstrate! that! the! dual! orthosteric! or! dual! orthosteric/allosteric! inhibition! observed!with!VP16:ACID!is!unique!to!ACID!and!is!not!a!general!phenomenon!observed!with!other!proteins!such!as!KIX,!a!coactivator!with!two!binding!sites!and!well!defined!allostery.!! It! has! previously! been! demonstrated! that! depsides! and! depsidones,! sekikaic! acid!and! lobaric! acid,! can! inhibit! the! KIX! domain.! The! results! above! demonstrate! that! the!depside! and!depsidone! core!may!be! a! ‘privileged! scaffold’! based!on! the!observation! that!these! types! of! molecules! have! demonstrated! low! micromolar! IC50s! against! two! unique!coactivator! domains,! ACID! and! KIX.! Furthermore,! the! selective! inhibition! observed!with!different! depsides! and! depsidones,! suggests! that! the! substituents! on! these! scaffolds! can!greatly!affect!the!inhibitor’s!selectivity!for!the!target!domain.!Based!on!the!observation!that!these! depsidones! exhibit! selectivity! for! the! target! activator:coactivator! PPI! (VP16:ACID)!over! unrelated! activator:coactivator! PPIs! (MLL:KIX,! CREB:KIX)! is! a! promising! result,!validating! future! utility! of! these! molecules.! One! possible! explanation! for! the! observed!inhibition! seen! with! these! depsidones,! is! that! they! are! general! VP16! helix! mimetics.! In!order!to!determine!if!the!molecules!are!general!VP16!helix!mimetics,!we!tested!the!ability!of!these!compounds!to!inhibit!the!VP16(438:454),!VP16(467:488),!and!VP16:derived!VP2!interaction!with!Med151:345.! The!VP16!TAD!has!been!demonstrated! to! interact!with! four!
A" B"
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distinct!domains!with!Med15.!49:51!This! implication!of! this!promiscuous!binding!profile! is!that! a! helix! mimetic! of! the! VP16! TAD!would! exhibit! significant! off:target! effects! due! to!inhibition!of!multiple! activator:coactivator!domains! simultaneously.! In! order! to! test! this,!we!looked!at!the!ability!of!norstictic!acid!and!psoromic!acid!to!inhibit!the!Med15!A+B!box!(Med151:345)!interaction!with!VP16(438:454),!VP16(467:488),!and!VP2!(Figure!3.16).!
!
Figure! 3.16! Investigating! inhibition! of! the! Med15! interaction! with! VP16! using!
norstictic! acid! and! psoromic! acid! Performed! with! Steve! Sturlis.! In! the! left! panel,! we!present! direct! binding! data!with!Med151:345!with! the! three! VP16! derived! tracers.! In! the!middle! panel,!we! present! assay! data! of! norstictic! acid! competition!with! VP16(438:454),!VP16(467:488),! and! VP2! binding! to! Med151:345.! In! the! right! panel,! we! present! present!assay! data! of! psoromic! acid! to! compete! with! VP16(438:454),! VP16(467:488),! and! VP2!binding!to!Med151:345.!The! results! of! these! competition! assays! demonstrated! that! norstictic! acid! and! psoromic!acid! are! not! potent! inhibitors! of! the! VP16:Med15! interaction! (Figure! 3.16).! All! the! IC50s!generated!with!norstictic!acid!and!psoromic!acid!against!the!VP16:Med15!interaction!were!greater! than! 30:fold! higher! than! the! IC50! values! obtained! against! the! VP16:Med25!interaction! (Figure! 3.14).! This! observed! results! suggests! that! the! identified! depsidones!from!the!pilot!screen!are!selective!for!the!ACID!domain!and!do!not!generally!act!as!VP16!helix!mimetics.!!!DETERMINING!ELECTROSTATIC!CONTRIBUTIONS!TO!MED25!ACID!BINDING!
Molecular!dynamics!experiment!with!small!molecule!and!Med25!ACID!! A! molecular! dynamics! (MD)! simulation! was! performed! with! Med25! ACID! and!norstictic!acid! in!order! to! investigate!potential! sites! the!molecule!could! interact!with! the!protein.!The!added!benefit!of!an!MD!simulation!performed!with!ACID!and!norstictic!acid!is!that! information!about! lowest!energy!binding!state!of!the!molecule!on!the!protein!can!be!
Direct Binding with VP16-Med15(1-345)











Kd = 16.0 ± 1.2 µM
Kd = 27.7 ± 3.8 µM









Norstictic acid competition of VP16-Med15(1-345) interaction









IC50 = 65.1 ± 12.6 µM
IC50 = 75.8 ± 11.5 µM
IC50 = 61.1 ± 31.1 µM








Psoromic acid competition of VP16-Med15(1-345) interaction








IC50 = 118 ± 28 µM
IC50 = 107 ± 19 µM
IC50 > 150 µM









determined.!Additionally,!areas!on!the!protein!that!binds!the!highest!density!of!ligand!can!be!highlighted,!providing!additional! information!about!the! inhibitors!possible!mechanism!of! action.! An! MD! simulation! performed! with! ACID! and! norstictic! acid! revealed! that!norstictic!acid!clustered!at!the!lysines!on!ACID.!This!is!somewhat!unsurprising!considering!that!there!are!several!lysines!on!the!ACID!protein!and!norstictic!acid!contains!a!carboxylic!acid! that! is! part! of! the! lactone! on! ring! B,! suggesting! that! electrostatics! likely! plays! an!important!role!in!the!interaction!between!the!depsidones!and!ACID.!The!highest!density!of!norstictic!acid!on!ACID!and!the! lowest!energy!members!of!norstictic!acid!on!ACID!can!be!seen!in!Figure!3.17!A!and!B.!
!
Figure! 3.17! Molecular! dynamics! (MD)! simulation! with! norstictic! acid! and! ACID!Performed! by! Jessica! Gagnon.! A.!MD! simulation! identifying!where! the! highest! density! of!norstictic!acid! is! found!on!ACID.!B.!MD!simulation!demonstrating!what!the! lowest!energy!members!of!norstictic!acid!and!ACID!are!based!on!where!the!highest!density!of!norstictic!acid!is!found.!
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activators!and!possibly!with!inhibitors!of!the!domain.!The!importance!of!electrostatics!on!VP16!has!also!been! investigated.!Experiments!performed!by! Jonker!and!coworkers!using!HADDOCK! docking! and! protein! NMR! to! look! at! the! VP16:PC4! interaction! demonstrated!that! several! of! the! negatively! charged! residues! in! the! α:helical! region! of! VP16! made!electrostatic! contacts! with! positively! charged! lysines! and! arginines! on! PC4.! This!observation! suggests! that! both! hydrophobic! and! electrostatic! interactions! are! important!for!VP16.35!Based!on!the!importance!of!electrostatics!in!these!previous!studies,!we!sought!to! determine! the! importance! of! electrostatics! in! the! VP16:ACID! interaction.! One!way! to!assess! the! importance!of!electrostatics!on!the!VP16:ACID! interaction! is! to!perform!direct!binding!assays!in!the!presence!of!increasing!concentrations!of!sodium!chloride!(NaCl).!We!demonstrated!that!the!Kd!of!the!VP16(465:490):ACID!interaction!steadily!increases!in!the!presence!of!increasing!!salt!(Figure!3.18).!
!
Figure!3.18!Effects!of!NaCl!on!the!VP16(4652490)2ACID!interaction!Performed!by!Steve!Sturlis.!Direct!binding!experiments!between!VP16(465:490)!and!ACID!were!carried!out!in!the! presence! of! 100,! 200,! 400,! 600,! 800,! and! 1000! mM! sodium! chloride! as! previously!described.!A!plot!of!sodium!chloride!vs!Kd!was!plotted!to!illustrate!the!steady!increase!in!Kd!values.!We!observed!higher!Kd!values!with!steadily!increasing!sodium!chloride!salt!concentrations.!Overall,!we!observed!a!greater!that!30x!increase!in!Kd!between!the!100!mM!and!1000!mM!NaCl!concentrations,!demonstrating!that!the!VP16:ACID!interaction!is!partially!dependent!on!electrostatics! for! interaction!with!VP16.!Based!on!the!observation!that!the!VP16:ACID!interaction! is! electrostatically! driven,! we! sought! to! determine! if! inhibition! with! the!depsidone!inhibitors!was!also!an!electrostatically!driven!interaction.!In!order!to!determine!if! the! inhibition! observed! with! the! identified! depsidones! is! an! electrostatically! driven!interaction,! we! performed! competition! assays! with! the! depsidones! in! the! presence! of!
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Kd = 0.47 ± 0.04 µM
Kd = 1.1 ± 0.1  µM
Kd = 3.4 ± 0.2 µM
Kd = 6.1 ± 0.5 µM
Kd = 10.4 ± 1.2 µM
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increasing! salt! concentrations! to! investigate! the! effect! salt!would!have! on! the! inhibition.!Similar! to! the! effects! seen! in! the! direct! binding! experiments,! we! saw! the! IC50! of! the!compounds! steadily! increase! in! the!presence!of! increasing! salt! concentration,! suggesting!that!the!interaction!between!the!inhibitor!and!ACID!is!also!at!least!partially!dependent!on!electrostatics!for!inhibition!(Figure!3.19).!!
!
Figure!3.19!Effect!of!sodium!chloride!on!norstictic!acid!inhibition!of!VP16(4652490)2
ACID! binding!Performed!by!Steve!Sturlis.!Carried!out!competition!assays!with!norstictic!acid! against! the! VP16(465:490):ACID! interaction! in! the! presence! of! increasing!concentrations!of!sodium!chloride!(NaCl).!!COVALENT!MODIFICATION!OF!MED25!ACID!WITH!DEPSIDONES!
QETOF!mass!spectrometry!data!demonstrating!covalent!binding!to!Med25!ACID!Next,! we! sought! to! determine! if! the! depsidones! and! depsides! that! we! identified!could!be!covalently!modifying!the!protein.!During!the!substructure!search,!we!noticed!that!the!molecules! that!we! identified! in! the! screen! contained! aldehydes! on! the! A! ring! of! the!depsidones! or! depsides.! Others! have! identified! aldehyde:containing!molecules! that! label!target!proteins!through!a!Schiff:base!(imine)!53,54!and!therefore,!we!wanted!to!determine!if!our!aldehyde!containing!inhibitors!covalently!modify!ACID!through!formation!of!an!imine!(Figure!3.20).!!
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IC50 = 15.3 ± 0.8 µM
IC50 = 26.1 ± 2.8 µM
IC50 = 63.9 ± 6.9 µM
IC50 = 114 ± 14 µM
IC50 > 125 µM
IC50 > 125 µM


























































Figure! 3.21!Mass! spectrometry! analysis! of! ACID! in! the! presence! of! norstictic! acid!Performed!with! Steve! Sturlis.! A.! Spectra! of!ACID!protein! to! provide! a! reference!mass.! B.!Spectra! of! ACID! in! the! presence! of! 4! equivalents! of! norstictic! acid! post! reduction! with!sodium! borohydride! (NaBH4).! To! obtain! spectra,! 10! μM! ACID! was! incubated! with! 4!equivalents! of! norstictic! acid! and! left! incubating! for! 2h! at! room! temperature.! Then,!complex!mixture!was!reduced!with!NaBH4!at!a! final! concentration!of!1!mM!and!dialyzed!overnight! to! get! rid! of! excess! molecule! and! salt.! The! sample! was! analyzed! using! mass!spectrometry!to!obtain!spectra.!From!the!mass!spectrometry!analysis,!it!is!demonstrate!that!norstictic!acid!can!covalently!label!ACID.!We!observed!similar!results!with!psoromic!acid.!Although!it!may!be!possible!to!get! higher! labeling! species! upon! addition! of! more! molecule,! these! species! are! likely!irrelevant! to! inhibiting! the! VP16:ACID! interaction! since! the! IC50s! of! the! molecules! are!obtained!at!a!4:1!ratio!of!inhibitor!to!protein!as!demonstrated!by!the!dose!response!curves.!Based!on!the!masses!observed,!the!labeling!event!is!consistent!with!imine!formation.!In!the!case!of!norstictic!acid!(372!Da),!formation!of!the!imine!would!result!in!the!loss!of!water!(:18!Da),!resulting!in!a!mass!addition!of!354!Da.!As!an!example,!the!addition!of!one!norstictic!acid!to!ACID!(18126!Da)!would!result!in!a!mass!of!18480!Da.!Additionally,!reduction!with!sodium!borohydride!(NaBH4)!would!produce!a!mass!increase!in!4!Da!due!to!the!reduction!of! the! imine! formed!on! ring!A!as!well! as! reduction!of! the!aldehyde! that! is! tied!up! in! the!lactone!on!ring!B!(Figure!3.21B!and!Figure!3.22).!
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Figure! 3.22! Schematic! of! inhibitor! imine! formation! and! reduction! with! sodium!
borohydride! In! the! first!step,! the!depsidone! inhibitor! forms!the! imine!with!an!amine!on!the! protein,! resulting! in! the! loss! of! water! (:18! Da).! Next,! the! addition! of! sodium!borohydride!(NaBH4)!causes!reduction!of!the!imine!on!ring!A!and!reduction!of!the!aldehyde!that!is!a!part!of!the!lactone!on!ring!B,!resulting!in!an!increase!of!4!Da.!
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Figure! 3.23! Mass! spectrometry! analysis! of! Med25! ACID! in! the! presence! of!


























ACID!and!norstictic!acid!! Based! on! the! results! from! the! MD! simulation! with! depsidones! and! ACID,! we!observed! the! greatest! density! of! the! inhibitor! localized! around! the! lysines,! presumably!driven!by!an!electrostatic! interaction.!Mass!spectrometry!analysis!of!complex!mixtures!of!depsidones! and! ACID! confirmed! imine! formation! between! the! depsidone! aldehydes! and!lysine! residues! on! ACID.! Based! on! IC50! data! generated! with! the! depsidones! and! the!observation! that! covalent! adducts! are! formed! between! the! depsidones! and! ACID,! we!sought!to!determine!if!these!depsidones!induced!chemical!shift!perturbations!on!ACID!that!are!consistent!with!the!above!observations.! In!order!to!perform!the!1H:15N!HSQC!protein!NMR!experiment!with!ACID!and!the!depsidones,!we!first!expressed!and!purified!15N:ACID!protein.!The!protein!was!expressed!and!purified!as!described!in!the!materials!and!methods!section.! The! expression,! purification,! and! identification! of! the! protein!was! confirmed! by!mass!spectrometry!(Figure!3.24)!
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throughout! the! experiment.! If! the!molecule! had!destabilized! the! protein,!we!would! have!observed!a!time:dependent!clustering!of!residues!in!the!1H:15N!spectra,!which!we!did!not!observe! in! our! experiment.! Additionally,! there! were! no! far:shifted! signals! in! the! 1H:15N!spectra!to!indicate!that!there!was!major!global!restructuring!occurring!upon!ACID!binding!to!norstictic!acid,!suggesting!that!any!restructuring!of!ACID!upon!binding!to!norstictic!acid!is!subtle.!The!amide!backbone!shifts!that!were!observed!were!mostly!peak!broadening!and!small!shifts!in!amide!backbone!signals.!A!large!number!of!the!peaks!can!be!assigned!using!the!assignment!previously!described,!but!not!all!the!residues!could!accurately!be!assigned!using!this!method.!Interestingly,!the!chemical!shift!perturbations!that!were!observed!were!mostly! clustered! at! two! major! areas! on! the! protein.! In! particular,! chemical! shift!perturbations! were! observed! for! ACID! residues! W408,! Q409,! G462,! L483,! G485,! L486,!G491,!G493,!G496,!C497,!V498,!L513,!S516,!L525,!and!N535.! In!Figure!3.25,!we! illustrate!the!chemical!shifts!observed!for!ACID!in!the!presence!of!DMSO!(red!signals),!3!equivalents!of! norstictic! acid! (purple! signals),! and! 5! equivalents! of! norstictic! acid! (blue! signals).! In!order!to!demonstrate!the!chemical!shift!perturbations!that!were!observed,!snapshots!were!taken!of!G462,!L464/K520/N535,!and!C497!(Figure!3.26).!
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Figure!3.26!1H215N!HSQC!experiment!performed!with!Med25!ACID!and!norstictic!acid!Performed!with!Felicia!Grey.!15N:labeled!ACID!protein!(30!μM)!was!incubated!with!DMSO!(negative! control),! 3! equivalents! norstictic! acid,! or! 5! equivalents! of! norstictic! acid.! The!spectra! from! the! experiment! are! overlaid:! DMSO! (red! signals),! 3! equivalents! (purple!signals),!and!5!equivalents!norstictic!acid!(blue!signals).!Snapshots!of!3!different!regions!of!the!overlaid!experiment!are!presented.!From!the!results!of!this!experiment,!it!is!apparent!that!norstictic!acid!induces!chemical!shift!perturbations! on! 15N:labeled!ACID.! As! illustrated! in! Figure! 3.26,!we! observed! both! peak!broadening! and! small! chemical! shifts! upon! labeling! ACID! with! norstictic! acid.! These!observed! chemical! shift! perturbations! further! support! the!notion! that!norstictic! acid! can!interact!with!ACID.!Interestingly,!the!observed!chemical!shifts!are!localized!to!two!specific!regions!on! the!protein,! specifically! the!H1!and!H2!binding!sites.!Overlaying! the!observed!chemical!shifts!with!norstictic!acid!and!the!previously!reported!chemical!shifts!from!VP16!H1!and!VP16!H2!binding! to!ACID,!we!see! that! there! is!considerable!overlap!between! the!sets!of!shifts!(Figure!3.27B).!This!result!suggests!that!norstictic!acid!binds!to!sites!on!ACID!similar!to!the!native!ligands!VP16!H1!and!VP16!H2.!!
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Figure! 3.28! Demonstrating! lysine! proximity! to! the! observed! chemical! shifts! with!
norstictic! acid! A.! Med25! ACID! is! depicted! with! the! H1! (yellow)! and! H2! (blue)! site!highlighted.!The! chemical! shifts!observed!with!norstictic! acid!are!highlighted! in! red.!The!lysines!on!ACID!are!highlighted!in!green.!B.! Identifying!the!lysines!in!closest!proximity!to!the!observed!chemical!shifts!with!norstictic!acid.!The!highlighted!regions!are!the!same!as!noted!in!A,!but!only!the!lysines!(green)!in!closest!proximity!to!the!observed!chemical!shifts!with! norstictic! acid! are! highlighted.! The! dashed! circles! highlight! the! general! H1! and!H2!binding!sites!on!ACID.!
Investigating! the! effects! of! conservative! point!mutations! on! VP16EACID! direct! binding! and!






investigate!effects!of!K"R!point!mutations!on!VP16:ACID!direct!binding!and!norstictic!acid!inhibition.! First,! the! conservative!mutations!of!K"R!will!maintain! the!positive! charge! as!noted!above.!These!conserved!mutations!are! important!because!we!demonstrated!earlier!that!the!VP16:ACID!interaction!and!norstictic!acid!inhibition!are!both!heavily!dependent!on!electrostatics! for! interaction.! If!we! used! charge! inversion! (K"E/D)! point!mutations,!we!would! potentially! affect! the! electrostatics! of! the! interactions! in! addition! to! affecting!potential!sites!of!imine!formation!with!norstictic!acid,!making!it!difficult!to!deconvolute!any!observed! effects.! Alanine! mutations! (K"A)! would! present! similar! problems! since! we!would! lose! the! positive! charge! attributed! to! a! lysine! that! could! be! important! for!electrostatic!interaction!as!well!as!a!potential!amine!that!could!be!used!for!imine!formation.!Therefore,!conserved!point!mutations!were!used!to! look!at! the! important! lysine!residues!for! inhibition! with! norstictic! acid.! By! using! conserved! K"R!mutations! we!maintain! the!electrostatic! interactions! required! for! both! VP16:ACID! interaction! and! inhibition! with!norstictic! acid.! Additionally,! by! using! conserved! K"R! mutations,! we! remove! residues!capable! of! forming! imines,! allowing! us! to! investigate! the! inhibition! of! norstictic! acid!without! the!covalent!contribution.!These!mutations!will!also!allow!us! to!determine! if! the!previously! highlighted! lysines! in! close! proximity! to! the! observed! chemical! shift!perturbations!are!the!likely!sites!of!imine!formation!with!norstictic!acid.!There!was!one!site!on! ACID! that! was! of! particular! interest! to! us,! a! triple! lysine! loop! (K518:K520)! that! is!directly!adjacent!to!the!VP16!H2!binding!site!on!ACID.!We!decided!to!focus!our!efforts!on!this!loop!first.!We!made!five!mutations!of!this!loop,!K518R,!K519R,!K520R,!KK518RR,!and!KKK518RRR! in! order! to! investigate! the! effects! of! these! mutations! on! VP16:ACID! direct!binding!and!the!effects!on!norstictic!acid!inhibition.!
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Figure! 3.29! Effects! of!H2! lysine!mutations! on!VP16(4382454)2ACID! and!VP16(4672
488)2ACID! direct! binding! Performed! with! Steve! Sturlis.! A.! In! the! top! panel,! ACID! is!highlighted!with! the! perturbed! residues! in! the!H2! binding! pocket! of! ACID! (blue).! In! the!middle!panel,!the!chemical!shifts!perturbations!observed!with!norstictic!acid!binding!(red)!are!overlaid!with!the!H2!binding!site!perturbations.! In!the!bottom!panel,! the!triple! lysine!stretch! directly! adjacent! to! the! H2! binding! site! is! highlighted! (green).! B.! Direct! binding!experiments! of! the! VP16(438:454):ACID! interaction! and! the! VP16(467:488):ACID!interaction! performed! with! each! of! the! mutants.! Kds! from! the! resulting! direct! binding!experiments! are! as! indicated.! Each! point! is! representative! of! the! mean! and! standard!deviation!of!conditions!run!in!triplicate.!The!data!was!fitted!using!graphpad!prism!4.0.!From!the!direct!binding!experiments! that!were!performed!with!each!of! the!ACID!H2!site!mutants! (K518R,!K519R,!K520R,!KK518RR,! and!KKK518RRR)!we! see! that! these!mutants!had!little!effect!on!the!Kd!of!the!VP16(438:454):ACID!or!VP16(467:488):ACID!interaction.!As!evidenced!in!Figure!3.29,!we!see!that!the!Kd!was!not!affected!by!the!mutants!more!than!2:fold! from! the! Kd! observed! with! the! wild! type! protein.! These! results! are! encouraging!because!it!suggests!that!the!conservative!K"R!mutations!are!capable!of!recapitulating!the!
VP16(438-454)-ACID direct binding
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electrostatic!interactions!made!by!the!native!lysines!with!the!VP16!TAD!without!affecting!binding.! Next,! we! sought! to! determine! if! these! K"R! mutations! affect! the! inhibition! of!norstictic! acid.! We! hypothesize! that! the! mutation! of! lysines! in! close! proximity! to! the!chemical! shift! peturbations! observed! with! norstictic! acid! inhibition! would! lead! to!increased!IC50!values.!The!K"R!mutations!would!retain!the!electrostatic! interactions,!but!would!prevent!norstictic!acid!from!forming!the!imine,!leading!to!an!increase!in!IC50!due!to!the!loss!of!covalent!binding!with!the!molecule.!
!
Figure!3.30!Effects!of!H2!site!lysine!mutations!in!competition!assays!performed!with!
norstictic! acid! on! the! VP16(4382454)2ACID! and! VP16(4672488)2ACID! interaction!Performed!by!Steve!Sturlis.!As! demonstrated! in! Figure! 3.30,! we! observed! steadily! increased! IC50s! as! the! number! of!lysines! mutated! to! arginines! increased.! As! depicted! in! Figure! 3.29,! no! single! lysine!mutation!to!arginine!was!capable!of!recapitulating!the!effect!observed!with!the!triple!lysine!mutant.! This! result! suggests! that! there! is! not! a! specific! lysine! responsible! for! imine!formation!with!norstictic!and!that!imine!formation!is!likely!possible!with!any!of!the!lysines!
Norstictic acid competition of VP16(438-454)-ACID











IC50 = 7.3 ± 1.0 µM
IC50 = 7.1 ± 1.2 µM
IC50 = 18.3 ± 5.0 µM
IC50 = 12.7 ± 1.7 µM
IC50 = 25.7 ± 5.4 µM
IC50 = 35.0 ± 10.1 µM




















IC50 = 5.0 ± 0.6 µM
IC50 = 6.1 ± 1.2 µM
IC50 = 14.3 ± 2.5 µM
IC50 = 7.6 ± 1.1 µM
IC50 = 25.3 ± 8.3 µM
IC50 = 26.8 ± 4.8 µM
IC50 = 29.5 ± 16.4 µM








Norstictic acid competition of VP16(467-488)-ACID






EC50 = 5.0 ± 0.6 µM
EC50 = 6.1 ± 1.2 µM
EC50 = 14.3 ± 2.5 µM
EC50 = 7.6 ± 1.1 µM
EC50 = 25.3 ± 8.3 µM
EC50 = 26.8 ± 4.8 µM











Figure! 3.31! Effects! of!H1! lysine!mutations! on!VP16(4382454)2ACID! and!VP16(4672
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results! that!would!be!expected.! Investigations!of! this!observed!result!will!be!tested!more!thoroughly!in!future!experiments!(Figure!3.31).!
!
Figure!3.32!Effects!of!H1!site!lysine!mutations!in!competition!assays!performed!with!
norstictic! acid! on! the! VP16(4382454)2ACID! and! VP16(4672488)2ACID! interaction!Performed!by!Steve!Sturlis.!As!demonstrated! in!Figure!3.32,! lysine!mutations! in! the!H1! site!of!ACID! lead! to! a!nearly!identical!increase!in!IC50!as!was!observed!with!the!triple!lysine!mutation!in!the!H2!site!of!ACID.!The!increase!in!IC50!values!with!H1!site!lysine!mutations!suggests!that!these!lysines!are!also!targets!of! imine! formation,!consistent!with!their!close!proximity! to! the!observed!chemical!shifts!perturbations!observed!with!norstictic!acid.!! Overall,! mutation! of! lysines! in! the! H1! or! H2! site! had! minimal! effects! on! direct!binding! of! the! α:helical! H1! peptide! and! the! α:helical! H2! peptide.! Surprisingly,! lysines!mutated!in!the!H1!or!H2!site!did!not!solely!affect!the!IC50!values!associated!with!the!H1!or!
Norstictic acid competition of VP16(438-454)-ACID








IC50 = 7.3 ± 1.0 µM
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Norstictic acid competition of VP16(467-488)-ACID








IC50 = 5.0 ± 0.6 µM
IC50 = 29.5 ± 16.4 µM









H2!interaction.!For!example,!the!KK411/413RR!mutation!in!the!H1!binding!site!would!be!expected! to! only! cause! the! norstictic! acid! IC50! to! increase! for! the! VP16(438:454):ACID!interaction,! but!we! also! observe! the!norstictic! acid! IC50! increase! for! the!VP16(467:488):ACID! interaction.!This! result! is! contrary! to! the!expected! results! from!mutating! lysines! to!arginines! in! either! the!H1! or!H2! site.! One! possibility! that! could! explain! this! observation!could!be!due!to!allosteric!effects! from!the!molecule.! In! figure!3.26,!we!demonstrated!that!there! was! significant! overlap! of! the! 1H:15N! HSCQ! chemical! shift! perturbations! with!norstictic!acid!and! the!previously!observed!chemical! shifts! reported! for!ACID! interaction!with! VP16! H1! and! VP16! H2.! However,! we! identified! a! region! of! chemical! shift!perturbations! with! norstictic! acid! on! helix! 2! of! Med25! ACID! that! were! unique! to! the!molecule!(Figure!3.33).!
!
Figure!3.33!Chemical!shift!perturbations!with!norstictic!acid!identified!on!helix!3!of!




expanding! on! the! possible! allosteric! mechanisms! of! norstictic! acid,! we! also! need! to!consider! the! role! of! cooperative! binding.! Others! have! previously! identified! cooperativity!with! the! VP16! TAD58:60,! suggesting! that! binding! of! one! subdomain! of! the! VP16! TAD!(VP16413:451! or! VP16452:490)! causes! increased! binding! of! the! other! VP16! subdomain.! If!inhibitors!such!as!norstictic!acid!can!bind!in!the!same!sites!as!the!native!ligands!VP16(413:451)!and!VP16(452:490),!it!is!possible!that!inhibition!could!also!be!acting!cooperatively.!In!a! cooperative!model! of! inhibition,!mutations! that! decreased! affinity! of! the! inhibitor! and!decreased! binding! on! one! site! would! cause! decreased! binding! on! the! other! site! since!cooperative! inhibition!would!be! inhibited,!providing!a!possible!explanation! the!observed!effects!with!norstictic!acid!inhibition!and!H1/H2!arginine!mutants.!!!CELLULAR!EXPERIMENTS!TESTING!THE!EFFECTS!OF!NORSTICTIC!AND!PSOROMIC!ACID!
Inhibition!of!Med25!ACIDEmediated!transcriptional!activity!of!ATF6α!! Next,!we! sought! to! determine! if! the! inhibition! that!we! observed! in!vitro! could! be!observed!in!cellular!assays.!We!first!attempted!to!develop!an!assay!to!investigate!the!ability!of! these! compounds! to! inhibit! a! Gal4:VP16TAD! chimera! from! activating! a! Gal4:driven!luciferase!reporter.!We!normalized!the!luciferase!output!of!this!assay!with!a!constitutively!expressed! β:Gal! reporter.! Unfortunately,! in! our! hands! the! Gal4:VP16TAD! construct! was!very! toxic! to! the! cells! and!made! assaying! compounds!with! this!method! difficult.!We! are!currently!pursuing!additional!studies!to!look!at!Gal4!fusions!based!on!just!the!VP16!H1!or!H2!domain!to!minimize!toxicity.!Due!to!the!toxicity!observed!with!the!Gal4:VP16!chimera,!we! looked! at! other! analogous! cellular! assays! to! assay! the! inhibitory! effects! of! our!compounds.! Experiments! performed! by! Sela! and! coworkers! looked! at! the! ER! stress!transcription! factor!activating! transcription! factor!6! (ATF6α)!and! its! interaction!with! the!Mediator!complex.12!More!specifically,! their!studies! found!that!ATF6α!TAD!is!responsible!for!recruiting!the!Mediator!complex.!Within!the!ATF6α!TAD!is!an!8!amino!acid!sequence,!DFDLDLMP! that! closely! resembles! the! VP16! TAD! sequence,! DFDLDMLG,! referred! to! as!VN8.61! Competition! using! the! VN8! sequence! against! ATF6α! demonstrated! that! VN8! can!compete!with!ATF6α!for!binding!to!the!Mediator!complex,!suggesting!that!ATF6α!and!VP16!have!the!same!or!overlapping!interaction!surfaces!on!Mediator!complex.!Given!the!recent!
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studies! demonstrating! VP16! binds! to! the!Mediator! complex! through!Med2527! and!more!specifically,!the!ACID!domain!of!Med25,!3,4!suggests!that!ATF6α!could!also!interact!with!the!Med25,!and!possibly!through!interaction!with!the!ACID!domain.!Follow:up!studies!by!Sela!and!coworkers!demonstrated!that!the!ATF6α!TAD!did!in!fact,!interact!with!the!Med25!ACID!domain! and! that! the! VN8! peptide! was! able! to! compete! with! the! ATF6α! TAD:ACID!interaction,! suggesting! that! the! ATF6α! TAD! and! VP16! TAD! use! overlapping! interaction!surfaces!on!ACID.!Given!the!ability!of!our!depsidones!to!inhibit!the!VP16:ACID!interaction,!we!reasoned!that!our!depsidones!should!also!be!able!to!inhibit!the!ATF6α!Med25:mediated!transcriptional! processes! through! inhibition! of! the! ACID! domain.! One! such! ATF6α:mediated! transcriptional!process! that! that!was!demonstrated! to!be!dependent!on!Med25!interaction!is!the!ER!stress:induced!HSPA5!gene.5!We!hypothesized!that!pre:treating!cells!with! norstictic! acid! or! psoromic! acid! before! inducing!HSPA5! expression!would! result! in!inhibition!of!HSPA5!expression!compared!to!untreated!cells!(Figure!3.34).!
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The! observed! inhibition! with! norstictic! acid! and! psoromic! acid! on! HSPA5! expression!demonstrates! that! the! identified! depsidones! are! capable! of! inhibiting! Med25:mediated!transcriptional!processes!that!rely!on!interaction!with!the!Med25!ACID!domain.!Based!on!this!observation!we!sought!to!determine!if!inhibition!could!be!observed!with!other!Med25:mediated!transcriptional!processes!dependent!on!interaction!with!the!ACID!domain.!!!
Inhibition!of!Med25!ACIDEmediated!transcriptional!processes!of!ERM!Recently,! ERM,! one! of! the! transcriptional! activators! in! the! PEA3! subfamily! of! Ets!proteins,! has! been! reported! to!make! direct! interaction!with! the!Med25! ACID! domain.! A!combination!of! luciferase!assays,!pull:downs,!and!squelching!experiments! identified!a!34!amino! acid! region! in! the! ERM!TAD! that! is! responsible! for! interaction!with!Med25!ACID.!Furthermore,! isothermal! titration! calorimetry! (ITC)! performed! with! this! 34! amino! acid!sequence!of!the!ERM!TAD!(ERM38:72)!was!demonstrated!to!have!a!Kd!of!543!+!40!nM!with!Med25!ACID,6! similar! to! the!affinities!observed!with! the!VP16!H1!and!H2!subdomains.!A!sequence! comparison! comparing! the! VP16! TAD! and! the! ERM! TAD! demonstrates! the!ERM(38:72)!subdomain!share!high!sequence!similarity!with!VP16!H1!(Figure!3.35A).!We!adapted!the!ERM(38:72)!peptide!for!an!FP!assay!by!conjugating!the!peptide!to!fluorescein!isothiocyanate.!Direct!binding!experiments!performed!with!this!peptide!and!purified!ACID!confirmed! the! reported!Kd! for!ERM(38:72)! (Figure!3.35B).! Furthermore,!we! see! that! the!ACID!H1!and!H2!lysine!to!arginine!mutations!do!not!affect!direct!binding!between!ERM(38:72)!and!ACID,!similar!to!the!effects!observed!with!VP16(438:454)!and!VP16(467:488).!We!also!observed!similar!inhibition!potency!with!norstictic!acid!against!the!ERM(38:72):ACID!interaction.! This! results! is! consistent! with! what! would! be! expected! given! the! sequence!similarity!between!ERM!and!VP16!H1!and!the!observed!effects!of!norstictic!acid!inhibition!against!the!VP16(438:454):ACID!interaction.!
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Figure!3.35!The!ERM2ACID! interaction! and! inhibition!of! interaction!with!norstictic!
acid!Performed!with!Steve!Sturlis.!A.!A!sequence!alignment!of!the!ERM!TAD!and!the!VP16!TAD,! residues! with! the! same! identity! are! highlight! in! grey! and! conserved! residues! are!outlined! in!a!black!box.!B.!Evaluating! the!Kd!of! the!ERM(38:72):ACID! interaction!using!a!direct!binding!FP!assay!using!a!fluorescein:tagged!ERM(38:72)!peptide!and!purified!ACID!protein!(Med25394:543).!C.!The!effects!of!lysine!to!arginine!mutations!in!the!ACID!H1!and!H2!site!on!ERM!direct!binding.!D.!The!effects!of! lysine! to!arginine!mutations! in! the!ACID!H1!and! H2! site! on! norstictic! acid! competition! of! the! ERM(38:72):ACID! interaction.! All! data!points! are! represented! as! the! mean! and! standard! deviation! of! conditions! performed! in!triplicate.! Curves!were! fitted! using! non! linear! regression! fit! in! graphpad! prism! software!4.0.!Based! on! the! observation! that! norstictic! acid! has! a! low! micromolar! IC50! against! the!ERM(38:72):ACID! interaction,! we! sought! to! determine! if! these! results! could! be!recapitulated! against! a! cellular! process.! One! such! process! that! is! regulated! by! the! ERM!transcriptional! activator! and! its! interaction! with! the! ACID! domain! to! recruit! the!transcriptional!machinery!is!MMP:1.6!MMP:1!has!previously!been!demonstrated!to!be!very!important!for!migration!in!breast!cancer!and!inhibition!of!MMP:1!has!been!demonstrated!to! inhibit! the! migration! of! MDA:MB:231! breast! cancer! cells.62! Therefore,! we! sought! to!determine! if! norstictic! acid! and! psoromic! acid! could! inhibit! migration! of! MDA:MB:231!cells.!In!order!to!assess!the!ability!of!norstictic!acid!and!psoromic!acid!to!inhibit!migration!of!MDA:MB:231!cells,!we!performed!wound!healing!assays!with!MDA:MB:231!cells!in!the!presence!of!DMSO!or!compound.!In!general,!these!wound!healing!assays!are!performed!by!
Direct binding with ERM38-72 and Med25 ACID












Kd = 0.46 ± 0.04 µM
Kd = 0.44 ± 0.11 µM
Kd = 0.13 ± 0.05 µM
Kd = 0.16 ± 0.06 µM
Kd = 0.39 ± 0.05 µM
Kd = 0.37 ± 0.04 µM








Direct binding with ERM(38-72) and Med25 ACID














Direct binding with ERM(38-72) and ed25 ACID
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Norstictic acid competition of ERM(38-72)-ACID













IC50 = 6.4 ± 1.3 µM
IC50 = 4.3 ± 0.7 µM
IC50 = 10.1 ± 1.5 µM
IC50 = 3.5 ± 2.1 µM
IC50 = 14.0 ± 3.2 µM
IC50 = 19.1 ± 2.7 µM
IC50 = 15.8 ± 3.5 µM









scratching!a!cell!monolayer!with!a!pipette!tip!to!form!a!wound,!compounds!are!added!and!closure!of! the!wound!(migration)! is!monitored.! In!wound!healing!assays!performed!with!MDA:MB:231! cells,! we! demonstrated! greater! migration! (wound! closure)! for! DMSO!controls! compared! to! cells! in! the! presence! of! either! norstictic! acid! or! psoromic! acid,!suggesting! that! these! compounds! are! capable! of! reducing! migration! of! MDA:MB:231!(Figure!3.36).!
!
Figure! 3.36!Monitoring!migration! of! MDA2MB2231! cells! dosed! with! norstictic! acid!
and! psoromic! acid! Performed! by! Paul! Bruno.! A.! General! procedure! for!monitoring! cell!migration!using!wound!healing!assay.!B.!Migration!of!MDA:MB:231!cells!in!the!presence!of!DMSO,!100!μM!norstictic!acid,!and!100!μM!psoromic!acid.!Images!are!of!cell!“wounds”!24!hours!post!“wound”!formation.!!









coworkers!performed!two:hybrid!assays!with!the!RAR!ligand:binding!domain,! identifying!the! Med25! as! an! interaction! partner.24! The! interaction! was! localized! to! the! NR! box! of!Med25! and! the! RAR! ligand:binding! domain;! however,! assays! that! overexpressed!Med25!did!not!result!in!greatly!enhanced!activity!of!RAR,!suggesting!that!recruitment!of!Med25!is!not!solely!sufficient!for!transcriptional!upregulation.!It!has!been!previously!demonstrated!that!CBP,! 63:65! a!histone! acetyl! transferase! (HAT),! is! recruited! to! induce!RAR! target! gene!upregulation,!resulting!in!a!hypothesis!that!both!CBP!and!Med25!need!to!both!be!recruited!to! induce! RAR! transcriptional! activity.! Pull:downs!with! the!Med25! domains! VWR,! ACID,!and!NR!box!demonstrated!that!the!ACID!domain!interacts!with!CBP,!specifically!to!the!N:terminus!of!CBP.!This!result!provides!a!possible!mechanism!for!how!RAR!can!recruit!both!Med25!and!CBP!to!its!promoter.!More!specifically,!an!interaction!between!RAR!and!the!NR!box!of!Med25!recruits!Med25!to!the!RAR!promoter!then,!Med25!can!recruit!CBP!through!the!Med25!ACID!domain!and! the!N:terminus!of!CBP,! resulting! in!CBP! recruitment! to! the!RAR! promoter24! (Figure! 3.34).! Overexpression! of! both! Med25! and! CBP! resulted! in!substantial! increases! in! transcriptional! activity! at! the!RAR!promoter,!when! compared! to!overexpression! of! Med25! or! CBP! individually.! This! result! suggests! that! interruption! of!Med25!ACID!and!CBP!N:terminus!interaction!would!result! in!reduced!recruitment!of!CBP!to! the! RAR! promoter! and! reduced! transcriptional! activity! at! the! RAR! promoter.! We!hypothesize! that! using! psoromic! acid! and! norstictic! acid! to! inhibit! the! Med25! ACID!interaction!with!the!CBP!N:terminus!will!result!in!reduced!activity!at!the!RAR!promoter.!In!order! to! test! this! hypothesis,! we! co:dosed! cells! transfected! with! a! luciferase! reported!containing! a! retinoic! acid! receptor! promoter! (pRARE:luc)! along! with! a! constitutively!expressed!β:Gal!reporter!(pCMV:β:Gal)! to!monitor!off:target!effects.!All! luciferase!signals!were!normalized!to!β:Gal!signal.!The!results!of!the!assay!are!as!illustrated!in!Figure!3.37.!
!
Figure! 3.37! Inhibiting! RARα! transcriptional! activity! with! psoromic! acid! and!
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recruitment! as! described! by! Lee! and! coworkers.! RARα!makes! specific! contacts!with! the!Med25!NR!box!(yellow)!and!the!ACID!domain!(blue)!recruits!CBP!through!interaction!with!CBP!N:terminus.!On!the!right,!we!demonstrate!decreased!RARα!transcriptional!activity!in!the! presence! of! ACID! inhibitors! norstictic! acid! and! psoromic! acid.! Cells! transfected!with!pRARE:luciferase! reporter! and! pCMV:β:Gal! were! co:dosed! with! retinoic! acid! and! either!DMSO!or!compound!as!noted!above.!All!DMSO!levels!were!kept!below!1%!v/v!for!cellular!dosings.!All!signals!were!normalized!to!β:Gal!activity!and!represent!the!mean!and!standard!deviation!of!4!replicates.!Given! the! observed! inhibition! using! norstictic! acid! and! psoromic! acid! against! three!different! Med25! ACID:mediated! transcriptional! processes,! we! are! confident! that! these!depsidone! inhibitors!can!effectively! inhibit! the!Med25!ACID!domain.!The!success! that!we!had! identifying! inhibitors! of! the! VP16:ACID! interaction! using! a! pilot! screen! against! our!high:throughput!assay!suggests!to!us!that!a!larger!screen!could!yield!other!interesting!and!more!potent!inhibitors!of!ACID.!!FULL! NATURAL! PRODUCT! EXTRACT! SCREEN! AGAINST! THE! ERM(38:72):ACID!INTERACTION!! When! we! initially! had! started! this! project! to! find! inhibitors! of! the! Med25! ACID!domain,! there! was! limited! structural! information! of! the! ACID! domain! and! even! less!literature!identifying!potential!interaction!partners.!This!lead!us!to!develop!the!assay!and!perform! the! screen! based! on! the! information! known! about! the! VP16:ACID! interaction.!During!the!course!of!our!screen!and!validation!of!the!hits,!additional!papers!were!published!identifying!new!transcriptional!activators!that!interact!with!ACID!such!as!ERM!and!ATF6α.!The! activity! of! these! transcriptional! activators! was! also! demonstrated! to! be! at! least!partially! dependent! on! the! interaction!with! ACID! to! upregulate! target! genes,! suggesting!that!identification!of!an!inhibitor!would!be!highly!valuable!as!a!mechanistic!tool!for!these!newly! identified! interactions!and! for! identifying!new! therapeutic! strategies!against! these!transcriptional!activators.!One!such!transcriptional!activator!that!is!of!particular!interest!to!us!is!ERM,!a!transcriptional!activator!of!the!PEA3!subfamily!of!Ets!transcription!factors.!The!ERM! transcriptional! activator! has! been! implicated! in! several! diseases! such! as! breast!cancer66,67!and!prostate!cancer.7!More!specifically,!ERM!dysregulation!has!been!associated!with! tumors! with! greater! metastatic! potential,! which! correlates! with! poorer! clinical!outcome.! Additionally,! the! TAD! of! ERM! has! only! been! demonstrated! to! contain! one!
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subdomain! capable! of! interaction! with! ACID,! whereas! VP16! contains! two! subdomains!capable! of! interacting! with! ACID.! This! observation! suggests! that! ERM!may! prove! to! be!easier! to! target! by! inhibiting! ACID! compared! to! VP16.! Given! the! role! of! ERM! in! human!disease!and!the!fact!that!only!one!subdomain!needs!to!be!inhibited!to!block!the!ERM:ACID!interaction,! we! performed! a! high:throughput! screen! using! the! natural! product! extract!library! in! the! CCG.! We! chose! to! use! the! natural! product! extract! library! due! to! the!identification! of! natural! products! from! the! pilot! screen! of! the! VP16:ACID! interaction.!Additionally,!identification!of!two!structurally!related!depsidone!inhibitors!of!Med25!ACID!suggests!that!there!are!privileged!scaffolds!that!may!be!well!suited!to!inhibit!Med25!ACID.!This!was! further! supported!by!an!additional! assay! looking! to! see! if! other!depsidone!and!depsides! exist! that! could! possibly! target! the!ACID!domain.! It! has! been!well! documented!that!lichen!organisms!are!rich!in!depsides!and!depsidones,!with!some!organisms!containing!as!much!as!5:10%!of!their!dry!weight!in!depsides!and!depsidones.68!Using!our!VP16:ACID!high:throughput!assay,!we!looked!a!plate!containing!different!lichen!extracts!from!various!lichen!organism!to!assess!whether!additional!depside!and!depsidone!inhibitors!may!exist!that!can!inhibit!this!interaction!(Figure!3.38).!
!
Figure!3.38!Investigating!inhibition!with!lichen!extracts!against!the!VP16(4672488)2
ACID! interaction! Performed!with! Steve! Sturlis.!We! identified! the!plate! by! searching! for!plates!that!were!rich!in!lichen!organism!extracts.!The!inhibition!assay!was!performed!the!same!way!as!the!pilot!screen.!Z’!score!was!0.89!and!18!hits!exhibited!>80%!inhibition.!We!observed!a! significantly!higher! amount!of! inhibition!when! testing! the! lichen!extracts!against!the!VP16(467:488):ACID!interaction.!In!the!original!pilot!screen,!we!had!a!1.6%!hit!rate!as!compared!to!the!lichen!extracts,!which!had!a!53%!hit!rate.!This!observation!is!not!
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entirely!surprising!since!we!identified!two!depsidones!and!one!depside!inhibitor!of!Med25!ACID!from!the!pilot!screen,!suggesting!that!this!core!may!serve!as!a!‘privileged!scaffold’!for!ACID! inhibition.!This! is! further!supported!by!the!high!hit!rate!of! this! lichen!extract!plate,!which! contains! extracts! that! are! rich! in! depsides! and! depsidones! and! validates! our!previous! hypothesis.! Based! on! this! observation,! we! reasoned! that! screening! the! natural!product!extracts!would!provide!molecules!with!greater!potency!as!well!as!access!to!other!possible! ‘privileged! scaffolds’! afforded! by! the! unique! chemical! matter! contained! in! this!library.! Using! the! same! assay! conditions! developed! for! the! VP16(467:488):ACID! high:throughput!pilot!screen!with!the!ERM(38:72):ACID!interaction,!we!tested!the!complete!set!of!~36,000!natural!product!extracts!(NPEs)!(Figure!3.39).!
!
Figure!3.39!Full!natural!product!extract!screen!against!ERM(38272)2ACID!interaction!Performed!with!Steve!Sturlis.!High:throughout!assay!was!performed!with!~36,000!natural!product!extracts,!producing!the!data!above.!As! evidenced! in! Figure! 3.39,! we! observed! several! extracts! that! demonstrated! potency!against!the!ERM(38:72):ACID!interaction.!We!are!currently!in!the!process!of!deconvoluting!these! extracts! to! determine! the! identity! of! the! active! compounds! in! the! extracts! with!greatest!potency.!Future!studies!will!be!completed!to!determine!the!identity!and!effects!of!these!compounds!on!Med25:mediated!ERM!transcriptional!activity.!!
3.4!Conclusions!Herein! in! chapter!3,!we!described!a!high:throughput! assay! could!be!developed! to!screen! against! the! Med25! ACID:VP16! interaction.! Through! an! iterative! process! used! to!truncate!the!VP16!TAD,!we!were!able!to!identify!the!minimal!interaction!domains!required!
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for! ACID! binding.! From! these! experiments,! we! were! able! to! determine! that! the! affinity!afforded! by! the! two! subdomains! of! VP16! (VP16413:451! and! VP16452:490)! could! be!recapitulated!with! the!minimal! α:helical! regions! of! the! two! subdomains,! suggesting! that!these! regions! are! the! major! contributing! regions! for! binding! to! the! ACID! domain.! By!identifying!the!minimal!interaction!regions!of!VP16!binding!to!ACID,!we!were!able!to!adapt!a!high:throughput!assay!based!on!the!minimal!interaction!interface,!a!feat!that!would!not!have! been! possible!with! full:length! VP16! due! to! its! limited! solubility.! Further! validation!was!completed!with!our!high:throughput!assay!demonstrating!its!stability!to!DMSO!(up!to!5%!v/v),! detergents! (NP:40)! and! the! large! dynamic! range! that! allowed! for! consistent! Z’!scores!>0.8.!Using! this! assay,! we! performed! a! pilot! screen! of! 4,046! compounds! in! the! known!bioactive!molecules! set! at! the! CCG.! The! initial! hits! from! the! pilot! screen!were! validated,!resulting! ! in! identification! of! depside! (baeomycesic! acid)! and! depsidone! (norstictic! acid!and! psoromic! acid)! inhibitors! of! the! ACID! domain.! We! demonstrated! good! selectivity!against!another!activator:coactivator!PPI!(MLL:KIX!and!CREB:KIX)!and!demonstrated!that!these!inhibitors!were!not!general!helix!mimetics!of!the!VP16!TAD!as!evidenced!by!the!high!IC50! values! obtained! against! another! reported! VP16! interaction.! Additional! studies!including!molecular! dynamics! and! salt! titrations! in! direct! binding! assays,! demonstrated!that! both! the!VP16:ACID! interaction! and! inhibition! of!ACID!with!depsidones! are! at! least!partially! drive! by! electrostatics.! Mass! spectrometry! demonstrated! that! these! depsidone!inhibitors!were! capable! of! covalently!modifying!ACID! through! imine! formation!on! lysine!side!chains.!Protein!NMR!experiments!with!ACID!and!norstictic!acid!demonstrated!that!the!chemical!shift!perturbations!closely!overlapped!with! the!shifts!observed!with! the!natural!ligands!(VP16413:451!and!VP16452:490),!suggesting!that!norstictic!acid!and!the!natural!ligands!utilize! similar! binding! sites! on! ACID.! Based! on! the! observed! imine! formation! with! the!depsidones! and! the! overlapping! binding! sites! between! the! molecules! and! the! natural!ligands!as!evidenced!by!protein!NMR!and!MD!simulations,!we!were!able!to!identify!a!select!set! of! lysines! hypothesized! to! be! the! site! of! imine! formation.! This! set! of! lysines! include!K518,! K519,! and! K520! in! the! ACID! H2! site! and! K411! and! K413! in! the! ACID! H1! site.!Mutation! of! these! lysines! to! arginines! allowed! us! to! observe! the! inhibition! effects! of!norstictic!acid!without!the!imine!formation.!These!experiments!resulted!in!higher!IC50s!for!
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Plasmids!The!plasmid!encoding! the!His6:tagged!KIX! from!mouse!CBP!(residues!586:672)!has!been!previously!described!(pHis6:PL:KIX).!69.!Plasmid!pET:21b:Med25(394:543):His6!was!a!kind!gift! from! Patrick! Cramer! (pACID:His6).! Protein! expression! plasmids! pACID(K518R):His6,!pACID(K519R):His6,! pACID(K520R):His6,! pACID(KK518RR):His6,! pACID(KKK518RRR):His6! were! generated! by! Steven! M.! Sturlis,! and! pACID(KK413RR):His6! was! generated! by!Paul! A.! Bruno! using! site:directed! mutagenesis! (SDM)! as! previously! described.70! pGL3:RARE:luciferase!was!purchased!from!Addgene!and!previously!described.71!pCMV:β:Gal!and!pBSSK!(non:coding!plasmid)!were!kind!gifts!from!Jorge!Iñiguez:Lluhí.!
!
Protein!expression!Non:labeled!Med25!ACID!(Med25394:543)!protein!was!expressed!and!purified!together!with!Steven! M.! Sturlis.! Plasmid! pET:21b:Med25(394:543):His6! (pACID:His6)! was! a! kind! gift!from! Patrick! Cramer.! This! plasmid!was! transformed! into! Rosetta! pLysS! cells! (Novagen).!Rosetta!pLysS!cells!transformed!with!pACID:His6!were!used!to!inoculate!a!25!mL!TB!starter!culture!with!0.1!mg/mL!ampicillin!and!0.034!mg/mL!chloramphenicol.!The!next!morning,!5!mL!from!the!starter!culture!was!added!to!1L!TB!with!ampicillin!and!bacteria!were!grown!at!37! °C!until! an!OD600!of!0.8! is! reached.!Temperature!was! reduced! to!18! °C! and! IPTG!was!added!to!a!final!concentration!of!0.5!mM!to!induce!expression.!Cells!were!left!overnight!at!18!°C.!Cell!suspensions!were!collected!and!centrifuged!at!5000xg!for!20!mins!at!4!°C.!Cell!pellets!were!frozen!at!:80!°C!until!ready!to!use.!Cell!pellet!from!expression!was!thawed!on!ice!and!resuspended!in!20!mL!50!mM!phosphate!buffer!(pH!6.8,!300!mM!sodium!chloride,!10!mM! imidazole).! Cells! are! lysed! by! sonication! on! ice.! Cellular! lysates!were! cleared! by!centrifugation! !at!9500!rpm,!20!min!at!4!°C!and!added!to!Ni:NTA!beads!(Qiagen).!After!1!hour!incubation!at!4!°C,!resin!is!pelleted!with!centrifugation!at!2500!rpm,!2!min,!4!°C!and!washed!with! phosphate! buffer! above! containing! 30!mM! imidazole.! This!washing! step! is!repeated!an!additional!4!times.!Protein!is!eluted!with!2!mL!of!phosphate!buffer!containing!400!mM!imidazole!three!times.!The!combined!eluates!are!purified!by!cation!exchange!FPLC!(Source!15S,!GE!Healthcare;! 0:1M!NaCl! in!50!mM!PBS! containing!1!mM!DTT).!The!FPLC!purified!protein!is!dialyzed!overnight!into!10!mM!phosphate!buffer,!pH!6.8!containing!50!
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mM! sodium! chloride,! 10%! glycerol,! and! 0.01%!NP:40! as! noted.! After! dialysis,! protein! is!concentrated! using! Millipore! 3000! kDa! cut:off! centrifuge! concentrators.! The! protein! is!>90%!pure!as!determine!by!coomassie!stained!polyacrylamide!gel.!Protein!concentration!is!determined!by!UV:Vis!(ε!=!22460!M:1!cm:1).!!!15N:labeled! Med25! ACID! (Med25394:543)! was! expressed! together! with! Steven! M.! Sturlis.!Rosetta! pLys! transformed! with! pACID:His6! were! used! to! inoculate! 25! mL! of! LB! broth!starter! cultures!with!0.1!mg/mL!ampicillin! and!0.034!mg/mL!chloramphenicol.!The!next!morning,! 5! mL! of! the! starter! culture! was! added! to! 1! L! LB! broth! with! ampicillin,! and!bacteria!were! grown! at! 37! °C! until! an! OD600! of! 0.8! is! reached.! Cells! were! pelleted! ! and!washed!with!M9!minimal!media.!Cells!from!1!L!culture!are!resuspended!in!1!L!M9!minimal!media!with!ampicillin!and!BioXpress!(Cambridge!Isotope!Laboratories)!added.!Cells!grown!in!shaker!at!37!°C!for!1!hr!before!temperature!is!reduced!to!18!°C!and!IPTG!is!added!at!a!final! concentration! of! 0.5!mM.! Cells!were! left! at! 18! °C! overnight.! Cell! suspensions!were!collected!and!centrifuged!at!5000xg!for!20!mins!at!4!°C.!Cell!pellets!were!frozen!at!:80!°C!until!ready!to!use.!Cell!pellet!from!expression!was!thawed!on!ice!and!resuspended!in!20!mL!50!mM!phosphate!buffer! (pH!6.8,! 300!mM!sodium!chloride,! 10!mM! imidazole).! Cells! are!lysed!by!sonication!on!ice.!Cellular!lysates!were!cleared!by!centrifugation!at!9500!rpm,!20!min!at!4!°C!and!added!to!Ni:NTA!beads!(Qiagen).!After!1!hour!incubation!at!4!°C,!resin!is!pelleted!with!centrifugation!at!2500!rpm,!2!min,!4! °C!and!washed!with!phosphate!buffer!above! containing!30!mM! imidazole.!This!washing! step! is! repeated!an! additional!4! times.!Protein!is!eluted!with!2!mL!of!phosphate!buffer!containing!400!mM!imidazole!three!times.!The!combined!eluates!are!purified!by!cation!exchange!FPLC!(Source!15S,!GE!Healthcare;!0:1M! NaCl! in! 50! mM! PBS! containing! 1! mM! DTT).! The! FPLC! purified! protein! is! dialyzed!overnight! into!10!mM!phosphate!buffer,!pH!6.8!containing!50!mM!sodium!chloride.!After!dialysis,!protein!is!concentrated!using!Millipore!3000!kDa!cut:off!centrifuge!concentrators.!The!protein!is!>90%!pure!as!determine!by!coomassie!stained!polyacrylamide!gel.!Protein!concentration!is!determined!by!UV:Vis!(ε!=!22460!M:1!cm:1).!!Med25! ACID! K518R! was! expressed! and! purified! by! Steven! M.! Sturlis.! Protein! was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!
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!Med25! ACID! K519R! was! expressed! and! purified! by! Steven! M.! Sturlis.! Protein! was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!!Med25! ACID! K520R! was! expressed! and! purified! by! Steven! M.! Sturlis.! Protein! was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!!Med25!KK518RR!was!expressed!and!purified!by!Steven!M.!Sturlis.!Protein!was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!!Med25! KKK518RRR! was! expressed! and! purified! by! Steven! M.! Sturlis.! Protein! was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!!Med25!KK411/413RR!was!expressed!and!purified!together!with!Steven!M.!Sturlis.!Protein!was!expressed!and!purified!as!reported!above!for!Med25!ACID!(Med25394:543).!!Non:labeled!Med15(1:345)!was!expressed!and!purified!as!previously!reported!by!Paul!A.!Bruno.14! Non:labeled! KIX! protein! was! expressed! and! purified! with! Steven! M.! Sturlis! as!previouisly!reported.69!Lab!stocks!of!Gal(1:100)!was!used!for!counter!screen.!This!protein!has!been!previously!reported.72!!
Peptide!synthesis!Peptides! are! synthesized! on! CLEAR! amide! resin! (Peptides! International)! using! standard!HBTU/HOBT/DIEA!coupling!conditions.!!Flo:VP16(413:437)! was! synthesized! and! purified.! Fluorescein! isothiocyanate! and! beta:alanine!was! coupled! to! a! sequence! containing!VP16! residues! 413:437! to!make! FITC:βA:APPTDVSLGDELHLDGEDVAMAHAD.!It!was!purified!by!reverse!phase!HPLC!(Agilent!1260)!on! a! C18! poroshell! column! (Agilent)! with! 20! mM! ammonium! acetate! in! water! and!!acetonitrile!as!eluents.!A!gradient!of!10:40%!acetonitrile!over!30!min!was!used.!Analytical!HPLC! trace! is! included! in! section! 3.6.! Peptide! was! lyophilized! to! a! fine! powder! and!
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reconstituted! as! a! DMSO! stock! and! diluted! in! PBS! buffer! to! an! appropriate! working!concentration.!The! concentration!of! Flo:VP16(413:437)!was!determined!by!UV:Vis! in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!!Flo:VP16(438:464)! was! synthesized! and! purified.! Fluorescein! isothiocyanate! and! beta:alanine!was! coupled! to! a! sequence! containing!VP16! residues! 438:464! to!make! FITC:βA:ALDDFDLDMLGDGDSPGPGFTPHDSAP.! It! was! purified! by! reverse! phase! HPLC! (Agilent!1260)!on!a!C18!poroshell!column!(Agilent)!with!20!mM!ammonium!acetate! in!water!and!!acetonitrile!as!eluents.!A!gradient!of!10:40%!acetonitrile!over!30!min!was!used.!Analytical!HPLC! trace! is! included! in! section! 3.6.! Peptide! was! lyophilized! to! a! fine! powder! and!reconstituted! as! a! DMSO! stock! and! diluted! in! PBS! buffer! to! an! appropriate! working!concentration.!The! concentration!of! Flo:VP16(438:464)!was!determined!by!UV:Vis! in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!!!Flo:VP16(465:490)! was! synthesized! and! purified.! Fluorescein! isothiocyanate! and! beta:alanine!was! coupled! to! a! sequence! containing!VP16! residues! 465:490! to!make! FITC:βA:YGALDMADFEFEQMFTDALGIDEYGG.!It!was!purified!by!reverse!phase!HPLC!(Agilent!1260)!on! a! C18! poroshell! column! (Agilent)! with! 20! mM! ammonium! acetate! in! water! and!!acetonitrile!as!eluents.!A!gradient!of!10:40%!acetonitrile!over!30!min!was!used.!Analytical!HPLC! trace! is! included! in! section! 3.6.! Peptide! was! lyophilized! to! a! fine! powder! and!reconstituted! as! a! DMSO! stock! and! diluted! in! PBS! buffer! to! an! appropriate! working!concentration.!The! concentration!of! Flo:VP16(465:490)!was!determined!by!UV:Vis! in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!
!Flo:VP16(438:454)! was! synthesized! by! Steve! M.! Sturlis! and! purified! by! Paul! A.! Bruno.!Fluorescein! isothiocyanate! and! beta:alanine!was! coupled! to! a! sequence! containing!VP16!residues! 438:454! to! make! FITC:βA:ALDDFDLDMLGDGDSPG.! It! was! purified! by! reverse!phase!HPLC!(Agilent!1260)!on!a!C18!poroshell!column!(Agilent)!with!20!mM!ammonium!acetate!in!water!and!!acetonitrile!as!eluents.!A!gradient!of!10:40%!acetonitrile!over!30!min!was!used.!Analytical!HPLC!trace!is!included!in!section!3.6.!Peptide!was!lyophilized!to!a!fine!powder! and! reconstituted! as! a! DMSO! stock! and! diluted! in! PBS! buffer! to! an! appropriate!
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working! concentration.!The! concentration!of! Flo:VP16(438:454)!was!determined!by!UV:Vis!in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!
!Flo:VP16(467:488)! was! synthesized! and! purified! by! Steven! M.! Sturlis.! Fluorescein!isothiocyanate!and!beta:alanine!was!coupled!to!a!sequence!containing!VP16!residues!467:488!to!make!FITC:βA:!ALDMADFEFEQMFTDALGIDEY.!The!concentration!of!Flo:VP16(467:488)!was!determined!by!UV:Vis!in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!Analytical!HPLC!trace!is!included!in!section!3.6.!!Flo:ERM(38:72)! was! synthesized! and! purified! by! Steven! M.! Sturlis.! Fluorescein!isothiocyanate!and!beta:alanine!was!coupled!to!a!sequence!containing!ERM!residues!38:72!to! make! FITC:βA:DLAHDSEELFQDLSQLQEAWLAEAQVPDDEQFVPD.! The! concentration! of!Flo:ERM(38:72)!was!determined!by!UV:Vis!in!10!mM!PBS!pH!7.4,!using!ε!=!72,000!M:1!cm:1!according!to!manufacturer!(Pierce).!Analytical!HPLC!trace!is!included!in!section!3.6.!!Flo:MLL,!Flo:pKID(CREB),!Flo:VP2!and!Fl:DNA!are!as!previously!reported.!72,73!!
Direct!binding!experiments!Direct!binding!assays!were!performed!in!triplicate!with!a!final!sample!volume!of!20!μL!in!a!low! volume,! non:binding,! black,! 384:well! plate! (Corning),! and! read! on! a! Pherastar! plate!reader! with! polarized! excitation! at! 485! nm! and! emission! intensity!measured! through! a!parallel! and! perpendicularly! polarized! 535! nm! filter.! FITC! (fluorescein! isothiocyanate)!labeled!peptides!were!diluted!in!storage!buffer!(10!mM!PBS,!100!mM!NaCl,!0.001%!NP:40,!10!%!glycerol,!pH!6.8)! to!a!centration!of!40!nM.!Then,!10!μL!of! the!peptide!solution!was!added!to!a!10!uL!solution!of!ACID!protein!that!had!been!previously!serially!diluted!2:fold!using!the!storage!buffer!noted!above!for!the!number!of!desired!dose!points.!This!resulted!in!a! final!concentration!of!20!nM!for! the!FITC!peptides.!The!samples!were! incubated! for!30!minutes!at!room!temperature!before!the!fluorescence!anisotropy!was!measured!(Pherastar!microplate!reader).!A!binding!isotherm!that!accounts!for!ligand!depletion!(assuming!a!1:1!binding!model!of!peptide!to!ACID)!was!fit!to!the!observed!anisotropy!values!as!a!function!of!ACID!to!obtain!the!apparent!equilibrium!dissociation,!Kd:!
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Equation!3.2!Where! “a”! and! “x”! are! the! total! concentrations! of! fluorescent! peptide! and! ACID,!respectively,! “y”! is! the! observed! anisotropy! at! a! given! ACID! concentration,! “b”! is! the!maximum!observed!anisotropy!value,!and!“c”!is!the!maximum!observed!anisotropy!value.!Each!data!point! is!an!average!of! three! independent!experiments!with! the! indicated!error!representing! the!standard!deviation!of! the! three!replicated.!Data!analysis!was!performed!using!GraphPad!Prism!4.0.!!Direct!binding!assays!testing!the!effect!of!tracer!concentration,!DMSO,!and!NP:40!effects!on!direct! binding! were! performed! using! the! procedure! above! including! either! a! higher!concentration!of!tracer,!including!DMSO!(5%!v/v),!or!NP:40!(0.001%!v/v).!!
Pilot!screen!of!VP16EACID!interaction!Pilot!screen!was!performed!with!Steven!M.!Sturlis.!The!concentration!of!ACID!protein!(850!nM),!tracer!used!(Flo:VP16(465:490)),!tracer!concentration!(20!nM),!and!inclusion!of!NP:40!(0.001%!v/v)!are!based!on!optimization!experiments!performed!in!chapter!3.!For!pilot!screen!of!VP16:ACID!interaction,!used!a!final!sample!volume!of!20!μL!in!a!low!volume,!non:binding,! black,! 384:well! plate! (Corning),! and! read! on! a! Pherastar! plate! reader! with!polarized! excitation! at! 485! nm! and! emission! intensity!measured! through! a! parallel! and!perpendicularly!polarized!535!nm!filter.!First,!5!μL!of!storage!buffer!was!added!to!each!well!of! the! 384:well! plates! using! a! Multidrop! dispenser! (Thermo! Fisher! Scientific).! Next,!compounds!were!added!to!each!well!using!a!pin!tool.!For!wells!that!were!used!as!negative!and!positive! controls,!DMSO!was!added! to! the!wells! in!place!of! compound.!Next,! 5!μL!of!ACID! at! a! concentration! of! 3.4! μM!was! added! to! each!well! using! a!Multidrop! dispenser!(Thermo! Fisher! Scientific).! For! positive! control!wells,! 5! μL! of! storage! buffer!was! added.!Once! protein!was! added! to! the!wells! containing! compound,! added! 10! μL! Flo:VP16(465:490)!at!a!concentration!of!40!nM,!bringing!the!final!volume!to!20!μL!in!each!well.!Let!plates!incubate! for! 30!minutes! before! reading! fluorescence! polarization! values! using! Pherastar!
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microplate!reader.!The!parameters!used!for!reading!fluorescence!polarization!are!outlined!above.!Data!was!analyzed!using!MScreen!database!software.!!
Substructure!search!of!CCG!database!and!testing!of!the!molecules!Substructure! search!was! performed! together!with! Steven!M.! Sturlis.! In! order! to! identify!other! molecules! that! contained! the! depside! or! desidone! core,! structures! of! either! the!depside!or!depsidone!core!was!used!as!a!scaffold! to!cross:reference! in! the!database.!The!structures! that! were! used! to! cross:reference! are! as! noted! in! Figure! 3.13A.! This!substructure!identified!an!additional!15!molecules!that!were!not!tested!in!the!original!pilot!screen.!The!15!molecules!that!were!identified!in!the!substructure!search!were!tested!with!the!5!molecules!containing!the!depside!and!depsidone!core!from!the!pilot!screen.!These!20!molecules!were!tested!in!a!dose!dependent!fashion!using!8!dose!points!that!were!prepared!by! the! CCG!with! the! highest! final! concentration! tested! at! 125! μM.!Data!was! exported! to!graphpad!prism!4.0.!Curves!and!IC50s!were!generated!using!the!non:linear!regression!fit!for!log(inhibitor)! vs! response.! All! data! points! were! represented! as! the! mean! and! standard!deviation!of!conditions!run!in!triplicate.!!
Competition!assay!dose!response!curve!with!norstictic!and!psoromic!acid!Competition! assay! was! performed! by! Steven! M.! Sturlis.! All! samples! were! performed! in!triplicate!and!assay!was!read!as! in!direct!binding!experiments.!All!assays!were! incubated!for! 30! minutes! at! room! temperature! before! the! fluorescence! emission! was! read! in! a!Pherastar! microplate! reader.! All! tracer:protein! complexes! were! set! at! 50%! bound! and!normalized! to! fraction! bound! of! 1.! Tracer:protein! complexes! tested! are! as! noted! in! the!graph.!All!tracer:protein!complexes!were!incubated!for!30!minuntes!at!room!temperature!to! reach! equilibrium! before! being! added! to! inhibitor! solution.! Compounds! was! serially!diluted!in!storage!buffer!and!subsequent!two:fold!dilutions!were!made!for!the!data!points!that! were! tested! in! a! volume! of! 10! μL.! After! the! dose! points! were! plated,! 10! μL! of! the!tracer:protein! complex!was! added! to! each!well.! Then,! incubated! plate! for! 30!minutes! at!room! temperature!before! reading! fluorescence!emission!on!Pherastar!microplate! reader.!The! anisotropy! data! was! plotted! in! graphpad! prism! software! 4.0! and! fitted! with! the!
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nonlinear! regression! equation! “log(inhibitor)! vs.! response! :! variable! slope”! in! order! to!determine!the!IC50!of!the!compounds!tested.!!
Direct!binding!experiments!with!salt!titration!The!direct!binding!experiments!were!performed!as!noted!above.!Assay!was!performed!by!Steven! M.! Sturlis.! Storage! buffer! (dilution! buffer)! had! salt! added! to! the! appropriate!concentration!prior!to!adding!components!to!384:well!plate.!All!data!points,!fitted!curves,!and!resulting!Kds!were!generated!using!Graphpad!Prism!4.0!software.!!
Competition!assay!with!norstictic!acid!and!salt!titration!Competition! assay! was! performed! by! Steven! M.! Sturlis.! All! samples! were! performed! in!triplicate!and!assay!was!read!as!in!direct!binding!experiments.!All!competition!assays!were!performed!as!reported!above.!In!order!to!test!for!effects!of!salt!titration!on!inhibition,!salt!at! the! indicated! concentration! was! pre:dissolved! in! storage! buffer! prior! to! running! the!assay.!!!
Mass!spectrometry!analysis!of!depsidone!covalent!adducts!ACID! protein! was! diluted! appropriately! in! storage! buffer! to! a! concentration! of! 10! μM!protein.! Compound! was! added! to! the! diluted! protein! to! a! concentration! equal! to! 4!equivalents!of!compound!to!protein!(40!μM).!The!protein:small!molecules!complex!mixture!was! incubated! for! 2! hours! at! room! temperature! with! gentle! shaking! using! an! orbital!shaker.!After! the! two!hour! incubation,!performed!mass! spectroscopy!using!an!Agilent!Q:TOF! HPLC:MS.! The! complex! mixture! was! run! on! a! Poroshell! 300SB:C8! reverse! phase!column.!A!gradient!of!5:100%!acetonitrile!with!0.1%!formic!acid!in!water!with!0.1%!formic!was!used!to!purify!and!analyze!the!complex!mixture.!Analysis!was!performed!using!Agilent!Qualitative! Analysis! Program.!Workflow!was! configured! for! “Bioconfirm”! and! extraction!data! format!was!set! to!use!Centroid! for!chromatogram!data!and!Profile! for!mass!spectral!data.! Extracted! mass! spectrometry! spectrum! had! the! background! subtracted,! before!deconvoluting! spectra! using! maximum! entropy! deconvolution! using! the! mass! range!provided.!!
!
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Mass!spectrometry!of!depsidone!reduced!imine!covalent!adducts!Sample!set:up!was!performed!the!same!way!as!noted!above!for!mass!spectrometry!analysis!of!depsidone! covalent! adducts.!After!2!hour! incubation! time,!100!mM!solution!of! freshly!prepared!sodium!borohydride!was!added!to!the!protein:small!molecule!mixture!to!a!final!concentration! of! 1! mM! sodium! borohydride.! A! hole! was! made! in! the! top! of! the! tube!containing!protein,!molecule,!and!sodium!borohydride!to!prevent!pressure!from!building.!Let! sodium! borohydride! incubate! with! protein! and! small! molecule! for! 1! hour! before!diluting!5:fold!and!dialyzing!overnight!to!remove!excess!salt!and!molecule!from!the!sample.!Mass! spectrometry! was! performed! as! noted! above! to! determine! the! presence! of! the!reduced!imine!and!the!overall!degree!of!labeling!of!protein!with!small!molecule.!
!
Mass!spectrometry!analysis!of!benzaldehyde!covalent!adducts!Procedure!was! repeated! as! outlined! in! the! procedure! for!mass! spectrometry! analysis! of!depsidone! covalent! adducts.! Instead! of! depsidones,! 4! equivalents! of! benzaldehyde! was!added!to!the!protein!and!left!to!incubate!for!2!hours!before!performing!mass!spectrometry!analysis.!
!
1HE15N!HSQC!protein!NMR!with!ACID!and!norstictic!acid!15N:labeled! ACID! protein! was! expressed,! purified,! and! concentrated! as! outlined! above.!Frozen!aliquot!of!protein!was!thawed!and!diluted!to!the!appropriate!concentration!for!the!desired!signal!strength!in!the!1H:15N!HSQC!spectra.!This!concentration!was!determined!in!a!control! experiment!with!protein! (data!not! shown)! at! an! earlier!date.! 15N:labeled!protein!was!diluted!to!a!concentration!of!30!μM.!Then,!DMSO!(negative!control),!3!equivalents!of!norstictic!acid,!or!5!equivalents!of!norstictic!acid!was!added!to!the!15N:labeled!protein.!The!protein:molecule!mixture!was!incubated!for!2!hours!at!room!temperature.!At!the!end!of!the!incubation!period,!a!sample!of!the!complex!mixture!was!submitted!for!mass!spectrometry!analysis!to!confirm!covalent!adduct! formation!between!the!molecule!and!protein.!Sample!was! immediately! submitted! for! 1H:15N!HSQC! analysis! perform! by! Felicia! Gray! (Cierpicki!Lab).! All! protein:molecule! samples! were! prepared! so! that! they! could! be! immediately!submitted! for! 1H:15N! HSQC! analysis! after! mass! spectrometry! confirmation! of! covalent!adduct!formation.!
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Assaying! inhibitory! effects! of! norstictic! acid! and! psoromic! acid! against! ATF6α! endogenous!
HSPA5!gene!expression!For! endogenous! gene! expression! analysis,! 1x105! HeLa! cells! were! seeded! into! a! 24:well!plate!and!allowed! to!adhere!overnight.!Media!was!removed!and!replaced!with!Opti:Mem!media! containing! vehicle! or! compound! delivered! in! DMSO! (0.5%! v/v)! at! the! indicated!concentrations.! After! incubating! for! 12! h,! cells!were! treated!with! thapsigargin! at! a! final!concentration! of! 500! nM.!After! 3! h,! the!media!was! removed! and! total! RNA!was! isolated!using! RNeasy! Plus! RNA! isolation! kits! (Qiagen)! according! to!manufacturer’s! instructions.!Each!RNA!sample!was!used!to!synthesize!cDNA!using!iScript!cDNA!synthesis!kits!(Bio:Rad).!Quantitative!real:time!PCR!(qRT:PCR)!reactions!were!carried!out!in!triplicate!in!an!Applied!Biosystems! StepPlusOne! using! SYBR! green! master! mix! and! primers! for! human! RPL19!(Forward,! 5’:ATGTATCACAGCCTGTACCTG:3’;! Reverse,! 5’:TTCTTGGTCTCTCTTCCTCCTTG:3’),! HSPA5! (Forward,! 5’: CTGGGTACATTTGATCTGACTGG:3’;! Reverse,! 5’:CTTACCGACCTTTCGGTGGTCCTACG:3’).! ! RT:qPCR! analysis! was! carried! out! using! the!comparative!CT!Method!(ΔΔCT!Method)!as!described!in!chapter!4!to!estimate!HSPA5!mRNA!levels!and!IL:8!mRNA!levels!relative!to!the!reference!RPL19!mRNA!levels.!!
Wound!healing!assays!performed!with!norstictic!acid!and!psoromic!acid!Wound!healing!assays!were!performed!as!outlined!in!chapter!2.!
!
RARα!luciferase!reporter!assay!The! RARα! luciferase! reporter! containing! 3! tandem!RARα! sites! (RARα:luc)!was! obtained!from!Addgene.!CMV:β:Gal,!and!pBSSK!were!generously!provided!by!Dr.!Jorge!Iñigues:Lluhí!(The!University!of!Michigan!Pharmacology!Department).!All!cells!were!maintained! in!5%!CO2! at! 37°C.! HeLa! cells! were! grown! in! Dulbecco’s! modified! Eagle’s! medium! (DMEM,!Invitrogen)!supplemented!with!10%!FBS.!For!luciferase!assays,!4x105!cells!were!seeded!in!a! 6:well! dish! and! allowed! to! adhere! overnight.! The!media!was! removed! and! cells! were!transfected! in!Opti:Mem!(Invitrogen)!with!1!μg!RARα:luc,!200!ng!CMV:β:Gal,!and!800!ng!pBSSK! using! Lipofectamine! 2000! (Life! Technologies)! according! to! manufacturer’s!instructions.! After! 4.5! h,! transfection! solution! was! removed! and! replaced! with! DMEM!containing!10%!FBS.!At!24!h!after!transfection,!cells!were!trypsinized!and!resuspended!in!
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4.1!Abstract!NF:κB! is! a!ubiquitous! transcription! factor! responsible! for! the! expression!of! genes!that! regulate! numerous! processes! including! inflammation,! cell! proliferation,! and! cell!differentiation.! Additionally,! the! mis:regulation! of! NF:κB! signaling! is! often! the! result! of!constitutive!activation!of! the!NF:κB!pathway! thus,!highlighting! the!need! for! inhibitors!of!NF:κB!signaling.!A!pre:requisite! for!NF:κB!activation!requires!assembly!of! the!tetrameric!complex! between! the! dimer! of! the! NF:κB! essential! modifier! (NEMO,! IKKγ)! and! the! c:terminal! tails! of! IKKα/β.! The!C:termini! of! IKK!α/β! are! highly! conserved! and! it! has! been!previously!demonstrated!that!a!six:amino!acid!sequence!(737LDWSWL742)!within!IKK!α/β!is!crucial! for! IKK! complex! formation.! Furthermore,! when! a! cell:permeable! peptide! is!appended! to! this! NEMO! binding! domain! (NBD),! only!modest! inhibition! can! be! achieved!(IC50!>100!μM),! likely!due!to!proteolytic! instability.!Herein,!we!describe!a!peptidomimetic!strategy! using! olefin! metathesis! on! peptides! to! inhibit! NF:κB! activity.! Through!incorporation!of!two!olefins!into!the!NBD!sequence,!we!performed!ring:closing!metathesis!to!generate!a!constrained!peptide.!This!constrained!peptide!demonstrates!greater!potency!(8:10:fold)!and!efficacy!compared!to!the!unmodified!NBD,!representing!a!new!strategy!for!inhibiting!the!assembly!of!the!IKK!complex!that!has!not!previously!been!explored.!!
4.2!Introduction!! Nuclear! factor! kappa:light:chain:enhancer! of! activated! B! cells! (NF:κB)! is! a!transcriptional!activator!that!was!discovered!in!the!lab!of!David!Baltimore!at!promoter!of!the! immunoglobulin! light:chain! enhancer! in! B! cells.1! NF:κB! consists! of! five! family!members:!RelA(p65),!RelB,! c:Rel,!p50,!and!p52!(Figure!4.1).!All!of! these! family!members!
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contain! a! Rel! homology! domain! (RHD)! that! consists! of! the! DNA:binding! portion! of! the!protein,!the!dimerization!domain/IκB!binding!region,!and!the!nuclear!localization!sequence!(NLS).!The! family!members!RelA(p65),!RelB,! and!c:Rel! contain! c:terminal! transcriptional!activation!domains,!whereas!p50!and!p52!do!not!have!c:terminal!!transcriptional!activation!domains.!This!observation!suggests!that!RelA(p65),!RelB,!and!c:Rel!effect!gene!regulation!largely!through!activation!while!p50!and!p52!most!likely!serve!as!repression!proteins.2!
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chronic!stimulation!of! the! IKK!complex!within! the!canonical!pathway,! 7:9!highlighting! the!potential! therapeutic!potential! of! targeting!parts! of! the! canonical! pathway! to! inhibit! IKK!acitivity!and!subsequent!NF:κB!activation.!! The! identity! of! NF:κB! has! been! known! for! over! 25! years! and! knowledge! of! the!canonical! pathway! has! been! documented! for! well! over! a! decade.! In! that! time,! several!successful! strategies! have! been! employed! to! target! the! canonical! pathway! of! NF:κB!activation! with! the! most! successful! endeavors! involving! development! of! monoclonal!antibodies,10! kinase! inhibitors,! 11,12! protease! inhibitors,13! and! glucocorticoids.14! (Figure!4.3).!
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beneficial! for! fine:tuning! the! NF:κB! activation! response! through! activation! of! other!pathways! for! the! desired! response.! Because! of! this! crosstalk,! NF:κB! can! exert! a! great!variety!of!responses!compared!to!more!linear!signaling!pathways.!However,!the!crosstalk!with!NF:κB!and!other!activation!pathways!makes!it!extremely!difficult!to!target!the!NF:κB!activation!specifically.!For!example,!several!kinase!inhibitors!have!been!developed!for!both!IKKα!and! IKKβ,!but! their! long:term!utility!has!been! limited!due! to! their!off:target!effects!against! other! signaling! pathways! reliant! on! the! kinase! independent! activity! of! IKKα! and!IKKβ.!In!the!case!of!IKKα,!there!are!several!independent!functions!of!IKKα!that!are!involved!in! crosstalk! with! other! pathways.! IKKα! has! been! demonstrated! to! regulate! cyclin! D1!levels,16! inhibit! interferon!production!through!phosphorylation!of! IRF5/IRF7,17!as!well!as!upregulate! activity! of! both! ERα18! and! β:catenin,19! all! through! the! independent!phosphorylation! activity! of! IKKα.! The! independent! function! of! IKKβ! has! been!demonstrated! to! result! in! cell! cycle! arrest! through! phosphorylation! of! Foxo3a,20! insulin!resistance!through!IRS:1!phosphorylation,21!and!mast!cell!degranulation!through!SNAP23!phosphorylation.22! Similar! independent! effects! of! proteasomes! in! the! NF:κB! activation!signaling!pathway!have!been!reported.!The!26S!proteasome!is!very!important!in!the!NF:κB!signaling!pathway! including!both!the!proteasomal!processing!of!p102!to!p5023!as!well!as!degradation! of! IκB,24! resulting! in! release! of! the! activated! p50:p65! transcriptional!heterodimer.! The! importance! of! the! 26S! proteasome! pathway! for! activation! of! NF:κB!would!suggest!that!this!pathway!is!an!important!possible!therapeutic!target!to!inhibit!NF:κB!activation;!however,!the!26S!proteasome!pathway!has!been!implicated!in!several!other!pathways! such! as! endoplasmic! reticulum! (ER)! stress,! the! androgen! receptor! (AR),! and!activator!protein:1! (AP:1).25!Therefore,! it!would! seem!unlikely! that! inhibitors!of! the!26S!proteasome!would!yield!NF:κB:specific!inhibitors.!Monoclonal!antibodies!also!have!limited!utility! in! the! case! of! resistance! conferred! through!mutations! in! the! target! receptor.! 26,27!Furthermore,! glucocorticoids! have! been! demonstrated! to! bind! directly! to! the! NF:κB!transcriptional!activator,!inhibiting!NF:κB!from!being!able!to!activate!its!respective!target!genes.28!However,! glucocorticoids! have! obvious! off:target! effects! from! their! activation! of!the!glucocorticoid! receptor! (GR)!pathway,!ultimately! limiting! their!use! for!any! long:term!treatment.29!Based!on!these!observations,!it!is!absolutely!critical!to!identify!processes!that!are!specific!to!the!NF:κB!pathway!when!thinking!about!how!to!develop!new!inhibitors!of!
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NF:κB.!Given!the!importance!of!several!of!the!processes!noted!above!for!activation!of!both!the!canonical!and!non:canonical!NF:κB!pathway!as!well!as!the!activation!of!other!signaling!pathways,!identification!of!signaling!events!specific!to!the!canonical!signaling!pathway!will!be!crucial.!One!possible!target!that!fits!the!criteria!laid!out!above!is!the!IKK!complex!of!the!NF:κB!canonical!activation!pathway.!!THE!NF:κB!IKK!COMPLEX!
Background!! The!NF:κB! IκB!kinase! (IKK)!complex! is!a! tetramer!protein!complex!specific! to! the!canonical!activation!pathway!of!NF:κB.!This!tetramer!is!made!up!of!two!subunits!of!the!NF:κB! Essential!Modifer! (NEMO/IKKγ),! IKKα,! and! IKKβ.! Furthermore,! knockdown! of! NEMO!inhibited! the! activation! of! the! NF:κB! activation! pathway.30! Additionally,! it! was!demonstrated!with!NEMO!knockdowns!that!the!NEMO!is!not!required!for!activation!of!the!non:canonical! activation! pathway,! exhibiting! no! effects! on! the! independent! activity! of!IKKα.!Together,!these!results!demonstrate!that!NEMO!is!essential!for!assembly!of!the!IKK!complex! required! for! activation! of! the! canonical! NF:κB! signaling! pathway.! Furthermore,!these! results! demonstrate! that!NEMO! is! not! required! for! activation! of! the! non:canonical!NF:κB!signaling!pathway!and!inhibition!of!NEMO!does!not!affect!the!independent!functions!of! the! IKKα/IKKβ! proteins,! which! are! required! for! several! other! cellular! pathways! as!highlighted!in!Section!4.2.!These!findings!suggest!that!targeting!NEMO!by!either!inhibiting!NEMO! dimerization! or! inhibiting! binding! of! IKKα! and! IKKβ! to! the! NEMO! dimer,! could!provide!selective!inhibitors!of!canonical!NF:κB!activation.!! Studies!to!define!the!structural!requirements!of!the!IKK!complex!were!performed!by!May!and!coworkers.!Using!pull:downs!with!truncated!versions!of!NEMO!used!as!bait!along!with!full!length!IKKα!and!IKKβ!and!conversely,!pull:downs!with!IKKα!and!IKKβ!truncations!as!bait!with!full!length!NEMO,!May!and!coworkers!were!able!to!localize!the!interaction!to!the! N:terminus! of! NEMO! (NEMO44:86).! Interestingly,! May! and! coworkers! found! that! the!IKKα! and! IKKβ! interaction! with! NEMO! could! be! localized! to! the! same! 10! residues!(IKKα/β735:745).! Upon! further! investigation,! May! and! coworkers! found! that! the! IKKα/β!interaction!with!NEMO!required!the!same!6:amino!acid!sequence!to! interact!with!NEMO,!demonstrating!that!IKKα!and!IKKβ!share!a!highly!conserved!interaction!region!with!NEMO!
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(Figure! 4.4A).! This! highly! conserved! sequence! was! also! dependent! on! the! presence! of!residues!D738,!W739,!and!W741!as!evidenced!by!co:IPs!with!NEMO!mutants.!Furthermore,!when! a! cell! penetrating! peptide! was! appended! to! this! conserved! sequence,! May! and!coworkers!observed!inhibition!of!HeLa!cells!transfected!with!a!NF:κB!luciferase!reporter,!suggesting!that!this!sequence!was!capable!of! inhibiting!the! formation!of! the!IKK!complex!(Figure!4.4B).! This! peptide! loss! the! ability! to! inhibit!NF:κB! luciferase! reporter!when! the!critical! tryptophans! were! mutated! to! alanines,! suggesting! the! importance! of! the!hydrophobic!interactions!made!with!these!tryptophans!and!NEMO.!31!!
!
Figure! 4.4! Identification! of! a! conserved! NEMO! interaction! domain! in! IKKα/β! and!





















against! the!NEMO:IKK!would!be!useful!both!as!a!mechanistic!probe,!but!also!as!possible!therapeutic! agent.! We! hypothesize! that! a! major! contributing! factor! to! the! absence! of!inhibitors! against! the! NEMO:IKK! complex! is:! 1)! The! general! challenges! associated! with!targeting!PPIs!and!2)! the!amphipathic!characteristics!of! the! IKKα/β! interaction!sequence!737LDWSWL742!may!have!been!hypothesized!to!be!an!amphipathic!α:helix,!which!may!have!derailed! previous! attempts! to! find! inhibitors! such! as! utilizing! small! molecule! libraries!designed!for!α:helices.!!!




Figure! 4.5! The! minimal! NEMO2IKK! heterotetramer! A.! The! crystal! structure! of! the!minimal!NEMO:IKK! interaction,! 3BRV.!Non:helical! structure! identified!by!black!box.!B.!A!snapshot! of! the! unstructured! region! of! the! NEMO:IKK! interaction! demonstrating! the!interaction! of! the! major! IKK! hydrophobic! residues! (green)! in! contact! with! the! NEMO!protein!surface! (blue).!These!residues!are!all! facing! towards! the!NEMO!dimer,! creating!a!kinked! formation.! C.! Demonstrating! the! key! hydrogen! bonds! stabilizing! the! kinked!formation!of!IKK!with!the!hydrogen!bonding!between!D738!and!S740!playing!a!major!role.!














residues!to!bind!to!their!target.35!These!hot!spot!residues!are!based!on!the!change!in!free!energy! (ΔΔGavg)! when! a! residue! in! a! helix! is! mutated! to! an! alanine,! with! a! cutoff! of! 2!kcal/mol.!A!well:known!example!of!an!extended!helix!containing!multiple!hot!spots!is!p53.!It!was!demonstrated! that! the!p53! interaction!with!mdm2! is! reliant! on!hot! spot! residues!F19,! W23,! and! L26! making! up! residues! i,! i+4,! and! i+7! of! the! extended! α:helix.! This!observation!would!suggest!that!the!IKK!extended!helix!contains!multiple!hot!spot!residues.!However,! Golden! and! coworkers! challenged! this! notion! with! an! experimental! analysis!investigating! the! location! of! hot! spots! at! the! NEMO:IKK! interface! through! a! systematic!alanine! scan! of! the! IKKβ! peptide! used! in! the! crystal! structure! noted! above.36! From! this!data,!they!were!able!to!determine!the!specific!binding!energy!of!each!residue!at!the!NEMO:IKK!interface.!The!results!of!their!study!are!presented!in!Figure!4.6.!
!
Figure! 4.6! Hot! spots! determined! by! alanine! scanning! mutagenesis! The! histogram!above!shows!the!calculated!contribution!to!the!NEMO:IKK!binding!energy!for!each!amino!acid.!ΔΔG!=!:RTln(KD2(mutant)/KD2(WT))!using!the!KD2!values!obtained!from!Golden!et!al.!J.!Am.!













































































are!some!additional!residues!that!do!contribute!>!1!kcal/mol!to!the!over!binding!energy!of!the!NEMO:IKK!interaction,!but!these!values!are!lower!than!what!is!traditionally!seen!with!extended! helices! such! as! p53.! Interestingly,! the! IKK! residues! 737:742! that! possess! the!highly!conserved!6:amino!acid!sequence!required!for!IKKα/β!binding!to!NEMO,!contained!four!residues!(D738,!W739,!W741,!and!L742)!that!would!be!defined!as!hot!spots!with!the!other! two!residues!(L737!and!S740)!having!moderate!effects!on!binding.!Together,! these!results! suggest! that! IKK(737:742)! truly! serves! as! a! “molecular! anchor”! for! the! IKK!interaction! with! NEMO.! Additionally,! this! data! provides! a! rationale! for! how! the! NEMO!binding! domain! (NBD)! peptide! can! inhibit! the! predominantly! α:helical! NEMO:IKK!interaction.!Therefore,!we!hypothesize!that!developing!a!stabilized!peptidomimetic!of!the!NBD!peptide!will!result!in!a!more!potent!inhibitor!of!NF:κB!activation.!!PEPTIDE!STABILIZATION!STRATEGY!USING!OLEFIN!METATHESIS!
Traditional!peptide!stabilization!strategies!using!olefin!metathesis!! Olefin!metathesis!has!gained!considerable!popularity!over!the!past!two!decades!and!more!recently,!it!has!been!adapted!for!several!biological!applications.!Some!of!these!other!applications! that! olefin! metathesis! has! been! adapted! for! include:! sugars,39! proteins,40!antibodies,41!and!!peptides.42!The!Grubbs!group!first!demonstrated!the!utilization!of!olefin!metathesis!on!a!heptapeptide!studied!by!Karle!and!coworkers!that!consisted!of!two!repeats!of!valine:alanine:leucine!separated!by!α:aminoisobutyric!acid.43!!Blackwell!and!coworkers!demonstrated!that!substitution!of!the!i!and!i+4!residue!with!an!allyl!serine!derivative!could!be! cyclized! using! ring! closing! metathesis! facilitated! by! grubbs! catalyst.44! Additionally,!Blackwell! and! coworkers! were! able! to! demonstrate! that! ring! closing! metathesis! can! be!utilized! to! pre:organize! α:helices! as! well! as! maintain! α:helicity! better! than! the!unconstrained!parent!peptide.!Traditionally,!the!olefin!metathesis!stabilization!strategy!has!been! applied! to! peptides! that! have! intrinsic! helicity! and! adopt! greater! α:helicity! upon!binding!to!the!target!protein.!Over!the!years,!other!groups!have!championed!the!utility!of!olefin! metathesis! to! stabilize! peptides! for! use! as! chemical! probes.! The! Verdine! and!Walensky!groups!demonstrated!the!use!of!side!chain:to:side!chain!olefin!metathesis!of!L:peptides! to! synthesize! constrained! α:helix! peptides! of! p53! and! BCL:2.! 45,46! From! these!studies,! Verdine! and! Walensky! were! able! to! demonstrate! that! these! constrained,!
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metathesized!α:helices!were!stable!to!denaturants!and!proteases.!This!increased!stability!is!hypothesized!to!result!from!“locking”!the!peptide!in!an!α:helix,!which!does!not!allow!these!peptides! to! adopt! the! extended! chain! structure! favored! by! proteases.! Furthermore,! the!presence! of! the! hydrocarbon! bridge! is! hypothesized! to! interfere!with! the! protease! from!binding!to!the!peptide!backbone.!The!Schepartz!group!demonstrated!that!the!use!of!side:to:side!chain!olefin!metathesis!of!β:peptides!could!be!used! to!synthesize!constrained!14:helices,!the!helical!structure!adopted!by!β:peptides.47!The!Schepartz!demonstrated!that!this!strategy!could!be!utilized!to!reactivate!p53.!The!Arora!group!demonstrated!that!the!use!of!side! chain:to:backbone! olefin! metathesis! as! a! hydrogen! bond! surrogate! (HBS)! could! be!used! to! synthesize! constrained!α:helix!peptides!of!HIF:1α.48! In! studies!with!denaturants,!they!observed!similar!stabilization!of!α:helical! structure!with! the!metathesized!construct!compared! to! the! unmodified! sequence,! further! suggesting! that! olefin! metathesis! of!peptides!provides!enhanced!stability!compared!to!the!unmodified!sequence.!!
Applying!olefin!metathesis!to!the!NEMOEbinding!domain!peptide!! The! main! takeaway! point! from! olefin! metathesis! with! peptides! is! that! olefin!metathesis!can!be!utilized!to!constrain!peptides!in!structurally!useful!ways!and!that!olefin!metathesis!can!be!used!as!a!hydrogen!bond!surrogate.!The!highly!conserved!6:amino!acid!sequence!in!IKKα!and!IKKβ!used!to!interact!with!NEMO,!also!known!as!the!NEMO:binding!domain! (NBD),! utilizes! a! unique! kinked! structure! in! order! to! interact! with! NEMO.!Furthermore,! this! NBD! is! associated! with! the! highest! binding! energy! of! the! NEMO:IKK!interaction,! suggesting! that! targeting! this! hot! spot! should! inhibit! NEMO:IKK! complex!formation! and! subsequently,! inhibit!NF:κB! activation.!May! and! coworkers! demonstrated!that! a! cell:penetrating! peptide! appended! to! the! NBD! (NBD! peptide)! was! capable! of!inhibiting!NF:κB,!suggesting!that!targeting!this!hot!spot!was!possible!with!a!peptide.!One!of!the!drawbacks!of! the!NBD!peptide! is! that! it! requires!high! concentrations! for! the!desired!effects! (IC50! >150! μM),! presumably! due! to! proteolytic! degradation.! Yet,! this! inhibitor! is!continually! used! in! new! studies! and! recently! in! a! clinical! phase! I! trial,! highlighting! the!important!utility!of!the!NBD!peptide!both!as!a!mechanistic!probe!and!possible!therapeutic!agent.!Therefore,!we!sought!to!determine!if!an!olefin!metathesis!strategy!could!be!applied!to!the!NBD!peptide!to!synthesize!a!more!potent!NF:κB!inhibitor.!Based!on!the!observation!
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that! D738! and! S740! form! a! critical! hydrogen! bond! that! helps! organize! the! NBD! in! this!unique! kinked! structure,! we! focused! on! utilizing! olefin! metathesis! as! a! hydrogen! bond!surrogate! for! this! critical! hydrogen! bond.! There! have! been! several! olefin! amino! acid!derivatives!developed!over!the!years!for!olefin!metathesis!of!peptide!(Figure!4.7).!!
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too!large!and!would!not!be!able!to!maintain!the!kinked!NBD!structure!as!well!as!a!smaller!macrocycle.! In! the! case! of! the! pentinoic! acid! and! the! N:substituted! amino! acid,! the!macrocycle! would! only! be! the! 10:membered! macrocycle,! meaning! that! this! derivative!would! only! be! able! to! recapitulate! one! of! the! possible! hydrogen! bond! stabilized! kinked!NBD!macrocycles.! In! order! to! synthesize! a! constrained! NBD! peptide! that! would! closely!mimic! the! naturally! occurring! hydrogen! bonded! macrocycle,! we! incorporated! an!allylglycine!residue!at! the!D738!and!S740!sites.!Olefin!metathesis!of! this!construct!would!result! in! an! 11:membered!macrocycle,! resulting! in! a! constrained! construct! that! is!more!similar!to!native!structure!(13:membered!and!10:membered!macrocycle)!(Figure!4.8).!
!
Figure!4.8!Comparing!NBD!peptide!hydrogen!bond!macrocycles!with!different!olefin!
metathesis! amino! acids! On! the! left! is! the! NBD! peptide!with! the! resulting!macrocycles!from! the! intramolecular!hydrogen!bonds.!Additionally,! the!other!macrocycles! that!would!result!from!using!different!olefin!metathesis!amino!acids!are!presented.!!
















































determining! inhibitory!potential!difficult.!This! is!particularly! true! for! the!Antp!CPP.49!We!chose!to!use!the!octalysine!(K8)!CPP!to!be!used!with!our!NEMO:binding!domain!mimics!due!to! its! effective! transduction! effects! in! fibroblasts! and! 293T! cells.50! Additionally,! the!octalysine!CPP!has!also!been!previously!demonstrated!to!have!no!toxic!effects!in!cells!and!is!well! tolerated! in!animal!models.49! In!order! to!minimize!any!effects! that! the!CPP!might!have!on!NBD!interaction!with!NEMO,!a!diglycine!spacer!was!used,!a!common!spacer!used!for! other! peptide! inhibitors! appended! with! a! CPP.! 51,52! In! order! to! carryout! the! olefin!metathesis!on!the!NBD!mimic,!olefin!metathesis!conditions!were!developed!to!facilitate!the!synthesis!of!these!macrocycles.!The!11:membered!macrocycle!that!we!need!to!synthesize!is!relatively! uncommon! in! terms! of! olefin! macrocycles! typically! synthesized,! and! medium!macrocycles!(8!to!12:membered)!can!be!difficult!to!cyclize!using!ring!closing!metathesis.53!
! 173!
!
Figure! 4.9! Constructing! the! NBD! mimics! and! optimizing! reaction! conditions! A.!Outlining! the! general! model! used! to! make! NBD!mimics! with! five! different! NBD!mimics!











































































































































synthesized! to! test! the! effects! of! olefin! metathesis! stabilization.! B.! Initial! reaction!conditions!tested!to!facilitate!ring!closing!metathesis.!C.!NBD!mimics!#3!met!and!#4!both!need!to!undergo!olefin!metathesis.!Here!we!demonstrate!the!#3!met!and!#4!sequences!that!need!to!be!metathesized.!!In!order!to!work!out!the!reaction!conditions!needed!to!facilitate!olefin!metathesis!of!NBD!mimics,!we!looked!at!the!effects!of!catalyst,!time,!solvent,!and!temperature!on!the!reaction.!Initially,! we! sought! to! use! conditions! optimized! by! Bird! and! coworkers! for! olefin!metathesized! α:helices! that! utilized! dichloromethane! (DCM)! and! Grubb’s! 1st! generation!catalyst! carried!out!at! room! temperature! for!4h.54!We!modified! this!protocol!by!utilizing!Hoyveda:Grubbs! 2nd! generation! (HGII)! catalyst,! which! has! higher! turnover! cycles! than!Grubbs!2nd!generation!(GII)!catalyst.55!Additionally,!we!also!extended!the!reaction!time!to!12!hours!compared!to!the!reported!4!hours.!Unfortunately,!we!saw!no!products!resulting!from!metathesis!utilizing! this!protocol.!We!hypothesize! that!no! reaction!occurred!due! to!the! greater! ring! strain! associated! with! our! 11:membered! macrocycle! compared! to! the!olefin!metathesized!α:helices!reported!by!Bird!and!coworkers,!which!result!in!much!larger!macrocycles.54! Next,! we! sought! to! determine! if! increasing! the! temperature! would! help!facilitate!the!ring!closing!metathesis!reaction!and!overcome!the!transition!state!required!to!facilitate! the! 11:membered! macrocycle.! We! also! hypothesized! the! higher! temperature!would! increase! the!activity!of! the!HGII! catalyst! since! it! requires!higher! temperatures! for!initiation.56! These!modifications! to! the! reaction! conditions! also! did! not! yield! any! of! the!desired!products.!Next,!we! sought! to!determine! if! aggregation!was!playing!a! role! for! the!lack!of!product!conversion.! In!order! to! investigate! the!role!of!aggregation,!we!performed!the!metathesis! reactions! in!a!1:1!mixture!of!DCM!and!10%!LiCl:DMF,!a! solution! that!has!been! demonstrated! to! aid! with! olefin! metathesis! in! aggregation! prone! reactions.57!Additionally,! we! also! used! GII! catalyst! with! continuous! heating! since! it! has! been!demonstrated!that!GII!has!a!lower!initiation!temperature!the!HGII.!We!also!let!the!reaction!run! for! extended!period! time! (65h),!based!on!observation!of!other!groups! that! some!bis!olefin! containing! peptide! can! take! as! long! as! 72h! for! complete! conversion.58! These!conditions! did! produce! trace! amounts! of! the! desired! products,! suggesting! that!we!were!minimizing! aggregation! and! reaching! temperatures! necessary! to! facilitate! metathesis.!Based! on! this! observation,! we! chose! to! try! the! same! reaction! conditions,! but! in! a!
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microwave! reactor.! By! performing! the! reaction! in! a! microwave! reactor,! we! can! benefit!from! higher! temperatures! while! minimize! the! safety! risk! associated! with! the! high!pressures!generated!at!high!temperatures.!We!also!chose!to!swap!the!GII!catalyst!with!HGII!catalyst!since!the!high!temperatures!will!be!enough!to!overcome!the!initiation!temperature!required!by!HGII,!allowing!us!to!benefit!from!the!higher!turnover!numbers!offered!by!HGII.!With!these!conditions!we!were!able!to!achieve!50%!conversion!of!#3!met!and!a!little!under!20%!conversion!for!#4.!These!results!demonstrate!that!we!were!able!to!work!out!reaction!conditions!for!olefin!metathesis!of!the!11:membered!NBD!mimic!peptide.!Now,!we!are!able!to! attain! >90%! conversion! of! both! #3! met! and! #4! by! performing! the! ring! closing!metathesis!before!adding!the!CPP!using!solid!phase!peptide!synthesis.!We!hypothesize!that!the!dramatically!increased!yields!is!due!to!minimization!of!aggregation.!By!performing!the!ring!closing!metathesis!before!adding!the!CPP,!we!provide!the!catalyst!greater!access!to!the!olefins!needed!to!facilitate!the!reaction.!!STRUCTURAL!CHARACTERIZATION!OF!NEMO:BINDING!DOMAIN!MIMICS!! As!noted!earlier,! all! previous! examples!of!utilizing!olefin!metathesis! to! synthesize!constrained!peptides!have!focused!on!constraining!α:helices.!Furthermore,!utilizing!olefin!metathesis!to!constrain!α:helices!has!been!demonstrated!to!increase!helicity!compared!to!the!unmodified!parent! construct.!However,!we!are!utilizing!olefin!metathesis! in!order! to!stabilize! the! kinked! NBD! peptide.! The! stabilization! of! the! NBD! peptide! using! olefin!metathesis! should!not!adopt!α:helical! structure!and!should!adopt!a!kinked,!unstructured!conformation.! For! the! purpose! of! circular! dichroism,! we! hypothesize! that! this! kinked,!unstructured!conformation!will!produce!spectra!consistent!with!random!coil!structure.!We!used! circular! dichroism! in! order! to! demonstrate! that! utilizing! olefin! metathesis! to!synthesize!our!NEMO:binding!domain!mimics!adopts!a!structure!that!is!not!α:helical!and!is!consistent!with!random!coil!structure!(Figure!4.10).!
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!
Figure! 4.10! Using! circular! dichroism! (CD)! to! analyze! the! secondary! structure! of!
NEMO2binding!domain!mimics!A.!CD!spectra!of!NEMO:binding!domain!mimics,!exhibiting!random! coil! structure,! consistent! with! published! crystal! structure! of! the! NEMO:IKK!interaction.!B.!Example!curves!of!CD!spectra!for!α:helix,!β:sheet,!and!random!coil.!As! evidenced! in! Figure! 4.10,! we! see! that! the! NBD! mimics! do! not! exhibit! secondary!structure!consistent!with!α:helical!structure.!Furthermore,!the!NBD!mimics!exhibit!random!coil! structure!as!evidenced!by! the!signal!minima! in!between!195:200!nm!(Figure!4.10A),!consistent!with!the!representative!CD!spectra!of!random!coil!structure!depicted!in!Figure!4.10B.!The!random!coil!structure!observed!with!the!NBD!mimics!using!circular!dichroism!is!also! consistent! with! the! crystal! structure! of! the! NEMO:IKK! interaction! where! it! was!observed!that!the!NBD!peptide!was!bound!in!a!kinked,!unstructured!conformation.!!INVESTIGATING!THE!PROTEOLYTIC!STABILITY!OF!NEMO:BINDING!DOMAIN!MIMICS!! One! of! the! major! challenges! to! using! peptide! inhibitors! is! the! susceptibility! of!peptides!to!proteolysis.59!Protein!degradation!is!a!natural!metabolic!process!that!exists!in!
































































on! peptide! stability! All! peptide! proteasomal! stability! assays! were! performed! with!
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chymotrypsin.!Time!points!tested!during!proteolytic!stability!assay:!0,!15,!30,!60,!120,!180,!and!360!minutes.!In!the!left!panel,!is!the!unmodified!parent!peptide!inhibitor!time!course!with! chymotrypsin.! In! the! middle! pane,! is! the! NBD! mimic! with! the! allylglycines!incorporated,!but!no!metathesis!in!time!course!with!chymotrypsin.!In!the!right!panel,!is!the!NBD!mimic!with!metathesis!in!a!time!course!with!chymostrypsin!!As! demonstrated! in! Figure! 4.11! (top! panel),! we! observe! immediate! degradation! of! the!parent!peptide!inhibitor!with!no!modification,!suggesting!that!the!high!IC50!observed!with!the!inhibitor!is!likely!due!to!proteolytic!degradation.!The!unmetathesized!NBD!mimic!with!allyglycine!incorporated!also!underwent!immediate!proteolytic!degradation.!Interestingly,!the!immediately!degraded!parent!compound!forms!some!sort!of!stabilized!intermediate!as!evidenced!by! the!peak! at! 10!min,!with! additional! degradation!products! appearing! at! the!later!time!points!(180!and!360!minutes)!(Figure!4.11,!middle!panel).!As!predicted,!the!NBD!mimic! containing! the!metathesized! constraint!did!not! appear! to!undergo! any!proteolytic!degradation! in! the! presence! of! chymotrypsin,! demonstrating! that! introducing! a!metathesized!constraint! into!the!NBD!does! increase!the!proteolytic!stability!(Figure!4.11,!bottom!panel).!!!INTERACTION!OF!NEMO:BINDING!DOMAIN!MIMICS!WITH!NATIVE!NEMO!! In! order! to! develop! these! NEMO:binding! domain! mimics,! we! needed! to! make!modifications!to!the!6:amino!acid!sequence!demonstrated!to!interact!with!NEMO,!including!substitution!of!D738!and!S740.!These!two!residues!together!accounted!for!over!4!kcal/mol!of! the! binding! energy! of! the!NEMO:IKK! interaction,! highlighting! the! importance! of! these!residues! in! the! interaction.! It! is! possible! that! through! substitution! of! these! residues! to!allyglycine,!that!we!may!have!lost!the!ability!to!interact!with!native!NEMO.!In!order!to!test!this! hypothesis,! we! created! biotin:labeled! “bait”! peptides! containing! p:benzoyl!phenylalanine!(pBpa).!This!strategy!has!been!used!previously!to!demonstrate!interaction!of!the! bait! peptide! with! the! target! protein.! 62,63! We! sought! to! utilize! this! Bpa! containing!peptide!strategy!to!demonstrate!interaction!with!native!NEMO!in!cellular!lysates.!Given!the!importance!of!the!6:amino!acid!NBD,!the!residue!chosen!to!substitute!with!pBpa!needed!to!be!carefully!chosen!so!as!not!to!inhibit!the!interaction!with!NEMO.!It!was!demonstrated!by!May!and!coworkers!that!there!were!specific!tolerances!of!the!W739!and!W741!residues!to!accommodate!mutations!in!the!NBD.64!The!W741!could!only!be!mutated!to!a!Phe!and!still!
! 180!
maintain! interaction! with! NEMO,! but! mutation! to! Tyr! or! Leu! abolished! the! interaction,!suggesting! that! this! residue! is! highly! sensitive! to! mutation.! Residue! W739! could! be!mutated!to!Phe,!Tyr,!and!Leu!while!still!maintaining!the!interaction!with!NEMO,!suggesting!that! the! W739! residue! is! more! tolerable! to! mutations! than! W741.! Therefore,! we!incorporated!Bpa! at! residue!W739! to! investigate! the! interaction! of! these! “bait”! peptides!with!NEMO.!By!utilizing!Bpa:containing!“bait”!peptides,!we!can!covalently!capture!protein!interaction! partners! by! irradiating! the! “bait”! peptide! with! UV! light,! inducing! radical!formation!and!covalent!bond!formation!with!the!interaction!partner!(Figure!4.12B).!These!complexes!can!then!be!pulled!down!using!the!biotin!tag!and!probed!for!the!target!protein!to!demonstrate!engagement!of! the!“bait”!with! the! target!protein.!The! two!“bait”!peptides!made!to!demonstrate!interaction!with!NEMO!in!cellular!lysates!were!construct!#1!and!#2!(Figure!4.12A).!
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HeLa! cells! The!NBD!peptides! tested! are! listed! to! the! right.! Each! of! the! constructs!were!tested! in!a!3:point!dose! response.!Unmodified!NBD!peptides! (#1!and!#2)!were! tested!at!200,!100,!and!25!μM,!whereas!modified!NBD!peptides!(#3!met,!#3!no!met,!and!#4)!were!tested!at!25,!10,!and!2!μM.!All!luciferase!signals!were!normalized!to!their!respective!β:gal!signal.!All!dose!points!represent!the!mean!and!standard!deviation!of!3!replicates.!From!these!NF:κB!luciferase!reporter!assays,!we!learned!several!things.!First,!we!were!able!to!produce!IC50s!(IC50!~!100!μM)!very!similar!to!other!data!obtained!with!NF:κB!luciferase!reporters!and!the!NBD!peptides!(construct!#1).!We!were!also!able!to!demonstrate!that!the!NBD! peptide! with! the! two! critical! tryptophans! mutated! to! alanines! (construct! #2)!exhibited!minimal! inhibition! of!NF:κB! luciferase! activity,! as! expected.! Interestingly,! both!













this! construct! was! unable! to! inhibit! an! NF:κB! driven! luciferase! reported.! This! result!suggests!that!the!NBD!mimic!(#3!met)!relies!on!these!critical!tryptophans!for!inhibition!of!NF:κB! driven! luciferase! activity,! similar! to! the! unmodified! NBD! peptide! (#1).! Together!these! results! suggest! that! the! NBD!mimic! (#3! met)! has! utility! as! an! inhibitor! in! NF:κB!reporter! systems.! Next,! we! sought! to! determine! if! the! same! inhibitory! effects! could! be!observed!against!native!NF:κB!target!gene!expression.!!NEMO:BINDING!DOMAIN!MIMICS!INHIBIT!NF:κB!TARGET!GENES!IN!HELA!CELLS!
! Based! on! the! potent! inhibition! observed! with! the! NBD!mimics! against! an! NF:κB!luciferase! reporter,! we! sought! to! determine! if! these! results! could! be! recapitulated! for!inhibition!of!native!NF:κB!target!genes! in!HeLa!cells.! In!order!to! investigate!the!ability!of!the! NBD!mimics! to! inhibit! NF:κB! target! genes,! we! looked! at! two! different! NF:κB! target!genes,! MIP3α! and! IL:8.! The! MIP3α! gene! is! primarily! regulated! by! p50:p65! NF:κB!heterodimers,65! whereas! IL:8! is! primarily! regulated! p65:p65! NF:κB! homodimers.66!Although!different!NF:κB!promoter!complexes!regulate!the!MIP3α!and!IL:8!genes,!the!NF:κB!canonical! activation!pathway!mediates!activation!of!both!of! these!genes.!Therefore,! if!we!inhibit!assembly!of!the!IKK!complex,!which!is!critical!for!canonical!NF:κB!activation,!we!should!not!see!promoter!specific!inhibition!of!MIP3α!and!IL:8,!we!should!inhibition!of!both!target! genes.! In! order! to! assess! the! effects! of! the!NBD!peptides! on!MIP3α!and! IL:8! gene!expression,!we!dosed!cells!with!100!μM!of!unmodified!NBD!peptides!(#1!and!#2)!and!10!μM!of!NBD!mimics!(#3!met!and!#4).!Cells!were!left!to! incubate!with!peptides!for!1!hour!before!stimulation!of!NF:κB!activity!using!IL:1β.!Cells!were!incubated!with!peptides!and!IL:1β!for!an!additional!2!hours!at!which!point!the!media!was!removed,!the!cells!were!lysed,!and!mRNA!was! isolated.! Both!MIP3α! and! IL:8!mRNA! levels!were! assessed! using! RPL19!mRNA!levels!to!normalize!against!(Figure!4.14).!!
! 184!
!
Figure!4.14!Inhibition!of!NF2κB!target!genes!MIP3α!and!IL28!using!NBD!peptides!The!charts! above! are! representative! of! target! mRNA! fold! induction! of! MIP3α! and! IL:8!normalized! to! RPL19! mRNA! levels.! Samples! treated! with! NBD! peptides! (#1! and! #2)!received! 100! μM! doses,! whereas! samples! treated! with! NBD! mimics! (#3! met! and! #4)!received! 10! μM! doses.! All! data! points! represent! the! mean! and! standard! deviation! of! 3!replicates.!As!demonstrated!in!Figure!4.14,!similar!inhibition!and!potency!against!two!different!NF:κB!target!genes!was!observed,! similar! to! the!effects!observed! in! the!NF:κB!driven! luciferase!reporter!assay.!The!same! increase! in!potency!of!NBD!mimic!(#3!met)! compared! to!NBD!peptide! (#1)!was! observed!with! about! a! 10:fold! increase! in! potency.! Similarly,! both! the!alanine!mutant!NBD!peptide!(#2)!and!alanine!mutant!NBD!mimic!(#4)!exhibited!little!to!no!inhibition! in! comparison! with! their! tryptophan! containing! counterparts.! This! result! is!encouraging!because!it!suggests!the!NBD!mimic!(#3!met)!is!not!only!useful!as!an!inhibitor!for! NF:κB! reporter! assays,! but! also! as! an! inhibitor! to! investigate! that! effects! on! NF:κB!target! genes.! The! utility! of! the! NBD! mimic! for! inhibition! of! NF:κB! target! genes! is!particularly!encouraging!because!this!looks!at!the!native!NF:κB!signaling!pathway!in!cells,!as!opposed!to!NF:κB!reporter!systems,!which!are!often!highly!artificial.!The!ability!to!use!NBD!mimics!as!an!inhibitor!of!native!NF:κB!target!genes!also!greatly!expands!its!utility!in!other!cellular!systems!such!as!other!cell! lines!or!even!tumor!primary!cells! from!patients,!whereas!NF:κB! reporter! systems!are!often!optimized! for! specific! cell! lines,! limiting! their!utility.!!
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complex!was!absolutely! critical! for!activation!of! the! canonical!NF:κB!activation!pathway,!highlighting! the! potential! therapeutic! applications! of! an! inhibitor! that! blocked! the!association!of! the! IKKα/β!with!NEMO.!One!of! the!primary! reasons! that! the!NBD!peptide!was!able!to!successfully!inhibit!the!IKK!complex!formation!between!NEMO!and!IKKα/β!was!through! exploitation! of! a! conserved! 6:amino! acid! sequence! shared! in! the! C:terminus! of!IKKα! and! IKKβ! and! was! found! to! be! indispensible! for! the! interaction! with! NEMO.! This!result! suggests! that! an! inhibitor! developed! based! on! that! conserved! sequence!would! be!able!to!inhibit!both!IKKα!and!IKKβ!assembly!with!NEMO.!! Despite! the! successful! targeting! of! the! IKK! complex! with! the! NBD! peptide,! and!localization! of! the! NEMO:IKK! interaction! to! a! defined! 6:amino! acid! sequence,! no! small!molecules! have!been!developed! against! this! interaction.!We!hypothesize! that! part! of! the!reason!that!no!small!molecules!have!been!developed!against!the!NEMO:IKK!interaction!is!due!to!the!ambiguous!structure!of!the!NBD.!It!was!originally!noted!as!being!amphipathic,!which! always! requires! consideration! of! the! sequence! having! α:helical! structure.! It! is!possible!that!with!the!assumption!that!the!domain!is!helical,!this!interaction!may!have!been!targeted! for!with! the!wrong! types! of! small!molecule! libraries! or! even! the!wrong! type!of!peptidomimetic! strategies.! Given! new! structural! data,! the! key! 6:amino! acid! interaction!domain! is! actually! confirmed! to! be! unstructured.! Furthermore,! studies! by! Golden! and!coworkers!found!that!a!large!number!of!the!residues!that!contribute!to!the!overall!binding!energy! of! the! NEMO:IKK! interaction! reside! in! this! unstructured! region! serving! as! a!“molecular!anchor”!for!the!NEMO:IKK!interaction.!This!is!contrary!to!what!is!traditionally!observed! with! 4:helix! bundles! and! with! extended! α:helical! interactions,! such! as! p53.!Together! these! results! suggest! that! targeting! the! highly! conserved! 737LDWSWL742! in! the!IKKα!and!IKKβ!C:terminus!is!the!verified!hot!spot!of!the!NEMO:IKK!interaction!that!should!be!targeted!for!development!of!inhibitors!of!the!NEMO:IKK!interaction.!! Our! initial!efforts! focused!on!developing!a!peptidomimetic! inhibitor!of! the!NEMO:IKK! interaction! through! constraining! the! conserved! 737LDWSWL742! sequence!using!olefin!metathesis.! Traditionally,! olefin! metathesis! has! been! used! to! constrain! alpha! helices!through!side!chain:to:side!chain!ring!closing!metathesis!reactions!or!through!backbone:to:side! chain! ring! closing! metathesis! reactions! as! a! HBS! (also! known! as! hydrogen! bond!surrogates).! We! demonstrated! how! ring! closing! metathesis! reactions! could! be! used! to!
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!The!crude!peptide!was!purified!by!reverse!phase!HPLC!(Agilent!1260)!on!a!C18!poroshell!column!(Agilent)!with!0.1%!TFA!in!water!and!acetonitrile!as!eluents.!A!gradient!of!10:40%!acetonitrile!over!30!minutes!was!used.!Analytical!HPLC!traces!of!the!peptide!are!placed!in!section! 4.6.! HPLC! fractions! were! combined! and! lyophilized! to! a! fine! powder! and!reconstituted!as!a!DMSO!stock.!The!concentration!of!the!stock!was!determined!by!UV:Vis!spectroscopy! in!a!solution!of!6M!guanidium!hydrochloride,!20!mM!PBS,!pH!6.5!using!ε!=!11,380!M:1!cm:1!as!outlined!by!Gill!and!von!Hipple.67!!NBD!peptide!#3!no!met!was! synthesized! and!purified.!At! the! final! step,! the!peptide!was!deprotected!with!20%!piperidine/DMF!for!20!minutes,!washed!3x!with!DMF,!3x!with!DCM,!and! 3x! MeOH.! A! global! deprotection/cleavage! solution! consisting! of! 95%/2.5%/2.5%!TFA/EDT/H2O! was! added! to! resin.! The! resin! was! agitated! for! 4! hours! with! continuous!shaking.!After!4!hours,! the!eluent!was!collect!and!TFA!was!removed!by!evaporation!with!N2.!The!crude!peptide!was!precipitated!overnight!with!cold!diethyl!ether.!Diethyl!ether!was!decanted!off!and!precipitate!was!washed!3x!with!cold!diethyl!ether.!This!yielded!the!free!amine!of!the!crude!peptide:!






















solution!of!anhydrous!DMF!containing!400!mM!LiCl!and!anhydrous!DCM!for!a!total!volume!of!3!mL.!Solution!was!degassed! for!30!minutes!by!bubbling!N2!through!the!solution.!HGII!(10!mol%)!was!immediately!dissolved!in!minimal!anhydrous,!degassed!DCM!before!adding!to!resin!solution.!Microwave!reaction!vial!was!purged!with!N2!before!sealing!with!crimper!tool.!Reaction!vial!was!transferred!to!a!microwave!reactor!(Biotage)!and!heated!for!10:15!minutes!at!100! °C!with!continuous!stirring! to! facilitate!metathesis! reaction.!The! reaction!mixture!was!transferred!to!a!peptide!synthesizer!vial!and!washed!3x!with!DCM!and!3x!with!DMF! in! order! to! wash! away! any! catalyst.! Peptide! synthesis! was! continued! to! add! the!tyrosine! chromophore,! octalysine! CPP! (K8)! and! diglycine! linker.! At! the! final! step,! the!peptide!was!deprotected!with!20%!piperidine/DMF!for!20!minutes,!washed!3x!with!DMF,!3x! with! DCM,! and! 3x! MeOH.! A! global! deprotection/cleavage! solution! consisting! of!95%/2.5%/2.5%! TFA/EDT/H2O!was! added! to! resin.! The! resin!was! agitated! for! 4! hours!with! continuous! shaking.!After!4!hours,! the! eluent!was! collect! and!TFA!was! removed!by!evaporation!with!N2.!The!crude!peptide!was!precipitated!overnight!with!cold!diethyl!ether.!Diethyl!ether!was!decanted!off!and!precipitate!was!washed!3x!with!cold!diethyl!ether.!This!yielded!the!free!amine!of!the!crude!peptide:!












removed!by!evaporation!with!N2.!The!crude!peptide!was!precipitated!overnight!with!cold!diethyl!ether.!Diethyl!ether!was!decanted!off!to!yield!the!crude!peptide:!!The!crude!peptide!was!purified!by!reverse!phase!HPLC!(Agilent!1260)!on!a!C18!poroshell!column! (Agilent)!with! 20!mM!ammonium!acetate! in!water! and! acetonitrile! as! eluents.! A!gradient!of!20:50%!acetonitrile!over!30!minutes!was!used.!Analytical!HPLC! traces!of! the!peptide!are!placed!in!section!4.6.!HPLC!fractions!were!combined!and!lyophilized!to!a!fine!powder!and!reconstituted!as!a!DMSO!stock.!The!concentration!of!the!stock!was!determined!by!UV:Vis!spectroscopy!in!a!solution!of!10!mM!PBS!using!ε!=!21,500!M:1!cm:1.!!Biotin!NEMO!peptide! !#2!was!synthesized!and!purified.!At!the!final!step,!the!peptide!was!washed!3x!with!DMF,!3x!with!DCM,!and!3x!MeOH.!A!global!deprotection/cleavage!solution!consisting!of!95%/2.5%/2.5%!TFA/TIPS/H2O!was!added!to!resin.!The!resin!was!agitated!for!2!hours!with!continuous!shaking.!After!2!hours,!the!eluent!was!collected!and!TFA!was!removed!by!evaporation!with!N2.!The!crude!peptide!was!precipitated!overnight!with!cold!diethyl!ether.!Diethyl!ether!was!decanted!off!to!yield!the!crude!peptide:!
!The!crude!peptide!was!purified!by!reverse!phase!HPLC!(Agilent!1260)!on!a!C18!poroshell!column! (Agilent)!with! 20!mM!ammonium!acetate! in!water! and! acetonitrile! as! eluents.! A!gradient!of!20:50%!acetonitrile!over!30!minutes!was!used.!Analytical!HPLC! traces!of! the!peptide!are!placed!in!section!4.6.!HPLC!fractions!were!combined!and!lyophilized!to!a!fine!powder!and!reconstituted!as!a!DMSO!stock.!The!concentration!of!the!stock!was!determined!by!UV:Vis!spectroscopy!in!a!solution!of!10!mM!PBS!using!ε!=!21,500!M:1!cm:1.!
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used!for!the!experiment!if!100!ms!with!a!monochromator/slit!bandwidth!of!1.00!nm.!Any!wavelength!readings!that!resulted!in!a!dynode!voltage!reading!!>600!V!was!omitted!from!the! data! set.! All! NBD! peptides!were! dissolved! in! 10!mM!PBS,! pH! 6.8! (no! salt)! at! a! final!concentration! of! 50! μM.! Calculated! the! mean! residue! molar! ellipticity! (MRE)! using! the!following!equation:!! !"# ∙ !"! ∙ !"#$!! = !""#$%#&#%'(!"#$) ∙ 10!!!"ℎ!"#$%ℎ !! ∙ [!"#$%&'](!") ∙ !!(Equation!4.1)!Where!n!=!#!of!peptide!bonds!in!protein!and!ellipticity!is!the!raw!data!from!the!instrument.!The!resulting!data!was!plotted!as!wavelength!(nm)!vs.!MRE![θ]!(deg!cm2!dmol:1).!!
Proteolytic!stability!assays!with!NBD!peptides!Peptides!tested!in!the!proteolytic!stability!assay!with!NBD!peptides:!


















































anti:rabbit!goat:HRP!antibody!diluted!1:10000!in!5%!w/v!milk!in!western!wash!buffer!for!1! hour! at! room! temperature.! Washed! membrane! 5x! with! western! wash! buffer! for! 5!minutes!per!wash.!Developed!membrane!with!west!fempto!ECL!reagnets.!!
NFEκB!luciferase!reporter!assay!for!assessing!inhibition!of!NBD!peptides!The!NF:κB!luciferase!reporter!plasmid!carrying!6!tandem!κB:sites,!NF:κB:luc,!CMV:β:Gal,!and! pBSSK! were! generously! provided! by! Dr.! Jorge! Iñigues:Lluhí! (The! University! of!Michigan!Pharmacology!Department).68!All!cells!were!maintained!in!5%!CO2!at!37°C.!HeLa!cells! were! grown! in! Dulbecco’s! modified! Eagle’s! medium! (DMEM,! Invitrogen)!supplemented!with! 10%! FBS.! For! luciferase! assays,! 4x105! cells!were! seeded! in! a! 6:well!dish!and!allowed!to!adhere!overnight.!The!media!was!removed!and!cells!were!transfected!in!Opti:Mem!(Invitrogen)!with!400!ng!NF:κB:luc,!200!ng!CMV:β:Gal,!and!1,400!ng!pBSSK!using! Lipofectamine! 2000! (Life! Technologies)! according! to! manufacturer’s! instructions.!After!4.5!h,! transfection!solution!was!removed!and!replaced!with!DMEM!containing!10%!FBS.! At! 24! h! after! transfection,! cells! were! trypsinized! and! resuspended! in! DMEM!supplemented!with!10%!FBS!and!seeded!into!a!96:well!plate!at!a!density!of!8x103!cells!per!well.!After!an!additional!16!h,!media!was!removed!and!replaced!with!Opti:Mem!containing!vehicle!or!NBD!peptides!delivered!in!DMSO!(1%!v/v)!at!the!indicated!concentrations.!After!cells!incubated!with!either!vehicle!or!compound!for!1!h,!cells!were!treated!with!either!PBS!or!IL:1β!at!a! final!concentration!of!2!ng/mL.!After!an!additional!3!h,!media!was!removed!and! cells! were! lysed! with! 60! μL! of! passive! lysis! buffer.! Luciferase! and! β:Galactosidase!activities! were! determined! as! previously! described.69! NF:κB! luciferase! activity! and!response!curve!analysis!was!performed!using!GraphPad!software.!!
Assaying!inhibitory!effects!of!NBD!peptides!against!NFEκB!endogenous!gene!expression!For!endogenous!gene!expression!analysis,!1x105!cells!were!seeded!into!a!24:well!plate!and!allowed! to! adhere! overnight.! Media! was! removed! and! replaced! with! Opti:Mem! media!containing! vehicle! or! NBD! peptide! delivered! in! DMSO! (1%! v/v)! at! the! indicated!concentrations.!After! incubating! for!1!h,! cells!were! treated!with! either!PBS!or! IL:1β! at! a!final! concentration! of! 2! ng/mL.! After! 2! h,! the! media! was! removed! and! total! RNA! was!isolated! using! RNeasy! Plus! RNA! isolation! kits! (Qiagen)! according! to! manufacturer’s!
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5.1!Conclusions!Included! in! this! dissertation,! we! have! presented! strategies! for! targeting! large!surface! area,! low! affinity! protein:protein! interactions! (PPIs).! When! classifying! protein:protein! interactions,!we! can! categorize! them!based!on! affinity! of! interaction! and! surface!area.!Historically,!the!small!surface!area,!high!affinity!PPIs!have!been!the!most!successfully!targeted! using! small! molecules.! Part! of! this! is! due! to! the! availability! of! small! molecule!libraries! targeted! at! other! small! surface! area,! high! affinity! interactions! such! as! the!interactions! involved! between! enzymes! and! their! ligands.! This! is! not! to! say! that! large!surface! area,! low! affinity! PPIs! are! undruggable.! Petidomimetic! strategies! aimed! at!mimicking! α:helices! and! β:strands,! common! secondary! structure! elements! found! at! the!interface!of!protein:protein! interactions,!have!resulted! in!a! small!number!of! successes! in!the! development! of! inhibitors! of! large! surface! area,! low! affinity! PPIs.! One! of! the! major!challenges! of! developing! inhibitors! for! large! surface! area,! low! affinity! PPIs! is! that! these!inhibitors! often! result! in! IC50s! in! the! low! micromolar! to! mid! micromolar! range.! These!resulting!IC50s!often!lead!to!off:target!effects,!which!can!make!the!utility!of!these!inhibitors!challenging.! One! way! to! counter! these! off:target! effects! is! by! utilizing! a! combination!approach!with!inhibitors!targeted!at!the!same!pathway.!As!we!demonstrated!in!chapter!2,!combination!approaches! targeted!at! the! same!pathway!can! lead! to! synergistic! inhibition,!resulting!in!dose!reductions!and!greater!selectivity.!The!inhibitor!i1!was!developed!as!an!inhibitor!of!the!ESX:Med23!interactions,!leading!to!downregulation!of!the!ESX!target!gene!Her2!in!Her2+!breast!cancer!cells.!In!the!case!of!HNSCC,!an!EGFR!and!Her2!overexpressing!
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cancer,! we! demonstrated! the! ability! of! i1! to! enhance! the! activity! of! the! EGFR/Her2!inhibitor!afatinib!in!both!cellular!assays!and!a!clinical!mouse!model!of!HNSCC.!We!also!developed!a!high:throughput!assay! for! the!discovery!of!new! inhibitors!of!the!VP16:ACID!interaction.!It!has!been!previously!demonstrated!that!VP16!transcriptional!activity! is! dependent! on! its! interaction! with! Med25,! specifically! with! the! ACID! domain!within!Med25.!The!80!amino!acid!VP16!TAD!makes!interactions!with!the!ACID!domain!on!two! separate! faces,! denoted! H1! and! H2.! Given,! the! large! surface! area! of! the! VP16! TAD!(>3500!Å),!we!sought!to!determine!the!minimal!interaction!of!the!VP16:ACID!interaction.!From!these!experiments,!we!were!able!to!determine!the!VP16:ACID!interaction!is!mediated!by!the!two!α:helical!domains!within!the!VP16!TAD!with!an!affinity!in!the!high!nanomolar:low! micromolar! range.! With! these! findings! we! were! able! to! develop! a! fluorescence!polarization! (FP)! assay! targeting! the! minimal! interaction! of! VP16:ACID.! Based! on! the!limited! success!with! traditional! small!molecule! libraries! against! these! large! surface!area,!low! affinity! interactions,! we! chose! to! use! the! assay! to! perform! a! pilot! screen! against! a!collection! of! bioactive! small! molecules! and! natural! products.! We! hypothesized! that! the!inclusion! of! natural! products!would! produce! a! higher! hit! rate! due! to! the! access! to! both!larger!molecules!and!possible!new!‘privileged!scaffolds’!better!suited!at!targeting!this!large!surface!area,!low!affinity!PPIs.1!The!resulting!pilot!screen!yielded!natural!product!depside!and!depsidone!inhibitors!of!the!VP16:ACID!interaction,!validating!our!original!hypothesis.!These!molecules!demonstrated!selective!inhibition!against!VP16:ACID!when!compared!to!MLL:KIX,!pKID:KIX,!and!VP16:Med15!counter!screens.!These!molecules!also!demonstrated!that!they!were!able!to!covalently!modify!ACID,!interacting!with!lysines!located!peripherally!to!the!H1!and!H2!binding!sites!on!ACID.!Conserved!mutations!of!these!lysines!to!arginines!maintained! affinity! seen! with! the! natural! ligands,! but! decreased! the! IC50s! of! the!compounds,!suggesting!that!these!lysines!were!critical!to!the!binding!mechanism!of!these!compounds.!Data!from!these!experiments!demonstrated!that!modifications!at!either!the!H1!and!H2!binding!sites!affects!the!inhibition!at!both!the!H1!and!H2!site,!suggesting!that!these!molecules! might! possible! be! acting! through! a! dual! orthosteric/allosteric! mechanism.!Additionally,! these! molecules! were! able! to! inhibit! ACID:mediated! transcriptional! events!carried! by! the!ATF6α,! ERM,! and!RARα! transcriptional! activators.! Together,! these! results!demonstrate! the! identification! and! validation! of! Med25! ACID! inhibitors.! Based! on! the!
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promising! results! obtained,! we! have! adapted! our! screen! for! screening! the! ERM:ACID!interaction! using! the! natural! product! extracts.! Using! this! library! of! compounds! has!produced!substantially!higher!hit!rates.!We!are!currently! in! the!process!of!deconvoluting!hits!from!this!natural!product!extract!screen.!Lastly,! we! demonstrated! the! development! of! a! new! inhibitor! against! the! NF:κB!activation! pathway.! There! have! been! several! successful! inhibitors! developed! against! the!NF:κB!signaling!pathway,!but!the!resulting!inhibitors!all!have!significant!off:target!effects,!limiting!their!long:term!use.!The!off:target!effects!that!these!inhibitors!elicit!is!often!due!to!their! inhibition/activation! of! other! signaling! pathways.! For! example,! kinase! inhibitors! of!the!NF:κB!exhibit!off:target!effects!due!to!the!independent!kinase!activity!of!IKKα!and!IKKβ!involved! in! cross! talk! with! other! pathways! such! as! ERα! and! Foxo3a! to! name! a! few.!!Additionally,! the! existence! of! both! a! canonical! and! non:canonical! NF:κB! activation!pathways!further!complicates!targeting!NF:κB.!This!prompts!the!need!to!identify!points!in!the!NF:κB!signaling!pathway!that!are!unique!to!NF:κB.!Additionally,!inhibitors!that!target!only! the! canonical! pathways! as! opposed! to! the! non:canonical! pathway!would! be! highly!advantageous! given! the! importance! of! the! canonical! pathway! for! the! constitutive! NF:κB!activation! found! in! several! diseases.! One! such! process! that! is! highly! specific! to! the!canonical!NF:κB!signaling!pathway,!is!the!assembly!of!the!IKK!complex!made!up!of!a!NEMO!dimer,!IKKα,!and!IKKβ.!Knockdowns!of!NEMO!were!unable!to!activate!the!canonical!NF:κB!signaling!pathway,!but!were!able!to!activate!the!non:canonical!pathways!and!left!the!kinase!independent!activity!of!IKKα!and!IKKβ!unaffected.!This!demonstrates!that!targeting!the!IKK!complex!should!provide!more!specific!inhibitors!of!the!canonical!NF:κB!signaling!pathway.!As!we!noted!earlier,!a!recent!examination!of!characterized!PPIs!has!demonstrated!that!at!the!interface!of!these!interactions,!26%!of!the!residues!are!composed!of!α:helical!structure,!24%!of!residues!are!composed!of!β:strand!structure,!and!50%!of!residues!are!made!up!of!‘non:regular’!secondary!structure!(loops,!turns,!and!coils).!This!last!category!represents!a!tremendous! opportunity! for! development! of! inhibitors! since! these! interactions!make! up!half!of!the!secondary!structure!found!at!the!interface!of!PPIs.!Furthermore,!most!strategies!have! traditionally! focused! on! targeting! α:helical! and! β:strand! secondary! structures.! One!PPI!that!has!been!characterized!as!being!made!up!of! ‘non:regular’!structure!is!the!NEMO:IKK!interaction.!A!recent!crystal!structure!of!the!NEMO:IKK!interaction!revealed!a!4:helix!
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bundle! heterotetramer! composed! of! an! N:terminal! NEMO! dimer! complexed! with! the! C:terminal! tails!of! IKKα!and! IKKβ.! Interestingly,! the! IKKα!and! IKKβ!share! the!same!NEMO:binding! domain! (NBD)! to! bind! to! NEMO,! composed! of! a! 6:amino! acid! sequence!737LDWSWL742,! which! exists! as! a! kinked,! unstructured! region! in! the! largely! α:helical!NEMO:IKK!interaction.!A!cell:penetrating!peptide!appended!to!this!sequence!demonstrated!inhibition! of! NF:κB! activity,! albeit! with! a! modest! IC50! (>150! μM);! however,! this! result!validates! that! targeting! the! IKK! complex! is! a! viable! target! for! inhibitor! development.!Interestingly,! alanine! screening! of! IKK! with! its! interaction! with! NEMO,! revealed! the!unstructured! region! of! IKK! as! the! hot! spot! of! the! interaction,! contrary! to! what! is!traditionally! seen! with! extended! α:helical! interactions! such! as! p53.! Using! this! data,! we!utilized! olefin! metathesis! that! has! been! traditionally! used! for! constrained! α:helical!peptides! and! adapted! this! technique! to! the! kinked,! unstructured! NEMO:binding! domain!peptide.! We! achieved! this! by! exploiting! the! critical! D738:S740! hydrogen! bond! that!stabilizes! this!kinked!structure!and!replacing! it!with!a!metathesized!olefin.!By!doing!this,!we!are!able! to!synthesize!a!NBD!mimic! that!was!more!proteolytically!stable!and!8!to!10:fold! more! potent! than! the! unmodified! NBD! peptide! at! inhibiting! both! an! NF:κB! driven!luciferase! reporter! as! well! as! endogenous! NF:κB! target! genes! MIP3α! and! IL:8.!Furthermore,! we! demonstrated! that! the! modifications! that! we! made! did! not! affect! the!ability! of! the!NBD!mimic! to! interact!with!wild:type!NEMO.! This!was! demonstrated!with!covalent!crosslinking!experiments!with!the!NBD!mimic!that!validated!the!ability!of!the!NBD!mimic! to! interact! with! NEMO! in! cell! lysates.! Together,! these! results! suggest! that! olefin!metathesis! stabilization! of! the! NBD! peptide! is! a! viable! route! for! synthesizing! better!inhibitors! of! the! NF:κB! activation! pathway.! Furthermore,! this! result! also! suggests! that!olefin!metathesis!stabilization!may!be!a!viable!inhibitor!development!strategy!of!other!non:regular!secondary!structures!found!at!the!interface!of!PPIs!in!the!future.!!
5.2!Future!directions!
Deconvolution! and! validation! of! hits! from! natural! product! extract! screen! of! ERMEACID!
interaction!! In! chapter! 4!we! presented! the! results! obtained! from! the! pilot! screen! against! the!VP16:ACID! interaction! that! identified! depside! and! depsidone! inhibitors! of!Med25! ACID:
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mediated!transcription.!Based!on!the!encouraging!results!obtain!from!the!pilot!screen,!!we!carried!out!a!full!natural!product!extract!screen!against!the!ERM:ACID!interaction!using!the!FP!assay!screen!that!we!developed.!We!chose!to!perform!the!natural!product!extract!screen!against! the! ERM:ACID! interaction! due! to! the! new! research! implicating! ERM! in! cancer!metastasis.!2:4!The!results!of!the!natural!product!screen!against!the!ERM:ACID!interaction!are! depicted! in! chapter! 4.! Based! on! the! results! from! the! natural! product! extract! (NPE)!screen,! we! carried! out! counter! screens! against! MLL:KIX! and! Gal4:DNA! in! order! to!determine!which!NPEs!were!selective!for!ERM:ACID!interaction.!With!the!NPEs!that!were!left! after! the! counter! screens,! we! selected! the! top! 30! NPEs! as! determined! by! percent!inhibition! in! the! ERM:ACID! screen.! M.! Beyersdorf! regrew! the! strains! from! the! selected!NPEs!in!order!to!verify!the!activity!of!the!NPEs.!These!NPEs!were!assayed!against!the!RARα!luciferase!driven!reporter!system!that!was!used!in!chapter!4.!This!assay!is!relatively!high:throughput! and! allowed! for! quick! assessment! of! inhibitory! activity! of! regrown! NPEs!(Figure!5.1).!!! ! !! !
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Figure!5.1!Effects!of!regrown!NPEs!against!RARα!luciferase!reporter!assay!The!assay!was!tested!as!a!single!dose!(0.1%!v/v).!All!extracts!were!diluted!to!a!uniform!concentration!of! 35! mg/mL! concentration! before! using! in! assay.! HeLa! cells! transfected! with! pRARE:luciferase!reporter!and!pCMV:β:Gal!were!co:dosed!with!retinoic!acid!and!either!DMSO!or!compound!as!noted!above.!All!DMSO!levels!were!kept!below!0.1%!v/v!for!cellular!dosings.!All! signals! were! normalized! to! β:Gal! activity! and! represent! the! mean! and! standard!deviation!of!2!replicates.!
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will! be! tested! for! additional! activity! in! other! assays! such! as! invasion,! migration,! and!motility!assays!with!ERM:dependent!cell!lines.!!
Developing!an!in!vitro!binding!assay!to!determine!inhibition!constants!of!NBD!mimics!! In! chapter! 5,! we! demonstrated! how! a! stabilized! NEMO:binding! domain! (NBD)!peptide! could!be! synthesized!using! olefin!metathesis.! These! inhibitors!were!8! to! 10:fold!more! potent! than! the! unmodified! NBD! peptide,! validating! this! stabilization! strategy.!Furthermore,!we!demonstrated!that!this!stabilized!mimic!was!able!to!interact!with!NEMO!in! cellular! lysates,! suggesting! that! the! modifications! do! not! affect! binding! to! the! native!target.!We!are!currently!trying!to!get!an!in!vitro!assay!developed!in!order!to!determine!the!inhibition!constants!of!the!NBD!mimics!compared!to!the!unmodified!NBD!peptides.!Other!groups!that!have!developed!olefin!metathesis!stabilized!α:helices!have!demonstrated!that!the! binding! affinity! increases!with! the! constrained! analogs! compared! to! the! unmodified!construct.! 5:7! One! of! the! reasons! that! we! would! like! to! develop! an! in! vitro! assay! of! the!NEMO:IKK!interaction! is! to!determine! if!we!observe!an! increase!of!affinity!with!our!NBD!mimics.! This!would! suggest! that! pre:constraining! the! NBD! peptide! increases! affinity! for!NEMO.!Additionally,!the!development!of!an! in!vitro!binding!assay!would!provide!an!assay!that!could!potentially!be!adapted! for!high:throughput!screening.!The! identification!of! the!NBD! peptide! as! a! hot! spot! for! the!NEMO:IKK! interaction!would! suggest! that! any! screen!using! this! in! vitro! assay! would! provide! molecules! against! the! important! region! of! the!NEMO:IKK!interaction.!!
5.3!Concluding!remarks!! Protein:protein! interactions! (PPIs)!mediate! numerous! cellular! processes.! External!and! internal!stimuli!experienced!by!cells!activate!signaling!pathways! in!order! to!respond!appropriately! to! these! stimuli.! These! responses! are! dysregulated! either! as! a! cause! or!consequence!of!disease,!and!therefore,!small!molecules!that!can!restore!normal!function!or!inhibit! aberrant! function! of! these! signaling! pathways! possess! enormous! therapeutic!potential.! The! signaling! pathways! that! cells! use! to! respond! to! stimuli! make! use! of!numerous!PPIs! to! turn!on! the!necessary! transcriptional!activators!needed! to!activate! the!appropriate!target!genes!to!respond!to!the!stimuli.!There!are!three!general!PPIs!that!can!be!
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targeted! to! affect! the! activity! of! transcriptional! activators:! regulatory! proteins,! masking!proteins,!and! interactions!with!coactivators.!These!PPIs!can!be!classified! into!one!of! four!classifications! when! considering! surface! area! and! affinity! of! the! interaction.! There! have!been! a! number! of! successes! targeting! low! surface! area,! high! affinity! PPIs! with! small!molecules;! however,! targeting! large! surface! area,! low! affinity! interactions! remains!challenging.!One!of!the!reasons!this!is!challenging!is!because!we!do!not!possess!adequate!tools!to!target!these!interactions.!For!example,!small!molecule!libraries!that!have!been!used!to! target! small! surface! area,! high! affinity! PPIs! have! had! some! success,! but! this! is! not!entirely!surprising!considering!the!similarity!between!these!interactions!with!interactions!between!proteins!and!ligands,!which!are!highly!targetable!with!small!molecules.!Here!we!presented! three! different! strategies! to! target! these! large! surface! area,! low! affinity! PPIs:!combination!strategies,!screening!with!natural!products,!and!stabilized!peptides.!! Although! these! interactions! remain! particularly! challenging! to! target! with!traditional! inhibitor! development!methods,!we! have! presented! strategies! to! target! these!types!of! interactions.!These! strategies!will! need! to!be! refined!over! time!as!would!be! the!case! with! any! other! targeting! strategy,! but! the! present! strategies! have! provided! crucial!information!for!future!development!of!inhibitors!targeted!at!large!surface!area,!low!affinity!PPIs.!!!!!!!!!!!!!!
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5.4!Materials!and!Methods!
RARα!luciferase!reporter!assay!with!NPEs!The! RARα! luciferase! reporter! containing! 3! tandem!RARα! sites! (RARα:luc)!was! obtained!from!Addgene.!CMV:β:Gal,!and!pBSSK!were!generously!provided!by!Dr.!Jorge!Iñigues:Lluhí!(The!University!of!Michigan!Pharmacology!Department).!All!cells!were!maintained! in!5%!CO2! at! 37°C.! HeLa! cells! were! grown! in! Dulbecco’s! modified! Eagle’s! medium! (DMEM,!Invitrogen)!supplemented!with!10%!FBS.!For!luciferase!assays,!4x105!cells!were!seeded!in!a! 6:well! dish! and! allowed! to! adhere! overnight.! The!media!was! removed! and! cells! were!transfected! in!Opti:Mem!(Invitrogen)!with!1!μg!RARα:luc,!200!ng!CMV:β:Gal,!and!800!ng!pBSSK! using! Lipofectamine! 2000! (Life! Technologies)! according! to! manufacturer’s!instructions.! After! 4.5! h,! transfection! solution! was! removed! and! replaced! with! DMEM!containing!10%!FBS.!At!24!h!after!transfection,!cells!were!trypsinized!and!resuspended!in!DMEM!supplemented!with!10%!FBS!and!seeded!into!a!96:well!plate!at!a!density!of!8x103!cells!per!well.!After!an!additional!16!h,!media!was!removed!and!replaced!with!Opti:Mem!containing!vehicle!or!NPE!(0.1%!v/v)!as!a!solution!in!DMSO!co:dosed!with!retinoic!acid!(1!μM).! After! cells! incubated! with! either! vehicle! or! compound! and! retinoic! acid! for! 16! h,!media!was!removed!and!cells!were!lysed!with!60!μL!of!passive!lysis!buffer.!Luciferase!and!β:Galactosidase! activities! were! determined! as! previously! described.! RARα! luciferase!activity!and!response!curve!analysis!was!performed!using!GraphPad!software.!!!!!!!!!!!!!
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A.1!Abstract!A! 7:step! synthesis! of! pharbinilic! acid,! a!member! of! the! gibberellin! family! of! natural!products! and! the! first! naturally! occurring! allogibberic! acid,! is! reported.! An! efficient!decarboxylative! aromatization! reaction! enables! the! synthesis! of! pharbinilic! acid! and!related! analogs! for! evaluation! as! modulators! of! NF:kB! activity.! Remarkably,! one! analog!displays! a! 2! mM! IC50! in! an! NF:kB! activity! assay! and! inhibits! an! endogenous! NF:kB:regulated!pathway.!!
A.2!Introduction!Pharbinilic!acid!(1)!is!a!member!of!the!rare!class!of!allogibberic!acids,!isolated!from!the! seeds!of!morning! glory! (Pharbitis!nil)! used! in!Korea,! China! and! Japan! as! a!medicinal!agent.1!Allogibberic!acids!were!originally!reported!as!laboratory:generated!decomposition!products!of!gibberellic!acid!(2),!a!phytohormone!responsible!for!the!regulation!of!growth!and!developmental!processes!in!higher!plants.2!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*! This! work! is! part! of! a! collaborative! effort.! J.! R.! Anannd! synthesized,! purified,! and!characterized! all! synthetic! compounds.! P.! A.! Bruno!performed!NF:κB! reporter! assay! and!endogenous! gene! expression! analysis.! This! chapter! is! adapted! from! a! published! article:!Annand,!J.!R.;!Bruno,!P.!A.;!Mapp,!A.!K.;!Schindler,!C.!S.!Synthesis!and!biological!evaluation!of!pharbinilic!acid!and!derivatives!as!NF:κB!pathway!inhibitors!2015,!Advance!Article,!DOI:!10.1039/C5CC02918J:Reproduced! with! permission! of! The! Royal! Society! of! Chemistry!(RSC).!
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Figure!A.3!Synthesis!of!the!hydroxyl:allogibberic!methyl!ester!(9).!Our! synthetic! strategy! to! pharbinilic! acid! (1)! requires! a! mild! aromatization! protocol! to!form! phenol!9! under! non:aqueous! conditions! to! avoid! both! epimerization! of! the! C9b:H!present!in!the!epi:allogibberic!acid!core!as!well!as!the!undesired!C12:C13!rearrangement!of!the!C!and!D!rings.!Gibberellic!acid!(2)!was!initially!converted!to!its!corresponding!methyl!ester!(7)!using!methyl!iodide!in!acetone!in!98%!yield.!Griffith:Ley!oxidation!(TPAP/NMO)!of!the!secondary!alcohol!proved!superior!over!other!oxidation!conditions!investigated!(e.g.!DMP,!IBX,!PDC)!which!resulted!in!either!low!yields!or!a!complex!product!mixture,!leading!to! the! formation! of! enone! 8! in! 83%! yield.! Enone! 8! was! found! to! be! very! sensitive! to!Brønsted!acids,!both!in!aqueous!and!anhydrous!environments.!Treatment!of!8!with!dilute!mineral! acids! (e.g.! HCl,! H2SO4)! resulted! in! the! formation! of!9! along!with! the! undesired!C9a:H!epimer.!Changing! to!anhydrous!organic!acids! (e.g.! acetic!acid,! formic!acid,!pTsOH)!circumvented!the!issue!of!epimerization;!however,!only!the!product!of!Wagner:Meerwein!rearrangement!of!the!C12:C13!bond!without!A:ring!aromatization!was!observed.!We!next!investigated! selective! transformations! of! the! allylic! lactone! in! 8! using! transition! metal!catalysis.!The!desired!rearomatization!of!the!A!ring!was!accomplished!using!Pd(PPh3)4!(5!mol%)! in! aqueous! DMSO! at! 110°C,! however! concomitant! Wagner:Meerwein!
! 223!
rearrangement! was! also! observed! to! form! ketone! 10! as! the! sole! product.! Careful!investigation! of! the! reaction! conditions! revealed! that! the! Wagner:Meerwein!rearrangement!was!highly!sensitive!to!the!reaction!temperature.!As!a!result,!conducting!the!aromatization!at!80°C!provided!the!desired!phenol!9!in!90%!yield.!
!
Figure! A.4! Synthesis! of! derivatives! of! pharbinilic! acid! (1)! via! Wagner:Meerwein!rearrangement!of!the!C,D:bicyclic!ring!system!in!10!leading!to!ketone!12.!!With! a! route! to! phenol! 9! secured,! the! viability! of! a! palladium:catalyzed! oxidative!cyclization!approach!to!construct!the!A:ring!benzofuran!moiety!was!explored.!The!required!3:phenoxyacrylate! 11! was! readily! prepared! as! the! corresponding! conjugate! addition!product! of! methylacrylate! and! phenol! 9! in! 90%! yield.12! Treatment! of! 11! with!Pd(OAc)2/PPh3!and!AgCO2CF313!in!benzene!at!110°C!
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Figure! A.5! Completion! of! the! synthesis! of! pharbinilic! acid! (1)! in! seven! synthetic!transformations.!resulted! in!the! formation!of!benzofuran!12! (63%!yield)!as! the!sole!product!of!a!Wagner:Meerwein! rearrangement:decarboxylation! sequence.! Subsequent! attempts! to! avoid!decarboxylation! during! oxidative! benzofuran! formation! centered! around! changing! the!palladium! source! (Pd(OAc)2,! Pd(PPh3)4,! PdCl2)! as! well! as! the! corresponding! oxidant!(AgCO2CF3,!PhI(OAc)2,!O2)!while!varying! the! temperature! from!ambient! temperature! to!110ºC.!However,!none!of! these!conditions! led!to!the! formation!of! the!desired!benzofuran!methyl!ester!and!the!sole!product!isolated!upon!reaction!of!phenoxyacrylate!11!remained!benzofuran!12.!As!we!were!unable!to!circumvent!decarboxylation!and/or!WM!rearrangement!from!
10,!we! revised!our! strategy! to! rely!on!bromophenol!13! to! enable! a! intramolecular!Heck!reaction!to!form!the!benzofuran,!avoiding!the!use!of!Lewis!acidic!additives!that!may!have!contributed!to!the!undesired!WM!rearrangement!and/or!decarboxylation.!Bromination14!of!
10! (NBS,! iPr2NH,! 60%! yield)! followed! by! conjugate! addition! with! methyl! propiolate!(DABCO,! THF)! provided! 14! in! 80%! yield.! Heck! annulation15! of! phenoxyacrylate! 14!proceeded! at! 80ºC,! preventing! the! undesired! rearrangement/decarboxylation! side!
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products,! and! afforded! the! pharbinilic! bismethyl! ester! 15! in! 60%! overall! yield.!Saponification!was!best!carried!out!under!anhydrous!conditions!(KOTMS,!THF)!to!provide!the!desired!natural!product,!1,!in!19%!overall!yield!in!seven!total!synthetic!transformations!starting!from!commercially!available!gibberellic!acid!2.!!
A.4!Effects!of!synthesized!derivatives!against!an!NF2kB!reporter!assay!Due!to!the!report!of!giberellic!acid!and!related!structures!as!NF:kB!inhibitors,16!we!examined!the!activity!of!1!and!analogs!(729,!11213,!15)!in!an!NF:kB!reporter!gene!assay.!In!this! experiment,! HeLa! cells! bearing! a! luciferase! reporter! plasmid! driven! by! NF:kB!were!treated!with!each!compound!for!1!h!followed!by!IL:1b!stimulation!of!NF:kB!activity.!Two!results! are! of! particular! note.! While! pharbilinic! acid! (1)! was! not! active! in! this! assay,!conversion! of! the! two! carboxylic! acid! moieties! to! methyl! esters! as! in! 15! significantly!enhanced!activity,!with!an! IC50!of!69!mM!(Table!1).!Additionally,! enone!8!was! the!most!active!of!the!group,!with!significant!inhibition!observed!even!at!2!mM!concentrations.!The!efficacy! of! 8! as! a! modulator! of! endogenous! NF:kB! was! further! assessed! through!examination!of!a!native!NF:kB:regulated!gene,!MIP3α.!17,18!As!shown!in!Figure!4,!analogous!levels! of! inhibition! were! observed.! Further! cellular! studies! are! currently! underway! to!characterize!the!mode!of!action!of!these!molecules!and!their!effects!in!other!cellular!models!of!NF:kB!pathways.!
 















pharbinilic acid bismethyl ester (15)
Compound (µM)     -      -        10  100       10  100        1   3.5  10        10 100       10  100       10  100      10  100      10  100 


















Figure!A.7!Inhibition!of!MIP3a!gene!expression.!Compound!8!was!tested!for!its!ability!to!inhibit! IL:1b!stimulated!MIP3a!gene!expression!in!HeLa!cells.!All!data! is!presented!as!the!mean!CT!and!S.D.!of!3!replicates!! In!summary,!we!have!developed!a!robust!and!concise!synthesis!to!the!first!naturally!occurring!allogibberic!acid,!pharbinilic!acid!(1),!which!is!tailored!to!the!inherent!reactivity!associated! with! the! gibberellins! to! proceed! under! mild! reaction! conditions! without!observing!any!epimerization!of!the!C9b:H!or!Wagner:Meerwein!rearrangement!of!the!C12:C13! bond.! Additionally,! we! have! looked! at! the! inhibitory! effects! of! these! compounds!against! NF:kB! activity,! identifying! compound! 8! as! a! potent! inhibitor.! The! flexible! and!concise! synthetic! strategy! will! enable! a! full! structure:activity! relationship! study! of! this!class! of! NF:kB! inhibitors,! leading! to! chemical! probes! against! this! centrally! important!transcription!factor.!!


























Compound 8 (µM)          -         -               1       2.5      5       10
IL-1β (2 ng/mL)                -        +               +        +        +         +
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